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The goal of my work presented in this dissertation was to fill the unmet need for 
compounds that can be used to interrogate the biology of the Cullin-RING ubiquitin 
ligases (CRLs) and the MLL1 methyltransferase. We conducted structure-based design, 
organic synthesis, and biochemical/biophysical assays to discover potent inhibitors 
targeting DCN1, DCN3 and, MLL1 methyltransferase.   
Chapter 2 describes the design, synthesis and evaluation of peptidomimetics 
targeting the DCN1-UBC12 protein-protein interaction. Starting from a 12-residue UBC12 
peptide, we successfully obtained a series of peptidomimetic compounds that bind to 
DCN1 protein with KD values of <10 nM. Determination of a co-crystal structure of a potent 
peptidomimetic inhibitor complexed with DCN1 provided the structural basis for their high-
affinity interaction. Cellular investigation of one potent DCN1 inhibitor, compound DI-404, 
reveals that it effectively and selectively inhibits the neddylation of cullin 3 over other cullin 
members. Further optimization of DI-404 may yield a new class of therapeutics for the 
treatment of human diseases in which cullin 3 CRL plays a key role. This work has been 
published in the Journal of Medicinal Chemistry 2018, 61, 1934−1950. 
In Chapter 3, we report the discovery of first-in-class, small-molecule inhibitors 
targeting the DCN3-UBE2F interaction, hereafter called DCN3 inhibitors. Our efforts have 
yielded potent and highly selective small-molecule DCN3 inhibitors, exemplified by TC-
 xiv 
6304 which binds to DCN3 with a Ki value of 35 nM and fails to bind to DCN1 at 
concentrations as high as 30 µM. Cellular thermal shift assays showed that TC-6304 
engages DCN3 in cells in a dose-dependent manner but does not affect the neddylation 
of any of the cullins that were examined, indicating the different roles of DCN3 when 
compared to DCN1. This study provides first-in-class, potent and selective small-
molecule inhibitors of DCN3. This work has been submitted at the time of thesis writing 
for publication in the Journal of Medicinal Chemistry. 
Chapter 4 describes the design, synthesis and evaluation of a chemical library 
focused on S-adenosylmethionine-based compounds which led to the discovery of first-
in-class, potent small-molecule inhibitors directly targeting the MLL1 SET domain. These 
are exemplified by compound TC-5115 with an IC50 value of 15 nM against MLL1 
methyltransferase, which is 48 times more potent than the pan-HMT inhibitor, SAH. 
Determination of co-crystal structures for a number of these MLL1 inhibitors reveals that 
they adopt a unique binding mode that interacts with SET-I domain of MLL1 
methyltransferase. This work is in preparation at the time of thesis writing for publication 
in the Journal of Medicinal Chemistry. 
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Chapter 1 Introduction 
 
1.1 Introduction to the Neddylation Pathway 
1.1.1 Neddylation Pathway  
The programmed and selective degradation of proteins is regulated by the 
ubiquitin-proteasome system (UPS) which maintains cellular homeostasis.1 The UPS 
plays an important role in many cellular regulation process, such as transcriptional 
regulation, signal transduction cell cycle regulation, and endocytosis.1  The process of 
ubiquitin ligation to the substrate protein involves the sequential action of three enzymes: 
the E1 ubiquitin-activating enzyme, the E2 ubiquitin conjugating enzyme, and the E3 
ubiquitin ligating enzyme.2 The neddylation pathway is analogous to the ubiquitin pathway  
and involves involved covalent attachment of NEDD8 to the substrate protein.3 However, 
the neddylation of a target protein will not directly result in protein degradation but in the 
modulation of the target protein activity. NEDD8 (neural precursor cell expressing 
developmentally downregulated-8) is a most studied ubiquitin-like protein with a highest 
sequence similarity to ubiquitin.4 This neddylation cascade starts with the activation of 
NEDD8 by the NEDD8 activating enzyme (NAE), the E1 enzyme. The activated NEDD8 
transfers to either UBC12 or UBE2F, the two E2 enzymes found in mammalian cells. In 
the final step, the E3 enzyme catalyzes the transfer of NEDD8 to the substrate cullins, 
resulting in the activation of a CRL.5 (Figure 1.1) 
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Figure 1.1 The neddylation pathway and the activation of CRLs 
 
1.1.2 Cullin-RING Ligase 
In mammalian cells, the Cullin-Ring ubiquitin ligases (CRL) are the most prominent family 
of E3 ligases in the UPS.6, 7 There are seven cullin complexes (CUL1, CUL2, CUL3, 
CUL4A, CUL4B, CUL5 and CUL7) in human cells with an individual cullin protein being 
the central component of each CRL.6 Activation of each CRL requires covalent 
attachment of NEDD8 to CULs. (Figure 1.1) Studies show that the neddylation of CULs 
regulates about 20% of all cellular ubiquitination.8 CUL1 CRL, the most studied system, 
forms a complex with UBC12, DCN1, RBX1 and NEDD8 proteins for efficient transfer of 
NEDD8 from UBC12 to CUL1.9  
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1.1.3 Current strategies targeting the neddylation pathway 
Evidence has shown that NEDD8 is over-expressed and the CRLs are highly 
activated in human cancer cells.10, 11 Therefore, targeting the neddylation pathway is an 
attractive approach to the development of novel therapeutics.3, 12, 13 MLN4924, an inhibitor 
of the neddylation activating enzyme, arose from the first attempt at targeting the 
neddylation pathway.8 Because MLN4924 inhibits the upstream protein, NAE in the 
neddylation cascade, it effectively causes broad inactivation of all CRLs. MLN4924 
causes apoptotic death of tumor cells by blocking the CRL-mediated protein turnover. 
MLN4924 also suppresses tumor cell growth in vivo, and it is now in clinical trials for 
cancer treatment.14  
 In 2014, the crystal structure of the most studied CUL1 CRL complex was solved.9 
In this complex, DCN1 interacts with both UBC12 and cullin 1 through two separate 
domains, enhancing cullin neddylation.9, 15 These findings suggest that targeting the 
protein-protein interaction between DCN1 and UBC12 within the CRL complex could be 
an alternative strategy with which to target the neddylation pathway. In 2007, our group 
and Guy et al. published DCN1 inhibitors DI-591 and NAcM-OPT, respectively.16, 17 DI-
591 selectively inhibits cullin 3 neddylation and dose dependently increases the protein 
level of CUL3 CRL mediated substrates.16 NAcM-OPT inhibits DCN1-dependent cellular 
neddylation, and cell proliferation in DCN1-amplified cell lines.17  
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Figure 1.2 Inhibitors targeting the neddylation pathway 
 
1.2 Introduction to MLL methyltransferase 
1.2.1 MLL1 methyltransferase and its relevance to disease 
In human cells, H3K4 methylation is catalyzed by the MLL family of 
methyltransferases, SET7/9. There are six members in the MLL family: MLL1, MLL2, 
MLL3, MLL4, SET1A and SET1B.18 Although they have different substrate specificity, and 
subunit compositions, all MLL proteins share the same catalytic core complex.19 The SET 
domain is the core catalytic center of the MLL which is located in the C-terminus of the 
protein. Other proteins, including the WD40 repeat protein 5 (WDR5), absent/small 
homebox 2 like protein (ASH2L), retinoblastoma-binding protein 5 (RBBP5) and DPY-30 
in a complex with the SET domain compose the catalytic machinery.20  
Rearrangements of the mixed-lineage leukemia (MLL) gene, also known as MLL1, 
have been detected in >70% of acute lymphoblastic leukemias (ALL) in infants and 5-
10% of acute myelogenous leukemias (AML) in adults.21, 22 AML patients carrying the MLL 
fusion gene (MLL leukemia) are unresponsive to current treatments and have a very poor 
prognosis.23 It is noted that the MLL translocations invariably occur on only one MLL allele, 
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which means the remaining wild-type MLL allele still retains the H3K4 methyltransferase 
activity.24 It has been shown that both the wild-type and fusion MLL proteins are required 
for MLL-AF9-induced leukemogenesis and maintenance of MLL-AF9-transformed cells.24 
Consequently, inhibition of the H3K4 methyltransferase activity of MLL has been 
proposed as a novel therapeutic strategy for the treatment of MLL leukemia.  
1.2.2 Current strategies targeting the MLL1 methyltransferase activity 
As described in the previous section, the SET domain of MLL1 is responsible for 
the catalysis of methylation on H3K4. However, the MLL1 protein alone is not enough to 
exert the full catalytic activity.25 Studies have shown that when MLL1 forms a complex 
with WDR5, RbBP5, and ASH2L, the methyltransferase activity is recovered.25  Structural 
studies also showed that MLL1 alone adopts an open conformation and WDR5 protein 
causes the MLL1 SET domain to adopt an closed, active conformation.26 Therefore, 
targeting the WDR5/MLL1 protein-protein interaction has become an emerging strategy 
for MLL1 HMT activity inhibition.  
Our group developed a series of cyclized peptidomimetic compounds based on 
the sequence of the Win motif that binds to WDR5. Compound MM-401 binds to WDR5 
with a Ki value <1 nM.27 Biochemical studies show that MM-401 selectively inhibits the 
MLL1 dependent H3k4 methyltransferase activity in the MLL protein family. MM-401 also 
inhibits the proliferation of MV4;11 MLL fusion cell lines.27 Another series of small 
molecule WDR5 inhibitors was developed by AI-awar et al.28, 29 High-throughput 
screening followed by structure-based optimization led to the discovery of compound 
OICR-9429 (Kd = 0.03 µM) which inhibits proliferation of AML cells.28, 29 Further 
 6 
optimization by another group yielded DDO-2117 with a Kd value of 13.6 nM and an IC50 
value of 7.6 nM in an HMT assay.30  
At present, there has been no known potent inhibitor targeting the MLL1 SET 
domain reported in the literature.  
 
 
Figure 1.3 WDR5 inhibitors 
 
1.2.3 SAM Analogs as methyltransferase inhibitors 
1.2.3.1 SAM cycle and its role in biology 
S-adenosylmethionine (S-adenosyl-L-methionine,  AdoMet or SAM was 
discovered in 1952.31 It is a molecule containing a sulfonium ion and generated from a 
single step coupling reaction of methionine with adenosine catalyzed by SAM synthase.32 
SAM is the second most ubiquitous cofactor after ATP. The major role of SAM is as a 
methyl donor for different nucleophiles (C-, N, O- or S-) catalyzed by various 
methyltransferases.33 The methylation of substrates, including histone protein, RNA, 
DNA, and carbohydrate, are important for epigenetic regulation, protein degradation and 
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signal transduction. In general, the methylation reaction is carried out by an SN2 
nucleophilic attack on the electrophilic methyl group of SAM.33 The generated molecule 
including the methylated substrate and the by-product S-adenosyl-L-homocysteine 
(AdoHcy or SAH). Hydrolysis of SAH, followed by methylation of homocysteine catalyzed 
by methionine synthase will regenerate methionine.33 The entire SAM cycle is illustrated 
in Figure 1.  
 
Figure 1.4 The SAM cycle  (A) Methyltransferases catalyze the reaction of the 
methyl group of cofactor SAM with the nucleophile. (B) Hydrolysis of SAH 
generates homocysteine. (C) Subsequent methylation catalyzed by methionine 
synthase regenerates methionine. (D) SAH is regenerated by the reaction of ATP 
with methionine, catalyzed by SAM synthase. 
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1.2.3.2 Early studies on SAM analogs targeting methyltransferases 
SAM/SAH has been recognized as a valuable chemical scaffold with which to 
investigate the function of methyltransferases. SAH is the product of demethylated SAM, 
and SAH itself features the inhibitory activity toward SAM-dependent methyl-
transferases.34 This general feature suggests the potential for developing 
methyltransferase inhibitors based on SAH.35, 36 In fact, much work has been done, for 
example by Coward and Wu since the 1970s to modify the structure of SAM/SAH in an 
attempt to target various methyltransferases.35-41 However, due to the structural 
modifications focused mainly on SAM itself, those compounds have general lack of 
specificity and usually have similar or weaker inhibitory activity than SAH.35-41 Wu et al. 
made systematic  structural modifications to the base, amino acid, and sugar portion of 
SAH and tested the inhibitory activity of the products in COMT, PNMT, HMT and 
HIOMT.38-40 This SAR study revealed that the 6-amino group of SAH is essential for 
inhibitory activity in COMT, PNMT, HMT and HIOMT.38 Replacement of the adenine in 
SAH by uracil, cytosine, guanine, or hypoxanthine resulted in loss of inhibitory activity.38 
Replacing the ribose moiety of SAH by cyclopentyl, 2,3-dihydroxycyclopentyl, or a five-
carbon cyclic system, resulted in a dramatic decrease of the inhibitory activity toward 
SAM-dependent methyltransferases.36 Further investigation of the 2’ hydroxyl and 3’ 
hydroxyl group of the ribose moiety showed differential inhibition among COMT, PNMT, 
HMT, and HOIMT. For example, removal of either the 2’-hydroxyl or the 3’-hydroxyl of 
SAH is detrimental for HOIMT inhibition, while 3’-deoxy compounds are tolerable in 
PNMT.40  Replacement of 5’-thioether with an ether, amine, or amide resulted in poor 
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inhibitory activity toward COMT and tRNA methylase.41 The terminal amine and terminal 
carboxyl group on SAH are required for several methyltransferase inhibition reactions.39  
 
Figure 1.5 Summary of SAR on modifying SAH for methyltransferases  
 
1.2.3.3 The bisubstrate strategy to design SAM based analogs targeting methyltransferases  
The bisubstrate inhibitor is composed of two linked fragments that bind to different 
binding pocket of an enzyme and mimic the ternary complex of an enzymatic reaction. 
Compared to single-binding site inhibitors, the bisubstrate inhibitor has more extended 
interaction with the target enzyme leading to better binding affinity and specificity.42 This 
design strategy has been utilized for a variety of targets, including kinases43, N-
acetyltransferase44, phosphorylase45 and methyltransferases.46, 47  
As discussed in a previous section, the early modifications based on SAH resulted 
in even weaker activity and poor selectivity among methyltransferases. Currently, the 
SAM-based inhibitor design for methyltransferase mainly focused on bisubstrate strategy.  
This strategy has been successfully employed for the design of direct inhibitors for a 
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number of histone methyltransferases such as MMSET,48 SET7/9,46, 47 SMYD3,49 
SETD2,50 EZH2,51 and DOT1L52, 53.  
 
Figure 1.6 SAM analog inhibitors targeting histone methyltransferases 
  
A research group in GlaxoSmithKline discovered a novel SMYD3 inhibitor 
GSK2807 with an IC50 value of 0.13 µM.54 GSK2807 is selective for SMYD3 over 9 other 
tested histone methyltransferases. The co-crystal structure of GSK2807 with SMYD3 
shows that the propyl dimethylamine moiety in GSK-2807 occupies the lysine tunnel in 
SMYD3. A different compound, DAAM-3 shows moderate inhibitory activity toward 
SET7/9 and the selectivity was not reported. The crystal structure of DAAM-3 with SET7/9 
showed that its N-hexyl group is inserted into the narrow lysine tunnel. 25 Compound 3 
and Pr-SNF are actually the same compound but were claimed as MMSET and SETD2 
inhibitors respectively in different publications. 48, 50 Pr-SNF shows moderate activity 
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toward SET7/9, CARM1 and PRMT1, but has no activity at concentrations up to 100 µM 
with SET8, G9a and GLP.50 Compound 27 was designed based on a homology model 
of EZH2. This compound exhibited fairly good selectivity to 10 HMTs and it is even more 
potent for Y641N mutant EZH2 enzyme.51 It is the only compound retaining the sulfur 
atom from SAM. EPZ-5676 was developed by Epizyme and it is currently being tested in 
clinical trials. EPZ-5676 is extremely potent toward DOT1L and it fails to inhibit a large 
panel of HMTs.52, 53 The reason for its selectivity is that DOT1L is the only HMT without a 
SET domain. In addition, all SAM analog HMT inhibitors, except EPZ-5676, has no 
cellular data reported in the literature.  
 
1.3 Overview of Thesis 
In the following chapters, we demonstrate the development of chemical probes targeting 
the DCN family of proteins and the MLL1 methyltransferase. Chapter 2 presents the 
structure-based design of high-affinity peptidomimetic inhibitors targeting the DCN1-
UBC12 protein-protein interaction. Chapter 3 describes the development of a BLI and an 
FP assay for DCN3, and is followed by focused-library screening and structure-based 
optimization for potent and selective first-in-class DCN3 inhibitors. Chapter 4 outlines the 
rational design of first-in-class MLL1 methyltransferase SET domain inhibitors using a 
bivalent approach. Through working at the interface between chemistry and biology, my 
dissertation inaugurates novel, first-in-class compounds which examine the neddylation 
system and the epigenetics mediated by MLL1 methyltransferase, opening a new path 
for innovations in understanding their roles in human disease. 
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One major cellular mechanism to eliminate misfolded or damaged proteins is to 
target them to proteasomes for degradation through a ubiquitin-dependent process.55, 56  
Cullin-RING ubiquitin ligases (CRLs) are one of the largest family proteins responsible for 
degradation of approximately 20% of cellular proteins.6, 57-59 In mammalian cells, there 
are eight cullin members, Cul1, Cul2, Cul3, Cul4A, Cul4B, Cul5, Cul7 and Cul9, each of 
which serves as the central component of the respective CRL.6, 60, 61 Covalent attachment 
to a Neural precursor cell Expressed Developmentally Down-regulated protein 8 (NEDD8) 
to each cullin member, a process known as neddylation, is necessary for activation of an 
individual CRL62-65. Neddylation involves a three-step enzymatic cascade, in which 
NEDD8 is first activated and attached to the E1 neddylation enzyme UBA3-NAE1. A 
second step requires its attachment to one of the two E2 enzymes (UBC12 or UBE2F) 
and in a third step, to cullin. A small-molecule inhibitor, MLN4924, which forms a covalent 
bond with NEDD8 and blocks neddylation, is capable of achieving a broad and effective 
inhibition of all CRLs.8 
Because each CRL modulates degradation of specific substrate proteins, 
compounds that can selectively regulate the activity of an individual CRL member are 
valuable research tools for further investigation of the roles of each CRL in biological 
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processes and human diseases, and such compounds may also have the potential to be 
developed as new therapies for human diseases. To this end, we have proposed a 
general strategy with which to target the protein-protein interaction network within the 
multi-protein neddylation E3 ligase complex as a means of inhibiting the activity of 
individual CRLs.16 
Analysis of the x-ray crystallographic structure of the Cullin1-RBX1-UBC12-NEDD8-
DCN1 complex9, 15 suggests that the protein-protein interaction between DCN1 and 
UBC12 may permit the design of small-molecule inhibitors, hereafter called DCN1 
inhibitors. We have recently published a structure-based design and extensive evaluation 
of DI-591 as a high-affinity, druglike, small-molecule inhibitor of DCN1.16 The posed 
model of inhibitor mediated CUL3 CRL inactivation is proposed in Figure 2.1. Another 
recent independent study has demonstrated the structure-based design of high-affinity, 
non-peptide, small-molecule DCN1 inhibitors.17 
 
Figure 2.1 Proposed model of activation of CUL3 CRL and the model of 
inactive CUL3 CRL blocked by inhibitor 
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In an effort parallel to our development of DI-591, we have carried out the design, 
synthesis and evaluation of peptidomimetic inhibitors of DCN1 based upon a tetrapeptide 
derived from a 12-residue segment of the UBC12 peptide. This has resulted in the 
discovery of potent, cell-permeable peptidomimetic DCN1 inhibitors with KD values <10 
nM. The co-crystal structure of one such inhibitor in a complex with DCN1 provides the 
structural basis for their high-affinity interaction and for further optimization. Evaluation of 
one potent inhibitor (36, DI-404) shows that in cells, it engages the DCN1 protein and 
effectively blocks its interaction with the UBC12 protein. DI-404 also selectively inhibits 
the neddylation of cullin 3 CRL over cullin CRLs in cells.  
 
2.2 Results and Discussion 
2.2.1 Identification of a 4-residue lead peptide 
As shown in Figure 2.2 A, our systematic truncation of the 12-residue UBC12 peptide 
identifies a tetrapeptide (2) derived from the N-terminus of UBC12 which retains a 
significant affinity to DCN1. Further modifications of this tetrapeptide, (2), leads to 
compound 3, which binds to DCN1 with a Ki value of 3.6 µM and is thus as potent as the 
12-mer peptide 1 (Ki = 5.1 µM) (Figure 2.2 A). We employed this tetrapeptide (3) as the 
starting point for systematic optimization aimed at improving its binding affinity to DCN1. 
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Figure 2.2 Chemical structures of designed peptides and the structural 
analysis of peptides-DCN1 interaction  (A) Chemical structures of the 12-
residue UBC12 peptide (1) and tetrapeptides 2 and 3. (B). Crystal structure of 
peptide 2 (green) with DCN1 extracted from the structure of peptide 1 with DCN1 
(PDB ID: 3TDU). (C) Predicted binding model of compound 3 (orange) in a 
complex with DCN1. Hydrogen bonds are depicted as cyan dash lines. (D). 
Detailed views of compound 3 and interacting residues in the P1-P4 pockets. 
 16 
Based upon the co-crystal structure of UBC12 peptide (1) complexed with DCN1 
(Figure 2.2 B),9, 15 we predicted a binding model for compound 3 (Figure 2.2 C), which 
shows that its naphthalene group occupies the P1 “core pocket” of DCN1, while the acetyl 
group, the side chain of Ile2 and the side chain of Leu4 interact with the P2, P3 and P4 
pockets, respectively. We performed stepwise modifications of compound 3 with the goal 
to optimize its interactions with residues in each of these four pockets. 
2.2.2 Development of a fluorescence polarization (FP)-based competitive binding 
assay  
To accurately evaluate the binding affinities of our designed compounds to DCN1, 
we designed and synthesized a fluorescently tagged tracer (4), (Figure 2.3 A). The KD 
value of 4 with DCN1 was determined to be 50.7 nM (Figure 2.3 B). We developed and 
optimized the fluorescence polarization (FP)-based competitive binding assay using 
compound 4 and recombinant human DCN1 protein.  With this assay, we determined the 
binding affinities of our designed compounds in this study. All IC50 and Ki values reported 
in the present study were obtained from at least three independent experiments. 
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Figure 2.3 Chemical structure of compound 4. B) Binding isotherm of 
compound 4 to DCN1.  
 
2.2.3 Modification of the N-terminal acetyl group, interacting with the P2 pocket 
As shown in Figures 2.2B and 2.2C, the methyl of the N-terminal acetyl group is 
directed towards the P2 hydrophobic pocket and, the carbonyl of this acetyl group forms 
a hydrogen bond with the hydroxyl group of Y181. The NH group bearing the N-terminal 
acetamide group forms a hydrogen bond with the backbone carbonyl group of P97 in 
DCN1. To probe the interactions with the P2 pocket formed by V102, L103 and F164 
(Figure 2.2D), the acetyl group in 3 was replaced by a formyl group giving 5 (Ki = 27.5 
µM), which is 8 times less potent than 3. Removal of the acetyl group produced 6, which 
has negligible affinity to DCN1 at 100 µM. These data confirm the importance of the N-
terminal acetyl group and are consistent with the previously reported binding affinities of 
12-mer residue peptides.15  
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Our predicted binding model (Figure 2.2D) shows that the P2 pocket can 
accommodate a larger hydrophobic moiety, and accordingly, several small hydrophobic 
groups were tested, giving the results shown in Table 2.1. Substitution of the methyl group 
in 3 with an ethyl group gave compound 7 (Ki = 1.1 µM), improving the binding affinity by 
a factor of 3. However, replacement of the ethyl group in 7 with a larger group, such as 
cyclopropyl (8, Ki = 5.4 µM), isopropyl (9, Ki = 3.5 µM), n-propyl (10, Ki = 8.0 µM), or 
isobutyl (11, IC50 > 20 µM) decreases the binding affinity. Binding affinity is also 
significantly reduced when the propionamide in 7 is replaced by a moiety that is similarly 
sized but less hydrophobic, such as methylurea (12, Ki = 4.0 µM) or methyl carbamate 
(13, IC50 > 50 µM). We concluded that the optimal N-terminal cap is a propionyl group, 
as in compound 7. 
 
Table 2.1 Structures and binding affinities of compound 3 and its analogues designed to 
investigate the interactions with the P2 pocket in DCN1. 
 
3 5 6 7 8 9 10 11 12 13
R1
IC50 (µM) 16.8  7.3 128  59 > 100 5.2  1.1 25.1  11.5 16.5  1.7 37.0  23.6 > 20 18.5  8.7 > 50
Ki (µM) 3.6  1.5 27.5  12.7 1.1  0.2 5.4  2.5 3.5  0.4 8.0  5.1 4.0  1.9
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2.2.4 Modifications at the C-terminus probing interactions with the P4 pocket 
Next we optimized the interactions of the C-terminal residue, Leu4 in 7, with the 
P4 pocket of DCN1. The co-crystal structure of peptide 1 complexed with DCN1 (Figure 
2.2B) and our modeling of 3 (Figure 2.2D) showed that the hydrophobic side chain of 
Leu4 in 3 is directed to the P4 hydrophobic pocket, while the carbamoyl group of Leu4 is 
oriented towards the solvent, away from the DCN1 protein and thus lacking any specific 
interaction with the protein. Based on these observations, we replaced Leu4 in 7 with 
various hydrophobic groups with the goal to improve the potency and at the same time to 
reduce the overall peptidic nature of the resulting compounds (Table 2.2). 
Table 2.2 Structures and binding affinities of compound 7 and its analogues, designed to 
investigate the P4 pocket in DCN1. 
 
Replacement of Leu4 in compound 7 with a phenyl group gave compound 14 (Ki 
= 7.5 µM), which decreases the binding affinity by a factor of 7. Replacement of Leu4 by 
a benzyl group afforded 15 (Ki = 0.81 µM), which maintains the binding affinity. 
Substitution of the benzyl group in 15 with 2-phenylethyl group yielded 16 (Ki = 2.5 µM), 
which is 3-times less potent than 15. We next incorporated a second phenyl ring at the α 
7 14 15 16 17 18 19 20 21
R2
IC50 (µM) 5.2  1.1 34.9  6.5 3.9  0.3 10.8  2.1 0.61  0.19 0.91  0.11 1.9  0.3 0.55  0.08 0.80  0.11
Ki (µM) 1.1  0.2 7.5  1.4 0.81  0.07 2.5  0.5 0.097  0.042 0.16  0.02 0.38  0.05 0.084  0.017 0.14  0.02
 20 
position of the benzyl group in 15 to restrict the orientation of the first phenyl group. The 
resulting compound 17 binds to DCN1 with a Ki value of 0.097 µM and is thus 8 times 
more potent than 15, revealing the benefit of restricting the conformation of the phenyl 
group. As shown in the predicted binding model of 17 with DCN1 (Figure 2.4), one of the 
phenyl rings of the benzhydryl group in 17 interacts with the P4 pocket and the other 
phenyl ring is oriented towards the solvent. In addition to enhancing the binding affinity 
by restricting the conformational freedom, replacement of the primary amide with a phenyl 
ring also reduces the overall peptidic nature of compound 17. 
 
Figure 2.4 Binding mode of compound 7 and 17 in DCN1 
 
Encouraged by the binding data for 17, we employed a bicyclic ring system to 
control the orientation of the phenyl ring in 15.66-68 As shown in Table 2, replacement of 
the benzyl group in compound 15 by (R)-2,3-dihydro-1H-inden-1-yl yielded 18, by (S)-
2,3-dihydro-1H-inden-1-yl (19), by (R)-1,2,3,4-tetrahydronaphthalen-1-yl (20) and by (S)-
1,2,3,4-tetrahydronaphthalen-1-yl (21). Compounds 18, 19, 20 and 21 bind to DCN1 with 
Ki values of 0.16 µM, 0.38 µM, 0.084 µM and 0.14 µM, respectively, showing that the 6-6 
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bicyclic ring system in 20 and 21 enhances the binding more effectively than the 5-6 
bicyclic ring system in 18 and 19. Further, the (R)-configuration in 18 and 20 appears to 
be the preferred conformation for the chiral center because it places the phenyl ring in a 
favorable position for binding to DCN1, consistent with the L-conformation of Leu4 in 7. 
Notably, compound 20 with the (R)-1,2,3,4-tetrahydronaphthalen-1-yl group is as potent 
as 17. In addition to the enhanced binding affinity, substitution of Leu4 in 7 with 
diphenylmethyl (17) or (R)-1,2,3,4-tetrahydronaphthalen-1-yl (20) also reduces the 
peptidic characteristic of the resulting compound by removal of one amide group. 
2.2.5 Modifications of Ile2 to probe interactions with the P3 pocket 
As shown in Figure 2.2 D, the Ile2 residue in 3 interacts with the P3 shallow 
hydrophobic pocket in DCN1. We modified the Ile2 in compound 17 with residues of 
different size, shape and hydrophobicity to explore the interactions of this residue with the 
P3 pocket in DCN1. Compounds 22, 24 and 25 with a cyclopentylglycine, 
cyclohexylalanine or a t-butylalanine group bind to DCN1 with Ki values of 36.3, 44.3 nM 
and 42.9 nM. All these compounds are modestly more potent than 17 (Ki = 96.7 nM). On 
the other hand, compound 23, containing cyclohexylglycine binds to DCN1 with Ki values 
of 97.3 nM and is similarly potent as 17. However, compound 26 with 2,2,2-
trifluoromethylalanine (Ki = 672 nM) and 27 with thiophen-2-ylalanine (Ki = 174 nM) are 
both weaker than 17. 
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Table 2.3 Structures and binding affinities of compound 17 and its analogues designed to 
probe the interactions with the P3 pocket in DCN1. 
 
2.2.6 Investigations of the interactions with the P1 core pocket 
As shown in Figure 2.2 D, the naphthyl group of compound 3 is inserted deeply 
into the P1 core pocket in DCN1, and so we next focused our modifications on the 
naphthyl group in compound 22. After extensive exploration, the benzothiazole ring was 
identified as a good replacement for the naphthalene group. Compound 28 containing a 
benzothiazole binds to DCN1 with a Ki value of 50.7 nM and is thus as potent as 22 (Table 
4). To further optimize the interactions of compound 28 with DCN1, different substituents 
on the benzothiazole ring were examined and the results are summarized in Table 4. 
Replacement of the benzothiazol-2-yl alanine in 28 with 4-fluorobenzothiazol-2-yl alanine 
or 4-fluorobenzothiazol-2-yl alanine yielded compounds 29 and 30, respectively, which 
are 20- and 4-times less potent than 28, respectively. Replacement of the benzothiazol-
2-yl alanine with 6-fluorobenzothiazol-2-yl alanine gave 31 (Ki = 54.4 nM), which is 
equipotent with 28. We next explored the influence of chloro substitution of the 
17 22 23 24 25 26 27
R3
IC50 (nM) 611  193 330  95 613  385 368  110 361  95 3266  490 967  122
Ki (nM) 96.7  41.6 36.3  20.6 97.3  83.0 44.3  23.8 42.9  11.3 672  101 174  22
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benzothiazole and found that a 5-chlorobenzothiazol-2-yl alanine group (32, Ki = 88.6 nM) 
has a decreased binding affinity while compound 33 with a 6-chlorobenzothiazol-2-yl 
alanine group (IC50 = 132 nM, Ki < 50 nM) is more potent than 28 (IC50 = 397 nM, Ki = 
50.7 nM).  
In view of the superior potency of compound 33, we employed a label-free Bio-
Layer Interferometric (BLI) method to determine the dissociation constant (KD) of 33 and 
several other compounds. In this BLI assay, compound 33 binds to DCN1 with a KD value 
of 8.1 nM, and compounds 22, 28 and 31 have KD values of 56.4 nM, 31.8 nM and 37.0 
nM, respectively (Table 2.4). Thus, compound 33 is 4 times more potent than compound 
28.  We next used the BLI assay to evaluate the binding affinities of new analogues of 
compound 33 to DCN1. 
Table 2.4 Structures and binding affinities of compound 22 and its analogues designed to 
investigate the P1 core pocket in DCN1. 
 
2.2.7 Optimization of the physicochemical properties of compound 33 
Compound 33 binds potently to DCN1 (KD = 8.1 nM), but it is quite hydrophobic. 
We next focused our optimization on improving the solubility of compound 33, while 
22 28 29 30 31 32 33
IC50 (nM) 330  95 397  96 4917  2596 1197  653 413  132 572  129 132  53
Ki (nM) 36.3  20.6 50.7  12.3 1029  543 224  122 54.4  17.4 88.6  20.0 < 50
KD (nM) OctetRED 56.4  6.3 31.8  8.2 not tested not tested 37.0  14.9 not tested 8.1  1.1
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retaining its high binding affinity to DCN1 (Figure 2.5 A). Replacement of the 
diphenylmethylamide in 33 with (R)-1,2,3,4-tetrahydronaphthalen-1-amide gave 
compound 34 (KD = 8.3 nM in the BLI assay), which binds to DCN1 as potently as 33. In 
compound 34, the aromatic ring of (R)-1,2,3,4-tetrahydronaphthalen-1-amide is predicted 
to penetrate into the P4 pocket while the aliphatic ring portion of the bicyclic ring system 
is exposed to solvent. This provides an opportunity of insertion of a polar atom into this 
aliphatic ring to improve the overall physiochemical properties without negatively affecting 
the binding affinity of the resulting compounds. Accordingly, compound 35 was designed 
by replacing the C1 atom in the (R)-1,2,3,4-tetrahydronaphthalen-1-amide ring with an 
oxygen atom. The resulting compound 35 binds to DCN1 with a KD value of 4.1 nM in the 
BLI assay, and its calculated ClogP value is decreased to 3.8 from the calculated ClogP 
value of 5.0 for compound 33. We also synthesized compound 38, in which the primary 
amine group of 35 is dimethylated. Compound 38 binds to DCN1 with a KD value of 5.7 
nM in the BLI assay. To further reduce the hydrophobicity of 35, an oxygen or nitrogen 
atom was inserted into the cyclopentyl ring in 35 to yield 36 (DI-404) and 37, respectively, 
which have calculated CLogP values of 1.9. Compound 36 binds to DCN1 with a KD value 
of 6.7 nM (Figure 2.5 B) and 37 has a KD value of 1467 nM (Figure 2.5 C) in the BLI 
assay. The much higher affinity for compound 36 than for 37 is almost entirely due to the 
much faster on-rate for 36 (Figure 2.5 B) than for 37 (Figure 2.5 C) since these two 
compounds have essentially the same off-rates.  
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Figure 2.5 Optimization of compound 33 and the Kinetic binding sensograms  
(A) Optimization of compound 33 leading to compound 36. CLogP values were 
calculated using ChemBioDraw Ultra (http://www.perkinelmer.com). (B) Kinetic 
binding sensorgrams of 36 were determined with concentrations ranging from 1.6 
nM to 100 nM. (C) Kinetic binding sensorgrams of 37 with concentrations ranging 
from 0.39 to 25 µM. In both (B) and (C), the steady state fitting of the equilibrium 
responses vs compound concentrations is based on 1:1 binding model. 
















1 0 0  n M
2 5  n M
6 . 3  n M
3 . 2  n M
5 0  n M
1 2 . 5  n M
1 . 6  n M
C o m p o u n d 3 6
















C o m p o u n d  3 6
0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 6 0 0
0 . 0 0
0 . 0 5
0 . 1 0
0 . 1 5
0 . 2 0
0 . 2 5










0 . 3 9  M
1 . 6  M
6 . 3  M
1 2 . 5  M
0 . 7 8  M
3 . 2  M
2 5  M
C o m p o u n d 3 7















C o m p o u n d  3 7
Compound 36: KD = 6.7±0.9 nM, kon = 2.9±1.0x10
5 M-1s-1, koff = 2.0±1.0x10
-3 s-1
Compound 37: KD = 1467±306 nM, kon = 2.4±0.2x10






2.2.8 Determination of the crystal structure of compound 38 in a complex with 
DCN1 
To gain structural insights for their high binding affinities, we attempted to determine co-
crystal structures for a number of compounds in a complex with DCN1. We have 
successfully determined the co-crystal structure of compound 38 in complex with DCN1 
at a resolution of 2.16 Å (Figure 2.6 A, PDB ID 6B5Q).  
 
Figure 2.6 Co-crystal structure of DCN1 complexed with compound 38. (A) 
Co-crystal structure of DCN1 (cyan) complexed with compound 38 (yellow, PDB 
ID 6B5Q). (B) Overlay of the DCN1-38 complex (PDB ID 6B5Q) with DCN1-UBC12 
(green) peptide (PDB ID 3TDU). Major conformational differences at F109 and 
F117 at the P1 pocket were found between these two complex structures. 
Hydrogen bonds are shown as red dashed lines. Halogen-aromatic interactions 
are depicted by purple dashed lines. 
Consistent with our modeling prediction, the 6-chlorobenzothiazol-2-yl group of 38 is 
buried deeply in the P1 hydrophobic pocket formed by I86, F89, C90, F109, F117, V102, 
A106 and F164 (Figure 2.6 A) and this deep penetration in the P1 pocket by 38 induces 
major conformational changes at F109 and F117 to make room to accommodate 38 
(Figure 2.6 B). Additionally, chlorine-aromatic interactions are observed between 38 and 
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F109 of DCN1.69, 70 The distance from the Cl atom in compound 38 to the center of 
aromatic ring of F109 is 4.96 Å, suggesting a Cl-π interaction. The Cl atom in compound 
38 also interacts with F117 with a distance of 3.4-4.0 Å to the edge of the phenyl ring. 
The combination of the Cl-π interaction of compound 33 with F109 in DCN1 and the 
hydrophobic interaction with F117 in DCN1 underlies a ~4-fold increase in potency of 
compound 33 as compared to compounds 28, 31 and 32 (Table 4). Compared to the 
acetyl group in 1, the additional methyl of the propionyl group in compound 38 fits well 
into the small hydrophobic pocket formed by L103, L184, Y181, A106 and V102. Similar 
to those in the co-crystal structure of the UBC12 peptide 1-DCN1 complex, the propionyl 
group of 38 forms hydrogen bonds with P97 and Y181 of DCN1 while the backbone amide 
of K3 in 38 forms a hydrogen bond with Q114 of DCN1. The phenyl of the (R)-chroman 
group in 38 projects into the hydrophobic pocket lined by I83, I86, Q87, P97 and C115, 
while the saturated portion of this bicyclic system is oriented towards the solvent. The 
cyclopentyl group in 38 is half-buried in the hydrophobic region formed by M177, A180, 
L184 and Y181. The repulsion between this hydrophobic pocket and the positive charged 
of piperidine in 37 prevents the burial of piperidine in 37 in DCN1, while the uncharged 
tetrahydro-2H-pyran in 36 is favorable to be buried in this pocket, which may explain, at 
least in part, the much higher affinity for compound 36 than for 37. 
The co-crystal structure of compound 38 complexed with DCN1 thus provides structural 
insights for the high binding affinity of compound 38 and its close analogues such as 
compound 36 to DCN1. 
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2.2.9 Cellular evaluation of compound 36 (DI-404)  
DCN1 is overexpressed in squamous cell carcinoma (SCC) cell lines.71 We 
evaluated compound 36 in two SCC lung cancer cell lines H2170 and SK-MES-1 with 
compound 37 included as the control compound. 
The cellular thermal shift assay (CETSA)72 was employed to investigate the target 
engagement of 36 in cells. As shown in Figure 2.7, cellular DCN1 protein was denatured 
at 53 oC in H2170 cells by treatment with DMSO, but the thermal stability of DCN1 protein 
was clearly enhanced, in a dose-dependent manner by 36. Compound 36 was effective 
in enhancing the thermal stability of cellular DCN1 protein at concentrations as low as 0.3 
µM. In comparison, the much less potent control compound 37 has a minimal effect on 
the thermal stability of cellular DCN1 protein at concentrations as high as 10 µM (Figure 
2.7). 
 
Figure 2.7 Engagement of compound 36 with DCN1 in cells. Compound 36 
engages cellular DCN1. H2170 cells were treated by 36 or 37 for 1 h, and then the 
cells were heated at 53 °C for 3 min, followed by frozen in liquid nitrogen and 
thawed through 3 cycles. DCN1 protein level in whole cell lysates was examined 















To determine if 36 disrupts the association of DCN1 protein with UBC12 protein in 
cells, a co-immunoprecipitation study was carried out on the lysate from H2170 cells 
treated with compound 36 or 37. Compound 36 decreases the association of cellular 
DCN1 protein with cellular UBC12 protein in a dose-dependent manner but the control 
compound (37) had no such effect (Figure 2.8). Furthermore, compound 36 has no effect 
on the levels of DCN1 and UBC12 proteins (Figure 2.8). These data suggest that 
compound 36 effectively inhibits the DCN1-UBC12 protein-protein interaction in cells. 
 
Figure 2.8 Effect of compound 36 on DCN1-UBC12 protein-protein 
interaction in H2170 cells 
 
Since DCN1 protein is an integral part of the neddylation activation complex, we next 
investigated if compound 36 can effectively inhibit the neddylation of an individual cullin. 
We treated H2170 cells with compound 36, with compound 37 included as a control. 
Our data showed that compound 36 inhibits the neddylation of cullin 3 in a dose-
dependent manner and is effective at concentrations as low as 0.3 µM (Figure 2.9). 
Treatment with 36 converts cullin 3 into a predominantly unneddylated form at 1 µM in 
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H2170 cells (Figure 2.9). 
 
Figure 2.9 Effect of cullin neddylation of compound 36 in H2170 cells. 
Compound 36 selectively inhibits the neddylation of cullin 3 over that of other cullin 
























lysed. The protein levels of neddylated cullin (N-Cul) and un-neddylated cullin (Cul) 
proteins and two substrates of cullins, NRF2 and CDT1, in whole cell lysates were 
examined by western blotting analysis. GAPDH was used as a loading control. 
While compound 36 effectively and potently inhibits the neddylation of cullin 3, it is 
much less effective in inhibition of the neddylation of cullin 1 and other cullins (Figure 2.9). 
In fact, it has only a modest effect in inhibition of the neddylation of cullin 1 at 
concentrations as high as 10 µM and has no obvious effect on neddylation of cullins 2, 
4A, 4B and 5 (Figure 2.9). Significantly, the much less potent control compound 37 has 
no effect on the neddylation of all cullin members examined, showing that the effect by 
compound 36 is specific to cullin 3 (Figure 2.9). As a consequence of selective inhibition 
of cullin 3 neddylation, compound 36 effectively increases the level of NRF2 protein, a 
substrate of cullin 3 CRL (CRL3), but has no effect on CDT1, a substrate of cullin 4A CRL 
(CRL4A) (Figure 2.9). 
2.3 Chemistry 
As shown in Scheme 1, a fluorescent labeled tracer (4) was produced by solid-phase 
peptide synthesis. 5-Carboxyfluorescein succinimide ester (5-FAM, SE) was attached to 
the side chain of the Lys12 of the linear peptide via a linker.  
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Scheme 2.1 Synthesis of compound 4. 
 
Peptides 5-13 were synthesized by solid-phase peptide synthesis using Fmoc 
chemistry as shown in Scheme 2. Rink amide resin was used as the solid support and 
the coupling reagent was diisopropylcarbodiimide. The crude peptides were cleaved from 
the resin by a TFA:TES:H2O (36:1:2) cleavage cocktail, which also removed the 
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protecting groups. After the cleavage, the solvents were evaporated and the residue was 
purified by RP-HPLC to give compounds 5-13. 
 
Scheme 2.2 Synthesis of compounds 5-13. 
 
 
Compounds 14-21 were synthesized as shown in Scheme 3. The intermediate (39) 
was synthesized with 2-chlorotrityl chloride resin as the solid support. Fmoc-Lys(Boc)-OH 
(40) was first loaded onto the 2-chlorotrityl chloride resin and Fmoc chemistry was then 
used to carry out the chain elongation. The crude carboxylic acid (39) was cleaved from 
the resin with 0.5% TFA in DCM and purified by HPLC. It then was coupled to various 
amines and this was followed by removal of the Boc protecting group, providing 
compounds 14-21. 
 
Scheme 2.3 Synthesis of compounds 14-21. 
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The unnatural amino acids (41) were synthesized as shown in Scheme 4. The acid 
group of Fmoc-Asp-O-allyl (42) was converted to different substituted benzothiazoles by 
treatment with oxalyl chloride, followed by the appropriately substituted 2-
aminobenzenethiol.16, 73 The O-allyl protecting group was removed in the presence of 
phenylsilane and Pd(Ph3P)4, giving compounds 41a-41c. 
 
Scheme 2.4 General synthetic route for amino acids 41. 
 
 
The general method for the synthesis of compounds 22-37 is shown in Scheme 5. 
Compound 43 is produced by coupling Fmoc-Lys(Boc)-OH (40) to various amines (R2-
NH2) with HBTU as coupling reagent and this is followed by removal of the Fmoc group 
by treatment with diethylamine. Employing a similar procedure, condensation of 43 with 
various Fmoc protected amino acids and subsequent deprotection of the Fmoc group 
gives compounds 44. Next, various Fmoc protected amino acids are attached to 44 and 
a propionyl group is introduced as the N-terminal capping group. Compounds 22-37 are 
generated by deprotection and purification. Compound 38 is afforded by treating 35 with 
formaldehyde and Na(AcO)3BH.  
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Starting from a tetrapeptide (2) derived from the UBC12 protein, we performed systematic 
modifications to optimize its interactions with four pockets (P1, P2, P3 and P4) in the 
protein DCN1, and its physiochemical properties. Our efforts have yielded a series of 
potent peptidomimetic compounds, exemplified by compound 36 (DI-404), which binds to 
DCN1 with a KD value of 6.7 nM. Our cellular studies demonstrate that 36 engages cellular 
DCN1 protein and inhibits the association of cellular DCN1 protein with the UBC12 
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protein. The cellular data further show that while 36 inhibits the neddylation of cullin 3 in 
a dose-dependent manner, it is much less effective in inhibition of the neddylation of cullin 
1 and has no effect on the neddylation of other cullin members that were examined. 
Determination of a co-crystal structure of compound 38, a potent and close analogue of 
36, provides structural insights for their high-affinity interactions with DCN1 and a 
structural basis for further design and optimization. Optimization of 36 (DI-404) may 
ultimately yield new therapies for the treatment of human conditions and diseases in 




Chapter 3 Discovery of Potent and Selective DCN3 Inhibitors  
 
3.1 Introduction 
Protein degradation is tightly regulated by the ubiquitin-proteasome system (UPS) 
to maintain cellular homeostasis.1  In mammalian cells, the Cullin-Ring ubiquitin ligases 
(CRLs) are the most prominent family of E3 ligases in the UPS.6, 7 There are seven cullin 
complexes (CUL1, CUL2, CUL3, CUL4A, CUL4B, CUL5 and CUL7) in human cells with 
an individual cullin protein being the central component of each CRL. Activation of each 
CRL requires covalent attachment of NEDD8 (neural precursor cell expressing 
developmentally downregulated-8), a process known as neddylation. This neddylation 
cascade starts with the activation of NEDD8 by the NEDD8 activating enzyme (NAE), the 
E1 enzyme. The activated NEDD8 transfers to either UBC12 or UBE2F, the two E2 
enzymes found in mammalian cells. In the final step, the E3 enzyme catalyzes the transfer 
of NEDD8 to the substrate cullins, resulting in the activation of a CRL.  
Because CRLs are responsible for degradation of some 20% of mammalian 
proteins, they play key roles in the regulation of a large number of biological processes.7 
The dysregulation of CRLs has been linked to several human diseases, including 
cancer.60, 74 Consequently, targeting CRLs represents a new strategy for the development 
of cancer therapeutics. The pioneering work in targeting CRLs by Millenium 
Pharmaceuticals Inc. has led to the discovery and clinical development of MLN4924, 
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which is a covalent inhibitor of the NAE E1 enzyme and is potent and effective in inhibiting 
all CRLs.8 However, selective targeting of individual CRLs has been very challenging. 
Recently, we proposed designing small-molecule inhibitors to target protein-protein 
interactions within the multi-component E3 ligase complexes as a strategy to target 
individual CRLs selectively.75, 76 Our efforts led to the discovery of small-molecule 
inhibitors of the DCN1-UBC12 protein-protein interaction, which selectively inhibits 
neddylation of Cullin 3.9, 15 These recent findings therefore suggest that targeting other 
protein-protein interactions within the multi-component E3 ligase complexes may be an 
attractive approach to selectively target individual CRLs. 
There are 5 family members of DCN proteins (DCN1-5) in human cells,77-79 and 
each DCN protein has a different N-terminal domain and a conserved C-terminal 
potentiating neddylation (PONY) domain. While the function of DCN1 has been 
extensively investigated, only limited studies on DCN3 protein have been reported.79,80, 81 
Biophysical data and x-ray crystallographic data show that while DCN1 binds to both 
UBE2F and UBC12 with similar affinities, DCN3 protein binds more strongly to UBE2F 
than to UBC12, and DCN1 and DCN3 have some differences in their binding residues 
that interact with UBE2F and UBC12. Therefore, it may be possible to design small-
molecule inhibitors, hereafter called DCN3 inhibitors that are capable of selectively 
binding to DCN3 over DCN1 and blocking the interactions of DCN3 with its binding 
partners.82  
In the present study, we report our discovery of first-in-class potent, selective and 
cell-permeable small-molecule DCN3 inhibitors. 
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3.2 RESULTS AND DISCUSSION 
3.2.1 Analysis of the binding pockets in DCN1 and DCN3 
The co-crystal structure of DCN1 in a complex with its binding partner UBC12 and 
the co-crystal structure of DCN3 in a complex with an acetylated N-terminal UBE2F 
peptide have been reported.82 We analyzed the binding pockets in DCN1 and DCN3 to 
facilitate the design of inhibitors selective for DCN3 over DCN1.  
The co-crystal structures revealed that both DCN1 and DCN3 proteins interact 
primarily with the acetylated N-terminal tetrapeptide segment of either UBC12 or UBE2F. 
For our design, we defined the DCN1 and DCN3 binding sites into four pockets, P1-P4 
(Figure 3.1A). The methionine residues in UBC12 and UBE2F penetrate deeply into the 
conserved, hydrophobic P1 pocket in both DCN1 and DCN3, respectively. The 
hydrophobic residues forming this P1 pocket are the same in DCN1 and DCN3 with the 
exception of two hydrophobic residues: Leu130 in DCN1 becomes Ile105 in DCN3, and 
Ile86 in DCN1 is replaced by Met111 in DCN3. The P2 pocket in DCN1 and DCN3 
interacts with the N-terminal acetyl group in both UBC12 and UBE2F and is conserved 
with a single residue change: Tyr181 in DCN1 becomes Leu208 in DCN3. The P3 pocket 
in both DCN1 and DCN3 is hydrophobic in nature and partly solvent exposed and 
interacts with isoleucine and leucine residue in UBC12 and UBE2F, respectively. The P3 
pocket in DCN1 and DCN3 differs with two residues, a change of tyrosine (Tyr181) in 
DCN1 to leucine (Leu208) in DCN3, and a change of alanine (Ala98) in DCN1 to threonine 
(Thr123) in DCN3. The P4 pocket in DCN1 and DCN3 is also partially solvent exposed 
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and several residues involved in this pocket in DCN1 and DCN3 are different (Figure 
3.1B). 
 
Figure 3.1 Crystal structure analysis of DCN1 and DCN3.  (A) Crystal structure 
of DCN3 with the UBE2F peptide (PDBID: 4GBA). Key binding residues in DCN3 
and the UBE2F peptide are shown in stick. Hydrogen bonds are depicted in cyan 
dashed lines. (B) Superposition of crystal structures of DCN3:UBE2F (PDBID: 
4GBA) and DNC1:UBC12 (PDBID: 3TDU). Key residues differences in the binding 
site of DCN1 and DCN3 are labeled and colored in pink and green, respectively. 
We propose that these differences in binding site residues between DCN1 and 
DCN3 can be exploited for the design of selective inhibitors for either DCN1 or DCN3. 
Indeed, in our previous study, we have designed DI-591 as a small-molecule inhibitor 
which is highly selective for DCN1 over DCN3.75 
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3.2.2 Identification of initial DCN3 inhibitors by screening our DCN1 inhibitor 
library 
In our previous studies, we designed and synthesized a series of small molecules 
as inhibitors of DCN1.75, 76  Since DCN1 and DCN3 share similar binding sites, we 
reasoned that some of our previously synthesized DCN1 inhibitors may display significant 
binding affinities to DCN3. 
We employed a label-free, biolayer interferometry (BLI) method to screen our 
previously synthesized small-molecule DCN1 inhibitors for their binding affinities to 
recombinant, human DCN3 protein. To validate this BLI assay, we tested the binding 
affinity of a known 25-residue UBE2FNAC1-25 peptide for DCN3. Our BLI experiments 
determined that the 25-residue UBE2FNAC1-25 peptide binds to DCN3 with Kd = 3.20 µM 
(Table 3.1), close to its previously reported Kd value.82 We also synthesized and used the 
BLI assay to test a number of truncated UBE2F peptides, with 5 to 9 residues. Our data, 
in Table 3.1 show that UBE2FNAC1-9 (first 9 residues) has a binding affinity very similar to 
that of UBE2FNAC1-25 (Kd = 2.73 µM vs 3.20 µM), but a peptide with the first 7 residues, 
UBE2FNAC1-7 is >30-times weaker than UBE2FNAC1-9 in binding to DCN3, and still shorter 
peptides UBE2FNAC1-5 and UBE2FNAC1-6 have no appreciable binding to DCN3 at 
concentrations up to 100 µM. 
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Table 3.1 Binding affinities of UBE2F peptides to DCN3 as determined in a direct BLI 
binding assay. 
 
Using the BLI assay, we evaluated a total of 67 small molecules from our collection 
of previously synthesized DCN1 inhibitors for their binding affinities to DCN3. While 64 
out of 67 these compounds had no obvious binding to DCN3 at concentrations up to 10 
µM, we identified three compounds (1-3), with very similar chemical structures, which 
display Kd values of 2-4 µM (Figure 3.2). 
 
Figure 3.2 Chemical structures and binding affinities of previously 
synthesized DCN1 inhibitors. Compounds 1-3 display significant binding 
affinities to DCN3. 
Peptide name Sequence Kd (µM)
UBE2FNAC 1-25 Ac-MLTLASKLKRDDGLKGSRTAATASD-NH2 3.20 ± 0.30
UBE2FNAC 1-9 Ac-MLTLASKLK-NH2 2.73 ± 0.15
UBE2FNAC 1-7 Ac-MLTLASK-NH2 103 ± 85
UBE2FNAC 1-6 Ac-MLTLAS-NH2 > 100
UBE2FNAC 1-5 Ac-MLTLA-NH2 > 100
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3.2.3 Computational prediction of the binding of lead compounds in complexes 
with DCN3  
To guide our optimization efforts, we performed computational modeling to predict 
the binding models of these initial three lead compounds to DCN3. In the co-crystal 
structure of DI-591 in a complex with DCN1,75 we observed that the F117 of DCN1 in the 
P1 pocket is rotated as compared to F117 in the co-crystal structure of DCN1 in complex 
with the UBC12 peptide and in this way a larger binding pocket to accommodate DI-591 
is created. Our docking simulations indicated that the corresponding conserved residue 
in DCN3 would have to rotate in order to accommodate ligands such as compounds 1-3. 
Therefore, we applied the rotation of F117 in DCN1 that was observed in the co-crystal 
structure of DI-591 in a complex with DCN1 (PDB ID: 5UF1) to a phenylalanine, F142 in 
DCN3 for molecular docking simulations in this study (Figure 3.3A). As described above, 
the major structural difference in the P1 pocket is that Met111 in DCN3 has been replaced 
by Ile86 in DCN1. Consistently, we observed that DCN3 has a narrower opening to the 
P1 pocket and prevents entry of the planar phenylthiazole ring of DI-591 (Figure 3.3A). 
This finding can explain why most of the compounds such as DI-591 with a fused-aromatic 
moiety in our DCN1 inhibitor library show no appreciable binding to DCN3 in the BLI 
assay.75, 76 On the other hand, the docking model for compound 1 in complex with DCN3 
suggests that compound 1 has a shape that permits its entry into the P1 pocket (Figure 
3.3B). The phenyl ring and the thiazole ring are in planes that have a dihedral angle of 
~45° between them. The thiazole ring forms an edge-π interaction with F189. The 
propionamide side chain fits well into the hydrophobic pocket formed by L128, L211, and 
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F189, and the phenylaniline fragment in 1 enjoys hydrophobic interactions with L128, 
L211, A207, L208 of the P3 pocket. The junction between the m-chlorophenyl ring and 
the thiazole ring in 1 is surrounded by V127 and M111 (Figure 3.3C), and the m-
chlorophenyl ring is surrounded by multiple hydrophobic residues in the deep P1 pocket 
of DCN3, including A131, L130, F134, F114, and F142 (Figure 3.3C). 
 
Figure 3.3 Modeling of DCN inhibitors on DCN1 and DCN3 proteins.  (A) 
Rotation of F117 observed in the crystal structure of DI-591 in complex with DCN1 
(PDBID: 5UFI) was applied to F142 in DCN3 to obtain docked poses of identified 
lead compounds 1-3 with DCN3. (B) Docking models of compound 1 with DCN3. 
Hydrogen bonds are depicted in yellow dashed lines. (C) Detailed view of the 
interaction of compound 1 with the P1 pocket of DCN3. 
3.2.4 Development of a fluorescence polarization-based, competitive binding 
assay for DCN3 
The ligand-free, BLI method is time-consuming and expensive and we developed 
a fluorescence polarization (FP)-based, competitive binding assay for DCN3 which 
supports rapid and accurate determination of the binding affinities of our synthesized 
DCN3 inhibitors.7,8   
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Our truncation analysis shows that in the BLI assay, the 9-residue UBE2FNAC1-9 
peptide binds to DCN3 with a Kd value of 2.73 µM (Table 3.1), which is comparable to that 
of the 25-residue UBE2FNAC1-25 peptide (Kd = 3.2 µM). After further shortening of the length 
of the 9-residue peptide producing the UBE2FNAC1-7 peptide, a dramatic decrease of 
binding affinity to DCN3 is observed (Table 3.1). We therefore employed the 9-residue 
UBE2FNAC1-9 peptide as the template for the development of a FP assay. 
In our modeled structures of these three initial DCN3 lead compounds, the 
substituted phenylthiazole group occupies the P1 binding pocket (Figure 3.3B). To obtain 
a high-affinity ligand for DCN3, we replaced the methionine residue side chain in the 
UBE2FNAC1-9 peptide with a 3-chlorophenyl-4-methylthiazole group. The resulting 
compound, TC-6038, has a Kd value of 75.7 nM, and is 36 times more potent than the 
UBE2FNAC1-9 peptide. Based on TC-6038, we added a lysine residue at the C-terminus to 
tether with 5-carboxyfluorescein (5-FAM), which led to the design of a fluorescently 
tagged peptide tracer (DCN3-Flu0). Unfortunately, the tracer DCN3-Flu0 has a Kd value 
of 484 nM in the BLI assay, which is adequate but not ideal for the development of a 
sensitive and accurate FP assay. In the crystal structure of DCN3 in complex with UBE2F, 
the Thr3 residue of UBE2F does not interact directly with DCN3, but there are two 
negatively charged residues, D192 and E194 approximately 7.5 Å away from the T3 
residue. Modeling suggested that mutation of the Thr3 residue to arginine would present 
additional hydrogen bonding interactions with D192 and E194. (Figure 3.4) Accordingly, 
we replaced the threonine residue in TC-6038 with arginine and the resulting compound, 
TC-6052, was found to have a Kd value of 45.7 nM, 2-times more potent than TC-6038. 
Based upon TC-6052, we synthesized DC3-Flu1 as a new tracer, which was determined 
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to have a Kd value of 184 nM in the BLI assay (Table 3.2). Our titration experiments 
determined that DC3-Flu1 has a Kd value of 139 nM to DCN3 (Figure 3.5), consistent with 
the Kd value obtained from the BLI binding assay. Importantly, the ΔmP value for DC3-
Flu1 is 120, which provides a large signal-to-noise ratio. Consequently, we have 
developed a competitive FP assay using DC3-Flu1 for determination of the binding 
affinities of our designed DCN3 inhibitors. 
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Table 3.2 Binding Affinity of Mutated UBE2F Peptides and the Tracers Determined in BLI 
Binding Assay 
 
Compound Structure Kd (nM)
TC-6038 85.8 ± 11.6
DCN3-Flu0 484 ± 175
TC-6052 46 ± 11
DCN3-Flu1 184 ± 42
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Figure 3.4 Modeled truncated UBE2F with T3R mutation with DCN3  Modeled 
structure of the T3R mutated UBE2F peptide with DCN3 based upon the co-crystal 
structure of DCN3 in complex with a UBE2F peptide (PDBID: 4GBA). DCN3 and 
the mutated UBE2F peptide are labeled in black and red respectively. Hydrogen 
bonds are depicted in yellow dashed lines. 
We evaluated the binding affinities of compounds 1-3 to DCN3 in the competitive FP 
assay. Compounds 1, 2 and 3 have IC50 values of 3.2, 4.5 and 5.2 µM, respectively, and 
have calculated Ki values of 0.67, 0.43 and 0.53 µM, respectively. We employed 




Figure 3.5 Binding isotherm of DCN3-Flu1 to DCN3 protein. 
 
3.2.5 Structure-activity relationship studies of the P1 binding pocket 
In our predicted binding model for compound 1 in a complex with DCN3, the m-
chloro substituent on the phenyl ring fits into the hydrophobic P1 pocket formed by A136, 
A131, F134 and F142 (Figure 3.3C). To further probe the importance of the meta-
substitution, we synthesized a series of compounds. 
Removal of the m-chloro substituent from the phenyl ring in compound 1 gave 
compound 4, which shows no significant binding up to 10 µM. Changing the position of 
the chlorine substituent from the meta to the ortho- or the para-position yielded 
compounds 5 and 6 respectively, neither of which show any appreciable binding to DCN3 
at concentrations up to 10 µM. Replacement of the substituted phenyl in compounds 1-3 
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with a cyclohexyl group resulted in compound 7, which also has no binding affinity to 
DCN3 up to 10 µM (Table 3.2). 
 
Table 3.3 Structure-activity relationship studies to probe the P1 binding pocket.  
 
3.2.6 Structure-activity relationship studies of the P2 binding pocket 
In our design of DCN1 inhibitors, we showed that the propionamide group in DI-
591, which interacts with the P2 pocket, is optimal for binding to DCN1.75, 76 Our analysis 
of the crystal structures showed that DCN1 and DCN3 are significantly different in their 
P2 pockets (Figure 3.3A). Accordingly, we made extensive modifications to our DCN3 
inhibitors with the objective of improving the binding affinity to DCN3 and at the same time 
reducing the binding affinity to DCN1 to obtain selective DCN3 inhibitors. The obtained 
SAR data are summarized in Table 3.4. 
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Table 3.4 Structure-activity relationship studies to probe the P2 binding pocket. 
 
 
Changing the propionamide group to acetamide resulted in compound 8, which has no 
appreciable binding to DCN3 up to 10 µM but still binds to DCN1 with an IC50 value of 2.4 
µM. Replacing the propionamide group with an isobutyramide group yielded compound 
9, which shows no binding to DCN3 up to 10 µM but binds to DCN1 with an IC50 value of 
1.3 µM. Changing the propionamide group to benzamide yielded compound 10, which 
fails to bind to either DCN3 or DCN1 up to 10 µM. 
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 In the co-crystal structure of DCN1 in a complex with DI-591, the carbonyl group 
of the propionamide group in DI-591 forms a hydrogen bond with the hydroxyl group of 
the Tyr181 side chain in DCN1. (Figure 3.3B) The Tyr181 residue in DCN1 is replaced by 
a phenyalanine residue (Phe189) in DCN3. Consequently, we have synthesized 
compound 11, in which the carbonyl group in compound 10 has been removed. 
Compound 11 binds to DCN3 with an IC50 value of 1.1 µM (Ki = 276 nM) and binds to 
DCN1 with an IC50 value of 7.7 µM (Ki = 2.4 µM). Hence, compound 11 is a moderately 
potent DCN3 inhibitor which, based upon the Ki values shows a 9-fold selectivity over 
DCN1. 
We installed a chlorine atom at the meta, ortho, or para-position of the phenyl ring 
in 11, obtaining compounds 12, 13 and 14, respectively. Compound 12 with a m-chlorine 
and 14 with a p-chlorine bind to DCN3 with IC50 values of 1.6 µM and 3.9 µM, respectively. 
However, 13 with an o-chlorine shows no binding to DCN3 up to 10 µM. We then placed 
a fluorine atom at the meta, ortho, or para-position of the phenyl ring in 12 and obtained 
15, 16 and 17, respectively.  Compounds 15, 16 and 17 bind to DCN3 with IC50 values of 
0.92 µM, 4.6 µM and 0.56 µM, respectively. Encouraged by these results, we synthesized 
the 3,4-difluoro compound 18 and the 3,5-difluoro compound 19 and found that they bind 
to DCN3 with IC50 values of 0.83 and 0.79 µM, respectively. 
We tested the binding affinities of these potent DCN3 inhibitors (15 – 19) to DCN1 
to determine their selectivity. All these compounds have IC50 value >10 µM, except 17 
which has IC50 value of 5.38 µM. While 15, 16 and 18 show partial inhibition of DCN1 at 
10 µM, 19 has no appreciable binding to DCN1 up to 10 µM. Hence, compound 19 is a 
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potent (Ki = 190 nM) and selective DCN3 inhibitor over DCN1.  We next performed further 
optimization on compound 19. 
3.2.7 Structure-activity relationship studies of the P3 binding pocket  
In both DCN1 and DCN3, the P3 pocket is a shallow, hydrophobic pocket, partially 
exposed to solvent. While the P3 pocket in DCN1 interacts with an isoleucine residue in 
UBC12, the P3 pocket in DCN3 interacts with a leucine residue in UBE2F. Comparison 
of the DCN1 and DCN3 P3 pockets showed that DCN3 has a slightly larger P3 pocket 
than DCN1. We performed modifications of 19 to probe the P3 pocket in DCN3, obtaining 
the results in Table 3.5. 
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Table 3.5 Structure-activity relationship studies to probe the P3 binding pocket 
 
For modifications of this site, we changed the primary amine in compound 19, 
which is directed towards the solvent exposed area to a dimethylamine with the objective 
of improving the cell permeability83. This yielded compound 20, which binds to DCN3 with 
an IC50 value of 0.72 µM (Ki = 150 nM), similar to 19.  Compound 20 shows no appreciable 
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binding to DCN1 up to 10 µM. Hence, 20 has a good affinity to DCN3 and an excellent 
binding selectivity over DCN1, so we employed 20 as the new template for subsequent 
modification. 
To assess the importance of the hydrophobic interactions of the benzyl group in 
compound 19, we synthesized 21 in which the benzyl group has been replaced by a 
methyl group.  Compound 21 binds to DCN3 with an IC50 value >10 µM, confirming the 
importance of the hydrophobic interactions with the P3 pocket. Replacing the methyl 
group in 21 with isobutyl resulted in 22, which has an IC50 value of 1.2 µM to DCN3 and 
only a very weak affinity for DCN1 (IC50 >10 µM). Changing the methyl group in 21 to a 
cyclohexyl yielded 23, which has a good affinity for DCN3 (IC50 = 368 nM) and a poor 
affinity for DCN1 (IC50 > 10 µM). Replacement of the methyl group in 21 with a 
methylcyclohexyl group led to 24, which binds to DCN3 with an IC50 value of 316 nM and 
has a weak affinity to DCN1 (IC50 > 10 µM).  
We next performed modifications of the phenyl group in 20 by installation of a 
chlorine substituent at the ortho-, meta- or para-position, which yielded 25, 26 and 27, 
respectively. Compounds 25, 26 and 27 bind to DCN3 with IC50 values of 2.99, 1.25 and 
0.70 µM, respectively and have no appreciable binding to DCN1 up to 10 µM.  Because 
27 with a p-chloro substituent has a better affinity to DCN3 than 25 and 26 with o-chloro 
or m-chloro substituents, we evaluated other groups at the para-position. We synthesized 
compound 28 with a p-fluoro, 29 with a p-trifluoromethyl, 30 with a p-methyl, 31 with a p-
ethyl and 32 with a p-hydroxyl. Compounds 28, 29, 30, 31, and 32 bind to DCN3 with IC50 
values of 1.2, 6.5, 0.31, 3.9 and >10 µM, respectively. These five compounds show no 
appreciable binding to DCN1 up to 10 µM. In fact, 30 (TC-6304) with a p-methyl 
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substituent on the phenyl ring only shows 15% inhibition of DCN1 in the competitive FP 
assay at 30 µM. Hence, 30 (TC-6304) with a p-methyl substituent on the phenyl ring 
demonstrates a good binding affinity to DCN3 (IC50 = 0.31 µM and Ki = 35 nM) and a 
binding selectivity of > 100-fold over DCN1. 
We further probed this P3 pocket by synthesizing compounds 33 and 34 which 
both contain a larger, hydrophobic group. Compound 33 with a 2,3-dihydro-1H-indene 
and 34, containing a 3-methyl-1H-indole group have IC50 values of >10 µM to DCN3, 
confirming that these groups are too large to be accommodated in the P3 pocket. 
3.2.8 Computational docking study of (TC-6304) 
TC-6304 binds to DCN3 with a high binding affinity and demonstrates an excellent 
binding selectivity over DCN1. To gain an insight into the high binding affinity of TC-6304 
to DCN3, we performed a computational docking study of TC-6304 and DCN3. 
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Figure 3.6 Computatioanl Docking of TC-6304 with DCN1/3  (A) Docking model 
of TC- 6304 with DCN3. Hydrogen bonds are depicted in cyan dashed lines. (B) 
Alignment of the docking model of TC-6304 with DCN1 (purple color) to DCN3. 
The predicted binding model for TC-6304 in a complex with DCN3 (Figure 3.6) 
shows that the m-chlorophenyl thiazole moiety interacts with the residues forming the P1 
pocket in a highly complementary manner. The m-chlorophenyl and thiazole moieties 
adopt a twisted relationship with a dihedral angle of 45° in order to fit into the P1 pocket. 
A hydrogen bond is observed between the backbone carbonyl of P122 of DCN3 and the 
NH moiety of the 3,5-difluoroaniline group of TC-6304.  The 3,5-difluoroaniline group fits 
nicely into the P2 pocket and has close hydrophobic contacts with the L208, L211 and 
L128 residues of DCN3. The 4-methyl-benzyl group interacts with residues F189, L208, 
A207, I204 and M139 which form the P3 pocket. The dimethylamino group is exposed to 
solvent and has no specific interactions with DCN3.  
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3.2.9 Evaluation of the interaction of TC-6304 with DCN3 protein in cells  
The cellular thermal shift assay (CETSA)72 is a powerful assay with which to determine if 
a small molecule ligand interacts with the intended target in cells by examining enhancement of 
the thermal stability of the targeted protein. We employed a CETSA experiment to evaluate the 
effect of compound 30 (TC-6304) on the thermal stability of both DCN3 and DCN1 proteins in 
cells (Figure 3.7). 
 
Figure 3.7 The cellular thermal shift assay. Examination of the thermal stability 
of DCN3 and DCN1 proteins in cells treated with a selective DCN3 inhibitor TC-
6304, its enantiomeric control compound TC-6304DD and our previously reported 
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selective DCN1 inhibitor DI-591. A549 cells were treated for individual compound 
at indicated concentrations for 1 h. The protein level of DCN3 or DCN1 was 
examined by western blotting analysis, with GAPDH used as the loading control. 
Our results show that TC-6304 effectively enhances the thermal stability of cellular 
DCN3 protein in a dose-dependent manner and has no significant effect on the thermal 
stability of cellular DCN1 protein. In contrast, DI-591, our previously reported selective 
DCN1 inhibitor effectively stabilizes cellular DCN1 protein at 1 µM but has no effect on 
the thermal stability of DCN3 protein. The CETSA experiment provides direct evidence 
that TC-6304 interacts with DCN3 in cells.   
3.2.10 Evaluation of TC-6304 for its effect on neddylation of cullin E3 ligases in cells 
In our previous study,7 we demonstrated that DI-591, a DCN1 inhibitor selectively inhibits 
neddylation of cullin 3 and has a minimal effect on the neddylation of other cullin 
members. We evaluated TC-6304 for its effect on neddylation of different cullin E3 ligases 
in cells, obtaining the results shown in Figure 3.8. 
 As expected, MLN4924, an E1 inhibitor, effectively inhibits neddylation of all 
cullins. Consistent with our previous data, DI-591 effectively and selectively inhibits 
neddylation of cullin 3. However, TC-6304 has no effect on the neddylation of all cullins 
at all concentrations tested. Although more studies are clearly needed to further 
investigate the biological consequence of selective binding to DCN3 by TC-6304, our data 
clearly show that DCN3 and DCN1 proteins have very different roles in regulation of 
neddylation activity of cullin E3 ligases. 
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Figure 3.8 . Evaluation of the effect of a selective DCN3 inhibitor TG-6304 on 
neddylation of different cullins in cell.  Lung cancer A549 cells were treated 
with TG-6304, DCN1 inhibitor DI591, or an inactive control TG-6304DD and an E1 
inhibitor MLN4924 for 24 h. Protein levels of neddylated (active) and un-neddylated 
(inactive) different cullin proteins, as well as DCN3 and CDT1, were examined by 




As shown in Scheme 1, a fluorescent labeled tracer (DCN3-Flu1) was produced by 
solid-phase peptide synthesis. 5-Carboxyfluorescein succinimide ester (5-FAM, SE) was 
attached to the side chain of the Lys of the linear peptide via a linker.8 
Scheme 3.1 Synthesis of tracer DCN3-Flu1. 
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Scheme 3.2 General Synthetic Route for Amino Acid 38 
 
The unnatural amino acid (38) was synthesized as shown in Scheme 2. The acid 
group of Fmoc-Asp-O-t-Bu (35) was converted to an acetamide then transformed to a 
thioamide using Lawesson’s reagent, giving compound 36. Cyclization of methylthiazole 
by the reaction of chloroacetone with 36 followed by bromination using NBS, and 
deprotection of the BOC by TFA, provided 37. Suzuki coupling of 37 with 3-
chlorophenylboronic acid led to compound 38.  
Scheme 3.3 Synthesis of compounds 1-7. 
 
The general method for the synthesis of compounds 1-7 is shown in Scheme 3. 
Compound 39 was produced by coupling 37 with tert-butyl (2-amino-3-phenylpropyl)
carbamate using HATU as the coupling reagent, and was followed by removal of the Fmoc 
protecting group by treatment with diethylamine to allow the installation of a propionyl 
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group to the amine.  Suzuki coupling of 39 with various R-substituted boronic acid gives 
compounds 1-7. 
Scheme 3.4 Synthesis of compounds 8-19. 
 
The general method for the synthesis of compounds 8-19 is shown in Scheme 4. 
The common intermediate (40) was produced by coupling 38 to tert-butyl (2-amino-3-
phenylpropyl)carbamate with HATU as coupling reagent, and this was followed by 
removal of the Fmoc protecting group by treatment with diethylamine. The primary amine 
(40) was reacted with acyl chloride to produce compounds 8-10. The Ullman-type N-
arylation coupling84 was carried out to install various aromatic rings on the N-terminus of 
40, giving compounds 11-19.  
Scheme 3.5 Synthesis of compounds 20-34. 
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The general method for the synthesis of compounds 8-19 is shown in Scheme 5. 
Compound 41 was synthesized using the method described in Scheme 2. N-arylation of 
41 was performed using the Ullman coupling reaction with 1,3-difluoro-5-iodobenzene to 
give compound 42. Compounds 20-34 were synthesized by coupling of 42 with different 
R-substituted amines (Scheme 5) with HATU as coupling agent.  
3.4 SUMMARY 
In this study, we report our design, synthesis and evaluation of non-peptide, small 
molecule ligands targeting the protein-protein interactions of DCN3 with UBC2E and 
UBC12, both of which are DCN3 binding partners in the cullin E3 ligase complexes. By 
screening our in-house chemical library of small-molecule DCN1 inhibitors, we identified 
three initial lead compounds, which belong to the same chemical class. Our subsequent 
structure-activity relationship studies, guided by structure-based design, have yielded a 
series of potent and highly selective DCN3 inhibitors, exemplified by TC-6304, which 
binds to DCN3 with a Ki = 35 nM and shows minimal binding to DCN1 up to 30 µM. Our 
CETSA data provides direct evidence that TC-6304 is cell-permeable, interacts with 
DCN3 protein in cells, and is capable of enhancing the thermal stability of DCN3 at low 
nanomolar concentrations. Furthermore, TC-6304 has no effect on the thermal stability of 
cellular DCN1 protein, whereas our previously reported selective DCN1 inhibitor DI-591 
effectively enhances the thermal stability of DCN1 protein but not of the DCN3 protein. 
While DI-591 effectively and selectively inhibits the neddylation of cullin 3, TC-6304 has 
no obvious effect on neddylation of any of the cullin members examined, indicating that 
DCN3 and DCN1 play very different roles in regulation of the neddylation of cullin proteins 
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and the activation of cullin E3 ligase complexes. This study has yielded first-in-class, 
potent, selective and cell-permeable DCN3 inhibitors with TC-6304 being the best 
example. Further studies are ongoing to further investigate the biological consequences 
of selective binding to DCN3 and blocking the interactions with its binding partners using 
TC-6304 and the results will be reported in due course. 
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Chapter 4 Discovery of Potent Small-Molecule Inhibitors of Mixed-Lineage 
Leukemia (MLL) Methyltransferase 
 
4.1 Introduction 
Rearrangements of the mixed-lineage leukemia (MLL) gene, also known as MLL1, 
have been detected in >70% of acute lymphoblastic leukemias (ALL) in infants and 5-
10% of acute myelogenous leukemias (AML) in adults.21, 22 AML patients carrying the MLL 
fusion gene have MLL leukemia, expect a very poor prognosis and are unresponsive to 
current treatments.  There is therefore an urgent need to develop new therapeutic 
strategies for MLL leukemia. 
MLL protein is a lysine methyltransferase, responsible for Histone 3 Lysine 4 
(H3K4) methylation. MLL translocations invariably occur on only one MLL allele. Because 
the MLL fusion proteins contain no SET [Su(var)3-9, Enhancer-of-zeste and Trithorax] 
domain, which is the catalytic unit of MLL, MLL translocations lead to a loss of the H3K4 
methyltransferase activity, but the remaining wild-type MLL allele retains the H3K4 
methyltransferase activity. It has been shown that both the wild-type and fusion MLL 
proteins are required for MLL-AF9-induced leukemogenesis and maintenance of MLL-
AF9-transformed cells. Therefore, inhibition of the H3K4 methyltransferase activity of MLL 
has been proposed as an attractive therapeutic strategy for the treatment of MLL 
leukemia.  
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Although MLL protein contains a catalytic SET domain, the protein itself has very 
low histone methyltransferase (HMT) activity.25 When MLL protein forms a complex with 
WDR5, RbBP5 and ASH2L, its HMT activity is dramatically enhanced.25 Therefore, 
targeting the protein-protein interactions within the MLL complex, in particular the WRD5-
MLL protein-protein interaction, has been pursued as a strategy to inhibit the MLL HMT 
activity.  In the last few years, we have reported the discovery of highly potent and cell-
permeable peptidomimetics of the WDR5-MLL protein-protein interaction.27 Potent, non-
peptidic, small-molecule inhibitors of the WDR5-MLL interaction have also been 
reported.28, 29 
Because MLL is a methyltransferase, an alternative therapeutic strategy is to 
develop small-molecule inhibitors that bind to its active site and directly block its HMT 
enzymatic activity.  This strategy has been successfully employed for the design of direct 
inhibitors for a number of histone methyltransferases including MMSET,48 SET7/9,46, 47 
SMYD3,49 SETD2,50 EZH2,51 and DOT1L52, 53 but, to date, no direct MLL inhibitor has 
been reported. 
Like other methyltransferases, MLL employs S-adenosylmethionine (SAM or 
AdoMet) as a major methyl donor which engineers the transfer of a methyl group to 
histone lysine residues.33, 85 In the present study, we describe the discovery of first-in-
class, potent, direct MLL inhibitors,  through the design, synthesis and evaluation of a 
SAM-based focused chemical library.  
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4.2 Results and Discussion 
4.2.1 Design of a Focused Chemical Library Based upon SAM 
Our strategy was to synthesize small molecules that mimic the transition state of 
the methylation chemical reaction of the lysine substrate by incorporation of the cofactor 
SAM with a portion of the lysine substrate as illustrated in Figure 4.1 (A). 
In our design, the adenosine and the 2-aminobutanoic acid moieties were retained 
because they are structural moieties necessary for binding to the cofactor binding site. 
The positively charged sulfur atom in the transition state structure was replaced with a 
nitrogen atom. To identify optimal moieties that mimic the transition state structure, we 
systematically explored various primary, secondary or tertiary amines, as well the linker 
length between the two nitrogen atoms in the potential inhibitor. We further attached either 
an aliphatic or an aromatic hydrophobic fragment to the nitrogen to explore the chemical 
space around the lysine tunnel that is known to be responsible for the selectivity between 
different methyltransferases. This focused chemical library was categorized, based upon 
the nature of the group attached to the nitrogen atom mimicking the charged sulfur atom, 
into the following eight Groups: pure aliphatic, cyclobutene amine, cyclobutene methylene 




Figure 4.1 Mechanism of lysine methylation and the Designed focused 
library.  Design of a focused SAM-based library.  (A) Proposed mechanism of 
lysine methylation catalyzed by SAM-dependent lysine methyltransferases. (B) 
Designed SAM analog library based on the proposed transition state structure. The 
library contains 8 Groups: aliphatic, I (azetidine), II (ethylamine), III (cyclobutane 
amine), IV (methylene azetidine), V (propyl amine), VI (cyclobutane methylene 
amine) and VII (triazole). The R functional groups include either an aliphatic or an 
aromatic hydrophobic fragment. 
4.2.2 Identification of MLL Inhibitors by Screening the Focused Chemical Library 
We screened this focused compound library for their ability to inhibit MLL 
methyltransferase at a single concentration of 10 μM and obtained the results shown in 
Figure 2. This screening led to the identification of 5 compounds, each of which achieved 
>90% inhibition of the MLL HMT activity. Additionally, 5 other compounds were found to 
achieve 70-80% inhibition of the MLL HMT activity. 
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Among the compounds tested, 4 out of the 5 compounds containing a methylene 
azetidine (Group IV) inhibit the MLL activity by >90%. In contrast, all the compounds in 
the aliphatic subset exhibit less than 40% inhibition. 





















Figure 4.2 Result of Single Dose Screening against MLL1 Methyltransferase.  
Categorical scatterplot representation of the results of focused library screened 
against MLL methyltransferase using an HMT assay at a single concentration of 
10 μM. Red-dashed line represents 90% inhibition cutoff. 
4.2.3 Validation of the Screening Hits 
To validate the screening hits, we determined the IC50 values for all compounds 
which achieved >85% inhibition in the screening using the Alpha LISA assay that we have 
developed for MLL.86 For Groups VI and VII, in which no single compound inhibited the 
MLL activity by >85%, we selected a representative compound with the highest inhibition 
and evaluated it in the MLL Alpha LISA assay. We included SAH (S-Adenosyl-L-
homocysteine), a known pan-HMT inhibitor, as a positive control.34 The results of these 
validation experiments are summarized in Table 4.1. 
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In the MLL Alpha LISA assay, SAH has an IC50 value of 724 nM. The most potent 
inhibitors in Groups I-II are 2-3 times more potent than SAH. The most potent inhibitor in 
Group III has an IC50 of 127 nM and is thus 5-times more than potent than SAH. Four 
compounds in Group IV, including compound 5, achieve the highest potencies with IC50 
values of 21-72 nM, and are >10-times more potent than SAH. The most potent 
compound in Group V has an IC50 value of 201 nM and is 3-times more potent than SAH. 
The most potent compound in Group VI has an IC50 value of 415 nM, similar to that of 
SAH. The most potent compound in Group VII has an IC50 value of 132 nM and is thus 5-
times more potent than SAH.   
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Table 4.1 Results of hit validation using Alpha LISA assay for MLL1 methyltransferase. 
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4.2.4 Further Modifications of the Most Potent Compound 5  
Compound 5, with an IC50 value of 21.8 nM is the most potent MLL inhibitor 
identified in the focused chemical library. We performed further modifications of the 
azetidine in 5 to gain a further understanding of the SAR for this site with the results 
summarized in Table 4.2. 
Substitution of the azetidine NH in 5 with a benzyl group resulted in compound 11, 
which has an IC50 value of 47 nM and is thus 2-times less potent than 5. Substitution of a 
chlorine atom onto each of three different positions of the phenyl ring in 11 led to a modest 
decrease in inhibitory potency (2-3 times). Replacing the phenyl group in 11 with 2-
thiophenyl or 3-thiophenyl yielded 16 and 15, respectively. While 16 has an IC50 value of 
67 nM, which is 3-times less potent than 5, compound 15 is equipotent with 5. 
Table 4.2. SAR of subset IV compounds. 
 
 74 
4.2.5 Determination of Co-Crystal Structures of MLL Inhibitors in a complex with 
MLL1 SET Domain  
To understand the structural basis for their potent inhibition of MLL activity, we 
determined co-crystal structures for 4 inhibitors: compound 16 (TC-5109), 14 (TC-
5139), 12 (TC-5140) and 18 (TC-5153) in a complex with the MLL SET domain. 
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Figure 4.3 Crystal structures of inhibitor and MLL1 methyltransferase. (A) 
Crystal complex of N-azetidine SAM analogs with MLL SET domain, SAH and the 
H3K4 substrate (PDB ID: 2W5Z). (B) Detailed view of compound TC-5140 in a 
complex with MLL. Yellow spheres are the calculated coordinate of the center of 
mass of the phenyl ring. The red dashed lines show the conserved hydrogen bond 
network. The yellow dashed line is cation-π interaction. The purple line is an edge-
face π-π interaction. The cyan dashed line shows intramolecular charged-charged 
interaction. (C) Superimposed structure of MLL, compound 18 (TC-5153) complex 
and MMSET/SETD2 and N-alkyl Sinefungin complex (PDB ID: 5LSY), SET-I 
domain colored purple and green in MLL and MMSET/SETD2, respectively. (D) 
Superimposed structure of MLL, TC-5153 complex and EZH2 and GSK126 
complex (PDB ID: 5WG6), SET-I domain colored purple and green in MLL and 
EZH2, respectively. 
 These co-crystal structures showed that the binding modes of adenosine and the 
α-amino-acid moieties of these 4 inhibitors align closely to the same moieties of SAH in 
its co-crystal structure with the MLL SET domain (PDB: 2W5Z). Unexpectedly, the 
methylene azetidine moiety in these inhibitors binds not to the lysine tunnel but is directed 
towards the solvent exposed site (Figure 3 A). The methylene azetidine moiety also forms 
an intramolecular salt bridge with the α-amino acid of the inhibitors and engages in a 
cation-aromatic interaction with Tyr3883 as shown in the MLL/TC-5140 structure (Figure 
3B). We also observed an edge-to-face π-π interaction between the chlorophenyl of TC-
5140 and His3839 at a distance of 4.2 Å. The aromatic-His3839 interaction was also 
found in the co-crystal structures of MLL in complex with TC-5109 and TC5139 containing 
a thiophene and a diphenyl group, respectively (Figure 3A). These crystal structures 
suggest that the azetidine group in our inhibitors provides the conformational orientation 
to permit additional interactions between the tail groups of the inhibitors and the MLL SET 
domain. 
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 Previous structural studies indicated that MLL has a more spacious active site and 
a more open lysine binding groove than other histone methyltransferases.87, 88 
Superimposition of our MLL SET domain structures with three closely aligned lysine 
methyltransferases (MMSET, SETDB2, EZH2) shows that the orientation of  SET-I of MLL 
is the only significant variation as it moves away from the C-flanking region 88 (Figures 3 
C, 3 D). The alignment further indicates that the loop preceding SET-I in MMSET, SETDB2 
and EZH2 would sterically clash with the N-azetidine moiety in our inhibitors. Previous 
studies also suggest that the SET-I must be reoriented to adopt a “closed” conformation 
in order to exert full catalytic activity on SAH.88, 89 Our co-crystal structures therefore 
suggest that our designed MLL inhibitors may lock the MLL SET domain into an “open” 
and consequently inactive conformation. Taken together, our co-crystal structures provide 
a structural basis for the high affinity interactions between these MLL inhibitors with MLL 
and for further structure-based optimization.  
4.3 Chemistry 
Scheme 4.1 Synthesis of compounds 11-18 
 
(a) tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-4-oxobutanoate, NaHB(OAc)3, 
DCE, rt, 4 h; (b) benzyl 3-formylazetidine-1-carboxylate, NaHB(OAc)3, DCE, rt, 3 
h; (c) H2, Pd/C, MeOH, rt, 1 h; (d) RCHO,  NaHB(OAc)3, DCE, rt, 2 h; (e) TFA, 
DCM, rt, 1 h. 
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The synthesis of compounds 11-18 containing a substituted N-azetidine series is 
illustrated in Scheme 1. Reductive amination of compound 19 with tert-butyl (S)-2-((tert-
butoxycarbonyl)-amino)-4-oxobutanoate produced compound 20. Compound 21 was 
prepared by reductive amination of compound 20 with  benzyl 3-formylazetidine-1-
carboxylate, NaHB(OAc)3 and DCE followed by removal of the protecting group by 
hydrogenation. Reductive amination of various aldehydes (RCHO) with compound 21 and 
the subsequent deprotection provided the final compounds 11-18.  
 
4.4 Summary 
In summary, we designed a library focused on SAM-analogs using a bisubstrate 
strategy intended to profile different methyltransferases. We use this chemical library to 
screen for inhibitors of MLL methyltransferase and found several compounds with potent 
inhibitory activity. Among them, compound 16 (TC-5115) exhibited an IC50 value of 16 nM. 
Co-crystal structures of MLL in complex with 4 potent inhibitors were determined, which 
revealed that these inhibitors may lock the MLL SET domain in an open, inactive 
conformation. 
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The goal of my work presented in this dissertation was to fill the unmet need for 
compounds that can be used to interrogate the biology of the Cullin-RING ubiquitin 
ligases (CRLs) and the MLL1 methyltransferase. We conducted structure-based design, 
organic synthesis, and biochemical/biophysical assays to discover potent inhibitors 
targeting DCN1, DCN3 and, MLL1 methyltransferase.   
In Chapter 2 of this dissertation, we have described the importance of the ubiquitin-
proteasome system for maintaining the homeostasis of the cell and its relevance to 
disease. CRLs are the largest family of the E3 ligase, and its activation requires 
neddylation on the cullin protein. After thoroughly investigating the structural topology and 
the interface among all components of the Cullin1-CRL complex, we hypothesized that 
we could achieve individual CRL inhibition by targeting the DCN1-UBC12 protein-protein 
interaction. We performed systematic truncation on the N-terminus of UBC12 and 
identified a tetrapeptide lead compound. The co-crystal structure of this tetrapeptide with 
DCN1 revealed identical binding mode as the DCN1-UBC12 complex. We next optimized 
its interaction with P1-P4 hydrophobic pocket on DCN1, as well as the physical-chemical 
properties, yielded DI-404 with Ki value of 6.7 nM. The cellular thermal shift assay 
demonstrated that DI-404 engage DCN1 in cells. In western blot experiments, we 
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observed that DI-404 selectively inhibit the neddylation of cullin 3. Also, a well-known 
substrate of cullin 3 CRL, NRF2 protein, was accumulated. We envision this tool 
compound could be used to investigate the biology of cullin 3 CRL. Further optimization 
based on this compound may ultimately yield new therapeutics for diseases related to 
cullin 3 CRL.  
The proof-of-concept study in Chapter 2 showed that selective cullin 3 CRL 
inhibition can be achieved by targeting protein-protein interaction within the CRL complex, 
specifically the interface of DCN1/UBC12. Encouraged by this finding, we reasoned that 
targeting other DCN family protein / E2 enzyme protein-protein interaction might inhibit 
other cullin family CRL functions. Through the literature survey, our analysis suggested 
that targeting DCN3 and UBE2F protein-protein interaction could be an alternative means 
for manipulating other CRLs. In the DCN1 project, we have made a significant number of 
small molecules during the iteration of the optimization process. Given that DCN1 and 
DCN3 shared similar binding sites, it is possible to find moderately active compounds that 
bind DCN3. Therefore, in Chapter 3 of the dissertation, we described reversing the 
selectivity profile from DCN1 to DCN3 by structure-based design.  
Since this DCN1-inhibitor library is highly tailored for DCN1, we only found three 
lead compounds with IC50 value less than 10 µM against DCN3 in the label-free, biolayer 
interferometry assay. Based on the chemical scaffold of the lead compounds, and our 
truncation analysis of UBE2F peptide, we designed and synthesized a fluorescently 
tagged peptide tracer DCN3-Flu1 (Kd = 138 nM) for fluorescence polarization assay 
development. Through extensive optimization for three hydrophobic pockets of DCN3, we 
discovered TC-6304 with a Ki value of 35 nM showing no binding up to 30 µM. In the 
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cellular thermal shift assay, we did observe a dose-dependent engagement of TC-6304 
with DCN3 in the cell. However, we did not find any significant change in cullin-
neddylation in all cullins tested. To our knowledge, our effort in Chapter 3 is considered 
to be the first documented report of potent DCN3 inhibitor.  
Chapter 4 is a collaborative project with the laboratory of Dr. Yali Dou. We aimed to 
develop tool compounds to address the question about the general function of H3K4 
methylation regulated by direct targeting the MLL SET domain. We first designed a 
focused chemical library based upon SAM to extensively explore the chemical space in 
the lysine tunnel in the MLL1 SET domain active site. Among this focused library, we 
identified a group of compounds with methylene azetidine moiety exhibited >90% 
inhibitory activity against MLL1 in a single-dose preliminary screening. The hits are 
validated by MLL Alpha LISA assay showing this group of compounds did outperform 
other groups of inhibitors. Further modifications yielded compound TC-5115 with IC50 
value of 15 nM for MLL1, which is 48 times more potent than the pan-methyltransferase 
inhibitor, SAH. Given that there is yet no reported potent MLL1 SET domain inhibitor, our 
compound is the first documented effort for direct targeting MLL1 SET domain.  
Collaborating with the laboratory of Dr. Jeanne Stuckey, we obtained four cocrystal 
structures of our inhibitor with MLL1 SET domain. All inhibitors share the same binding 
mode with SAH, and a similar molecular interaction between SAH and MLL1 was 
observed. The additional interaction between MLL1 and inhibitors explained the gain of 
the potency of Group IV compounds. Interestingly, we also observed a unique binding 
mode which is not seen in literature reported SAM-based methyltransferase inhibitors. 
The moiety that was designed to target the substrate-binding site bent over to the solvent-
 81 
exposed site and interact with the intrinsically flexible SET-I domain (motif) of MLL1. 
These crystal structures provide the solid starting point for further optimization, and I will 
discuss in detail in the next section.  
5.2 Future Directions 
5.2.1 The DCN project 
5.2.1.1 Screening against other proteins in the DCN family  
Our work described in Chapter 2 demonstrates the proof-of-concept that we can 
manipulate the individual CRL activity through targeting the protein-protein interaction of 
DCN1/UBC12 within the multi-component CRL complexes. In Chapter 3, although our 
potent DCN3 inhibitor did not show any significant effect on cullin neddylation, we 
demonstrated that it is possible to design other member of DCN family proteins through 
a structure-based design approach. In the DCN1 and DCN3 projects together, our efforts 
in medicinal chemistry work accumulated >350 compounds. Because DCN family 
proteins are homologous proteins, we could still utilize this in-house DCN1/3 inhibitor 
library for screening purposes. One challenge for this direction was that no crystal 
structure is available for DCN2, DCN4 and DCN5 in complex with the corresponding E2 
enzyme. Therefore, a well-refined homology model of those DCN proteins will be required 
to guide the optimization process.  
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5.2.1.2 Targeting other protein-protein integrations among different components in the CRL 
complex 
The primary goal for the DCN projects is to achieve selective inhibition of CRL.  In the 
analysis of the protein-protein interactions among components in the CUL1 CRL complex 
(RBX1~UBC12~NEDD8~CUL1~DCN1),9 we found that there are other potential PPI sites 
that could support inhibitor design. These potential interaction sites include CUL1-RBX1, 
UBC12-CUL1, RBX1-NEDD8, RBX1-UBC12, and NEDD8-CUL1 (Figure 5.1). However, 
those protein-protein interactions are not equally “druggable”. Further computational 
prediction tools such as SiteMap (Schrodinger, New York, NY)90 could be utilized to 
determine the best potential site for inhibitor design.  
 





5.2.2 The MLL1 methyltransferase project 
5.2.2.1 Structural modifications of current MLL1 inhibitors 
 
Figure 5.2 Further modifications of MLL1 inhibitors 
 
5.2.2.1.1 Improving the physical chemical properties 
In our design of SAM analogs that target MLL1 methyltransferase, we applied the 
bisubstrate approach. We replaced the sulfur atom of SAH with nitrogen and attached the 
amino acid to this nitrogen. Several fragments were attached to the amine to explore the 
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chemical space of the MLL1 SET domain. Although our compound achieved 2-digit 
nanomolar inhibitory acidity in vitro, activity in cells was not observed. From the literature, 
we found that it is common for SAM-based methyltransferase inhibitors to show potent 
inhibitory activity in biochemical assays but no cellular data is adduced. It has been 
suggested that adenine and the amino acid portion of SAM analogs are too polar. 
Interestingly, publications have shown that SAM itself can exert anticancer activity in 
various cancer cell lines.91, 92 One study showed that SAM alters the methylation 
landscape and has a dose-dependent effect on cell growth and invasion in the SKhep1 
cell line.93  
A modification to improve the physical chemical properties is shown in Figure 5.2. 
The modification is focused on the amino acid, the adenine, and the 2’- or 3’-hydroxyl 
moieties. The goal for the modifications is to reduce the hydrophilicity of the inhibitors. 
Earlier studies of the modifications on the SAH itself have been summarized in Chapter 
1. Briefly, most of the SAH modifications were either detrimental or resulted in weaker 
inhibitory activity. Removing the 2’-hydroxyl or 3’-hydroxyl moieties would be a first step, 
because MLL1 is one of the few HMTs that lacks hydrogen bond interactions. 
Replacement of adenine could be achieved by scaffold-hopping with computational 
simulation. Finally, the amino acid moiety would be very challenging because of its 
hydrogen bond network between HMTs.   
5.2.2.1.2 Targeting the lysine tunnel and the substrate binding site 
As was discussed in Chapter 4, we found from co-crystal structures, that our 
inhibitors do not occupy the lysine tunnel and the substrate binding site as molecular 
docking studies suggested.  Instead, the azetidine moiety and the hydrophobic tail are 
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directed towards the solvent exposed site. In addition, all four crystal structures share the 
same binding mode, suggesting that current inhibitors could serve as an anchor with 
which to extend to the substrate binding site. A proposed compound is illustrated in Figure 
5.2. The main purpose for this type of modification is to achieve the selectivity by 
optimizing the substrate binding pocket for MLL1.  
5.2.2.1.3 Design of MLL1 degraders (PROTAC) 
The PROTAC technology is an emerging approach to both therapeutic intervention 
and biological studies.94  PROTAC molecules are composed of a target protein inhibitor, 
a E3 binding ligand, and a linker between the two binders. PROTACs will bind 
simultaneously with the E3 ubiquitin ligase and the target protein, resulted in promotion 
of the ubiquitination and subsequent degradation of the target protein.94 To design a 
PROTAC, it is therefore necessary to determine which part of the inhibitor is directed 
towards the solvent exposed side of the protein. From the crystal structure, it is clear that 
an E3 ligase ligand and an appropriate linker could be attached the N-azetidine moiety 
as shown in Figure 5.2. One benefit of designing PROTAC structures is that we could 
attach a linker and an E3 ligase ligand to balance the hydrophilicity of SAM analog-based 
inhibitors. It is noted that MLL1 degraders will affect not only the catalytic function of SET 
domain. Other domains such as bromodomain, PHD domain might also be affected.  
5.2.2.1.4 Conformation restriction 
In all the crystal structures examined, we observed an intramolecular charge-
charge interaction between the carboxylic acid and the N-azetidine moiety. By covalently 
linking these two moieties while maintaining the bound conformation, lower entropy could 
be achieved and this could result in lower binding free energy.  
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5.2.2.2 Screening of current SAM-based library for other methyltransferases 
In this study, we discovered that the methylene azetidine (group IV) among the 
SAM-based library has binds preferentially to MLL1. In our effort to develop an MLL1 
methyltransferase inhibitor, we have prepared >150 SAM analogs in this library. We can 
utilize this in-house library to screen against other methyltransferases of interest. In fact, 
after three years since we initiated the MLL1 project, a research group in GlaxoSmithKline 
discovered a novel SMYD3 inhibitor GSK2807 with an IC50 value of 0.13 µM.54 GSK2807 
is selective for SMYD3 over other 9 tested histone methyltransferases and is also a SAM 
analog (Figure 5.3). We also made this compound in our SAM library in group V (propyl 
amine). This finding not only demonstrates that the bi-substrate design concept is a 
practical strategy for developing methyltransferase inhibitors but also suggests that SAM 
analog inhibitors can exhibit good selectivity for certain HMTs.  
 
Figure 5.3 An SMYD3 inhibitor, GSK2807 
 
5.2.2.3 Test current MLL1 SET domain inhibitors against a panel of HMTs. 
We currently have several potent MLL1 SET domain inhibitors, including TC-5115 
with the lowest IC50 value of 15 nM. In Chapter 4 we discussed the co-crystal structure 
analysis which suggested that our compound could have selectivity over other HMTs. In 
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our preliminary study, one of the Group IV (methylene azetidine) compounds, TC-3232 
does not bind to MMSET up to 100 µM. However, a larger panel of HMT profiling is still 
needed. It might be even more challenging to achieve selectivity within MLL-SET domain 
family. Potential ways to improve selectivity will be discussed in the following structural 






Appendix A: Experimental Section of Chapter 2 
 
Chemistry. General Information. All reagents and solvents were used as supplied without 
further purification and the reactions were performed under a nitrogen atmosphere in 
anhydrous solvents. The final products were purified by a reverse phase HPLC (RP-
HPLC) with solvent A (0.1% of TFA in H2O) and solvent B (0.1% of TFA in CH3CN) as 
eluents. The purity was determined by Waters ACQUITY UPLC and all the final 
compounds were > 95% pure. 1HNMR and 13CNMR spectra of the synthetic compounds 
were acquired at proton frequencies of 300 or 400 MHz  and chemical shifts are reported 
in parts per million (ppm) relative to an internal standard. High resolution mass spectra 
(HRMS) were obtained with an Agilent Q-TOF Electrospray mass spectrometer and low 








nonaazanonacosanamido)pentanediamide (4): The immobilized peptide on Rink 
amide resin was produced on an ABI 433 peptide synthesizer. The 4-methyltrityl (Mtt) 
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protecting group on the Lys12 side chain was removed by treatment with 0.5% TFA in 
DCM (10 mL). The resulting resin was treated with 1-(9H-fluoren-9-yl)-3-oxo-2,7,10,13-
tetraoxa-4-azapentadecan-15-oic acid and N,N'-Diisopropylcarbodiimide in DMF, and this 
was followed by removal of the Fmoc group with diethylamine. 5-Carboxyfluorescein 
succinimide ester (5-FAM, SE) was then added to a mixture of the washed resin and 
DIPEA in DMF and this mixture was shaken overnight. The peptide was cleaved from the 
resin by treatment with TFA:TES:H2O (36:1:2) cleavage cocktail and this was followed by 
HPLC purification, which yielded compound 4. HRMS (ESI-MS) m/z: calculated for 
C108H153N20O26+ 2146.1259, found 2146.1207 [M+H]+. 
General method for the synthesis of peptides 5-13. Peptides 5-13 were synthesized 
by solid-phase peptide synthesis using Fmoc chemistry shown in Scheme 2. 
(S)-6-Amino-N-((S)-1-amino-4-methyl-1-oxopentan-2-yl)-2-((2S,3S)-2-((S)-2-
formamido-3-(naphthalen-2-yl)propanamido)-3-methylpentanamido)hexanamide 
(5): HRMS (ESI-MS) m/z: calculated for C32H49N6O5+ 597.3759, found 597.3752 [M+H]+. 
(S)-6-Amino-2-((2S,3S)-2-((S)-2-amino-3-(naphthalen-2-yl)propanamido)-3-
methylpentanamido)-N-((S)-1-amino-4-methyl-1-oxopentan-2-yl)hexanamide (6): 
HRMS (ESI-MS) m/z: calculated for C31H49N5O4+ 569.3810, found 569.3804 [M+H]+. 
(S)-6-Amino-N-((S)-1-amino-4-methyl-1-oxopentan-2-yl)-2-((2S,3S)-3-methyl-2-((S)-
3-(naphthalen-2-yl)-2-propionamidopropanamido)pentanamido)hexanamide (7): 




(naphthalen-2-yl)-1-oxopropan-2-yl)cyclopropanecarboxamide (8): HRMS (ESI-MS) 
m/z: calculated for C35H53N6O5+ 637.4072, found 637.4074 [M+H]+. 
(S)-6-Amino-N-((S)-1-amino-4-methyl-1-oxopentan-2-yl)-2-((2S,3S)-2-((S)-2-
isobutyramido-3-(naphthalen-2-yl)propanamido)-3-
methylpentanamido)hexanamide (9): HRMS (ESI-MS) m/z: calculated for C35H55N6O5+ 
639.4228, found 639.4235 [M+H]+. 
((S)-6-Amino-N-((S)-1-amino-4-methyl-1-oxopentan-2-yl)-2-((2S,3S)-2-((S)-2-
butyramido-3-(naphthalen-2-yl)propanamido)-3-methylpentanamido)hexanamide 
(10): HRMS (ESI-MS) m/z: calculated for C35H55N6O5+ 639.4228, found 639.4232 [M+H]+. 
(S)-6-Amino-N-((S)-1-amino-4-methyl-1-oxopentan-2-yl)-2-((2S,3S)-3-methyl-2-((S)-
2-(3-methylbutanamido)-3-(naphthalen-2-
yl)propanamido)pentanamido)hexanamide (11): HRMS (ESI-MS) m/z: calculated for 
C36H57N6O5+ 653.4385, found 653.4389 [M+H]+. 
(S)-6-Amino-N-((S)-1-amino-4-methyl-1-oxopentan-2-yl)-2-((2S,3S)-3-methyl-2-((S)-
2-(3-methylureido)-3-(naphthalen-2-yl)propanamido)pentanamido)hexanamide 
(12): HRMS (ESI-MS) m/z: calculated for C33H52N7O5+ 626.4024, found 626.4024 [M+H]+. 
(Methyl ((S)-1-(((2S,3S)-1-(((S)-6-amino-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)-
amino)-1-oxohexan-2-yl)amino)-3-methyl-1-oxopentan-2-yl)amino)-3-(naphthalen-
2-yl)-1-oxopropan-2-yl)carbamate (13): HRMS (ESI-MS) m/z: calculated for 
C33H51N6O6+ 627.3865, found 627.3861 [M+H]+. 
 
General procedure for the synthesis of compounds 14-21: Step 1. Fmoc-Lys(Boc)-
OH was loaded onto a 2-chlorotrityl chloride resin by shaking a mixture of 2-chlorotrityl 
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chloride resin (1 equiv.), Fmoc-Lys(Boc)-OH (1 equiv.) and DIPEA (3 equiv.) in DCM 
overnight. Fmoc chemistry was used to carry out the chain elongation. The crude 
carboxylic acid was cleaved from the resin with 0.5% TFA in DCM. The cleavage solution 
was evaporated and purified by HPLC to yield N6-(tert-butoxycarbonyl)-N2-(((S)-3-
(naphthalen-2-yl)-2-propionamido-propanoyl)-L-isoleucyl)-L-lysine (39). 1HNMR (300 
MHz, CDCl3: CD3OD = 5:1), δ 7.78-7.75 (m, 3H), 7.64 (s, 1H), 7.45-7.44 (m, 2H), 7.34-
7.30 (m, 2H), 4.82-4.80 (m, 1H), 4.51-4.40 (m, 1H), 4.21-3.98 (m, 1H), 3.25-2.80 (m, 4H), 
2.18-2.15 (m, 2H), 1.82-1.26 (m, 18H), 1.04 (t, J=7.6, 3H), 0.90-0.84 (m, 6H); 13CNMR 
(75 MHz, CDCl3), δ 175.1, 174.2, 172.1, 171.7, 156.7, 134.2, 133.5, 132.4, 128.1, 128.0, 
127.6, 127.4, 126.1, 125.7, 79.3, 58.0, 57.8, 54.1, 52.3, 40.1, 38.0, 37.0, 31.4, 29.3, 28.4, 
24.8, 22.7, 15.2, 10.9, 9.7. ESI-MS m/z: calculated for C33H49N4O7+ 613.36, found 613.67 
[M+H]+. 
 Step 2. A solution of the acid (39) (0.05 mmol, 1 equiv.), the corresponding amine (0.10 
mmol, 2 equiv.), HBTU (38 mg, 0.10 mmol, 2 equiv.), HOBt (14 mg, 0.10 mmol, 2 equiv.) 
and DIPEA (27 µL, 0.15 mmol, 3 equiv.) in THF (5 mL) was stirred at room temperature 
for 2 h before being concentrated. The residue was then redissolved in EtOAc, washed 
with saturated NaHCO3, 1.0M HCl, brine and dried over Na2SO4. After removal of the 
solvent under vacuum, the residue was treated with TFA (3 mL) in DCM (10 mL) at room 
temperature for 3 h. The reaction mixture was evaporated and the crude product was 
purified by RP-HPLC to provide the compounds 14-21 shown in Table 4.2 in 70% to 85% 
yield. 
(S)-6-Amino-2-((2S,3S)-3-methyl-2-((S)-3-(naphthalen-2-yl)-2-propionamidopropan-
amido)pentanamido)-N-phenylhexanamide (14): 1HNMR (300 MHz, CD3OD), δ 9.74 
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(s, 1H), 8.32 (d, J=7.7, 1H), 8.04  (d, J=7.7, 1H), 7.83-7.77 (m, 3H), 7.70 (s, 1H), 7.57-
7.54 (m, 2H), 7.45-7.38 (m, 3H), 7.33-7.27 (m, 2H), 7.12-7.08 (m, 1H), 4.81-4.76 (m, 1H), 
4.50-4.45 (m, 1H), 4.24 (t, J=7.8, 1H), 3.54-3.36 (m, 1H), 3.10-3.02 (m, 1H), 2.88 (t, J=7.5, 
2H), 2.21-2.14 (m, 2H), 1.87-1.29 (m, 8H), 1.23-1.16 (m, 1H), 1.01-0.88 (m, 9H); 13CNMR 
(75 MHz, CD3OD), δ 177.2, 174.0, 173.6, 171.9, 139.4, 136.0, 134.9, 133.9, 129.9, 129.1, 
128.9, 128.6, 128.4, 127.1, 126.7, 125.5, 121.3, 59.4, 56.1, 54.9, 40.6, 38.6, 38.1, 32.3, 
29.9, 28.1, 26.0, 23.8, 15.9, 11.3, 10.3. HRMS (ESI-MS) m/z: calculated for C34H46N5O4+ 
588.3544, found 588.3546 [M+H]+. 
(S)-6-Amino-N-benzyl-2-((2S,3S)-3-methyl-2-((S)-3-(naphthalen-2-yl)-2-
propionamido-propanamido)pentanamido)hexanamide (15): 1HNMR (300 MHz, 
CD3OD), δ 8.36 (t, J=5.8, 1H), 8.21 (d, J=7.9, 1H), 8.12 (d, J=7.7, 1H), 7.96 (d, J=7.8, 
1H), 7.82-7.77 (m, 3H), 7.69 (s, 1H), 7.48-7.36 (m, 3H), 7.33-7.23 (m, 5H), 4.80-4.69 (m, 
1H), 4.44-4.31 (m, 3H), 4.20-4.15 (m, 1H), 3.33-3.26 (m, 1H), 3.08-3.00 (m, 1H), 2.85 (t, 
J=7.7, 2H), 2.19-2.12 (m, 2H), 1.84-1.29 (m, 8H), 1.22-1.12 (m, 1H), 0.97 (t, J=7.7, 3H), 
0.90-0.85 (m, 6H); 13CNMR (75 MHz, CD3OD), δ 177.2, 174.1, 173.6, 173.5, 139.7, 136.0, 
134.9, 133.9, 129.6, 129.1, 128.8, 128.6, 128.4, 128.3, 127.1, 126.7, 59.4, 56.1, 54.3, 
44.1, 40.5, 38.5, 38.0, 32.3, 29.9, 28.0, 26.0, 23.7, 15.9, 11.3, 10.3. HRMS (ESI-MS) m/z: 
calculated for C35H48N5O4+ 602.3701, found 602.3700 [M+H]+. 
(S)-6-Amino-2-((2S,3S)-3-methyl-2-((S)-3-(naphthalen-2-yl)-2-
propionamidopropanamido) pentanamido)-N-phenethylhexanamide (16): 1HNMR 
(300 MHz, CD3OD), δ 8.16-8.13 (m, 2H), 8.01-7.98 (m, 1H), 7.78-7.76 (m, 3H), 7.69 (s, 
1H), 7.44-7.37 (m, 3H), 7.28-7.18 (m, 5H), 4.78-4.74 (m, 1H), 4.25-4.15 (m, 2H), 3.46-
3.33 (m, 3H), 3.08-3.01 (m, 1H), 2.85-2.79 (m, 4H), 2.17-2.12 (m, 2H), 1.82-1.55 (m, 6H), 
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1.30-1.15 (m, 3H), 0.99-0.86 (m, 9H); 13CNMR (75 MHz, CD3OD), δ 177.2, 174.1, 173.6, 
173.4, 140.3, 136.0, 134.9133.9, 129.9, 129.5, 129.1, 128.9, 128.8, 128.6, 128.3, 127.4, 
127.1, 126.7, 59.4, 56.1, 54.2, 41.9, 40.5, 38.6, 38.0, 36.4, 32.4, 29.9, 28.0, 26.0, 23.7, 
15.9, 11.3, 10.3. HRMS (ESI-MS) m/z: calculated for C36H50N5O4+ 616.3857, found 
616.3857 [M+H]+. 
(S)-6-Amino-N-benzhydryl-2-((2S,3S)-3-methyl-2-((S)-3-(naphthalen-2-yl)-2-
propion-amidopropanamido)pentanamido)hexanamide (17): 1HNMR (300 MHz, 
CD3OD), δ 8.71 (d, J=8.3, 1H), 8.11 (d, J=7.7, 1H), 7.95 (d, J=7.9, 1H), 7.82-7.76 (m, 3H), 
7.68 (s, 1H), 7.46-7.23 (m, 13H), 6.17-6.14 (m, 1H), 4.74-4.69 (m, 1H), 4.47-4.42 (m, 1H), 
4.20-4.15 (m, 1H), 3.27-3.21 (m, 1H), 3.07-2.99 (m, 1H), 2.82 (t, J=7.7, 2H), 2.19-2.12 
(m, 2H), 1.83-1.73 (m, 2H), 1.70-1.48 (m, 4H), 1.38-1.34 (m, 2H), 1.20-1.10 (m, 1H), 0.97 
(t, J=7.6, 3H), 0.88-0.83 (m, 6H); 13CNMR (75 MHz, CD3OD), δ 177.2, 174.0, 173.6, 
172.8, 142.9, 142.7, 136.0, 134.9, 133.9, 129.6, 129.5, 129.1, 128.84, 128.77, 128.6, 
128.5, 128.41, 128.37, 127.1, 126.7, 59.4, 58.3, 56.1, 54.2, 40.5, 38.5, 38.0, 32.3, 29.9, 
28.0, 26.1, 23.7, 15.9, 11.3, 10.3. HRMS (ESI-MS) m/z: calculated for C41H52N5O4+ 
678.4014, found 678.4012 [M+H]+. 
(S)-6-Amino-N-((R)-2,3-dihydro-1H-inden-1-yl)-2-((2S,3S)-3-methyl-2-((S)-3-
(naphthalen-2-yl)-2-propionamidopropanamido)pentanamido)hexanamide (18): 
1HNMR (300 MHz, CD3OD), δ 8.25 (d, J=7.8, 1H), 8.19 (d, J=8.2, 1H), 8.10 (d, J=7.5, 
1H), 7.97 (d, J=7.6, 1H), 7.81-7.75 (m, 3H), 7.66 (s, 1H), 7.46-7.34 (m, 3H), 7.23-7.11 (m, 
4H), 5.35 (dd, J=7.7, 15.4, 1H), 4.73-4.68 (m, 1H), 4.37-4.33 (m, 1H), 4.21-4.16 (m, 1H), 
3.28-3.21 (m, 1H), 3.04-2.96 (m, 2H), 2.89-2.80 (m, 3H), 2.52-2.42 (m, 1H), 2.17-2.10 (m, 
2H), 1.90-1.80 (m, 3H), 1.72-1.37 (m, 6H), 1.28-1.14 (m, 1H), 0.98-0.87 (m, 9H); 13CNMR 
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(75 MHz, CD3OD), δ 177.2, 174.1, 173.52, 173.48, 144.5, 144.2, 136.0, 134.9, 133.9, 
129.1, 129.0, 128.8, 128.6, 128.4, 127.6, 127.1, 126.7, 125.7, 125.2, 59.5, 56.1, 55.9, 
54.3, 40.6, 38.5, 38.0, 34.2, 32.3, 31.1, 29.8, 28.0, 26.1, 23.8, 16.0, 11.4, 10.3. HRMS 
(ESI-MS) m/z: calculated for C37H50N5O4+ 628.3857, found 628.3859   [M+H]+. 
(S)-6-Amino-N-((S)-2,3-dihydro-1H-inden-1-yl)-2-((2S,3S)-3-methyl-2-((S)-3-
(naphthalen-2-yl)-2-propionamidopropanamido)pentanamido)hexanamide (19): 
1HNMR (300 MHz, CD3OD), δ 8.25-8.18 (m, 2H), 8.11 (d, J=7.6, 1H), 7.97 (d, J=7.9, 1H), 
7.82-7.76 (m, 3H), 7.69 (s, 1H), 7.45-7.37 (m, 3H), 7.23-7.17 (m, 4H), 5.34 (dd, J=7.5, 
15.2, 1H), 4.77-4.72 (m, 1H), 4.38-4.33 (m, 1H), 4.21-4.16 (m, 1H), 3.34-3.27 (m, 1H), 
3.07-2.95 (m, 2H), 2.89-2.79 (m, 3H), 2.50-2.43 (m, 1H), 2.19-2.11 (m, 2H), 1.92-1.83 (m, 
3H), 1.72-1.38 (m, 6H), 1.22-1.12 (m, 1H), 0.98-0.85 (m, 9H); 13CNMR (75 MHz, CD3OD), 
δ 177.2, 174.0, 173.5, 173.4, 144.6, 144.2, 136.0, 134.9, 133.9, 129.1, 129.0, 128.8, 
128.6, 128.4, 127.7, 127.1, 126.7, 125.8, 125.0, 59.3, 56.1, 55.9, 54.2, 40.6, 38.6, 38.0, 
34.2, 32.6, 31.1, 29.9, 28.0, 26.0, 23.8, 15.9, 11.3, 10.3. HRMS (ESI-MS) m/z: calculated 
for C37H50N5O4+ 628.3857, found 628.3859 [M+H]+. 
(S)-6-Amino-2-((2S,3S)-3-methyl-2-((S)-3-(naphthalen-2-yl)-2-propionamido-
propanamido)pentanamido)-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide 
(20): 1HNMR (300 MHz, CD3OD), δ 8.27-8.19 (m, 2H), 8.09 (d, J=7.5, 1H), 7.97 (d, J=7.6, 
1H), 7.81-7.75 (m, 3H), 7.67 (s, 1H), 7.45-7.35 (m, 3H), 7.18-7.07 (m, 4H), 5.07-5.05 (m, 
1H), 4.71-4.68 (m, 1H), 4.35-4.33 (m, 1H), 4.23-4.17 (m, 1H), 3.28-3.21 (m, 1H), 3.04-
2.80 (m, 5H), 2.18-2.11 (m, 2H), 2.03-1.28 (m, 12H), 1.25-1.15 (m, 1H), 0.98-0.88 (m, 
9H); 13CNMR (75 MHz, CD3OD), δ 177.2, 174.0, 173.5, 173.0, 138.7, 137.4, 136.0, 134.9, 
133.9, 130.1, 129.5, 129.0, 128.8, 128.6, 128.4, 128.3, 127.1, 126.7, 59.4, 56.0, 54.3, 
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40.5, 38.5, 38.0, 32.4, 31.2, 30.2, 29.8, 28.0, 26.1, 23.8, 21.4, 16.0, 11.4, 10.3. HRMS 
(ESI-MS) m/z: calculated for C38H52N5O4+ 642.4014, found 642.4015 [M+H]+. 
(S)-6-Amino-2-((2S,3S)-3-methyl-2-((S)-3-(naphthalen-2-yl)-2-propionamidopropan-
amido)pentanamido)-N-((S)-1,2,3,4-tetrahydronaphthalen-1-yl)hexanamide (21): 
1HNMR (300 MHz, CD3OD), δ 8.26-8.18 (m, 2H), 8.11 (d, J=7.7, 1H), 7.97 (d, J=8.0, 1H), 
7.82-7.77 (m, 3H), 7.70 (s, 1H), 7.45-7.37 (m, 3H), 7.13-7.08 (m, 4H), 5.04-5.03 (m, 1H), 
4.78-4.73 (m, 1H), 4.38-4.33 (m, 1H), 4.22-4.17 (m, 1H), 3.27-3.21 (m, 1H), 3.08-3.00 (m, 
1H), 2.89-2.79 (m, 4H), 2.18-2.09 (m, 2H), 1.96-1.29 (m, 12H), 1.22-1.12 (m, 1H), 1.02-
0.86 (m, 9H); 13CNMR (75 MHz, CD3OD), δ 177.1, 174.0, 173.5, 172.8, 138.8, 137.4, 
136.0, 134.9, 133.9, 130.2, 129.5, 129.1, 128.8, 128.6, 128.4, 128.3, 127.1, 126.7, 59.3, 
56.0, 54.3, 40.5, 38.6, 38.0, 32.5, 31.1, 30.2, 29.9, 28.0, 26.0, 23.7, 21.1, 15.9, 11.3, 10.3. 
HRMS (ESI-MS) m/z: calculated for C38H52N5O4+ 642.4014, found 642.4016 [M+H]+. 
General procedure for the synthesis of compounds 22-37.  
The amine 44 (0.1 mmol, 1 equiv.) was added to a solution of the corresponding Fmoc 
protected amino acid (0.1 mmol, 1 equiv.), HBTU (76 g, 0.2 mmol, 2 equiv.), HOBt (27 
mg, 0.2 mmol, 2 equiv.) and DIPEA (52 µL, 0.3 mmol, 3 equiv.) in DMF (5 mL) and the 
resulting mixture was stirred at room temperature for 1 h. The solution was diluted with 
EtOAc and washed with saturated NaHCO3, 1.0 M HCl, brine and dried over Na2SO4. 
After removal of the solvent under vacuum, the residue was treated with diethylamine (1.0 
mL) in CH3CN (9 mL) for 1 h. The reaction mixture was evaporated and the residue was 
redissolved in DCM (5 mL) and treated with propionic anhydride (39 mg, 0.3 mmoL, 3 
equiv.) and DIPEA (87 µL, 0.5 mmol, 5 equiv.) for 30 min. The reaction mixture was 
evaporated and treated with TFA (3 mL) in DCM (10 ML) at room temperature for 3 h. 
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This reaction mixture was concentrated and purified by RP-HPLC to provide the 
compounds 22-37 in 37% to 62% yield over three steps. 
(S)-6-Amino-N-benzhydryl-2-((S)-2-cyclopentyl-2-((S)-3-(naphthalen-2-yl)-2-
propion-amidopropanamido)acetamido)hexanamide (22): 1HNMR (300 MHz, 
CD3OD), δ 8.66 (d, J=8.3, 1H), 8.30 (d, J=8.0, 1H), 8.07 (d, J=7.3, 1H), 7.82-7.76 (m, 3H), 
7.68 (s, 1H), 7.46-7.24 (m, 13H), 6.15 (d, J=8.2, 1H), 4.76-4.70 (m, 1H), 4.49-4.42 (m, 
1H), 4.17-4.12 (m, 1H), 3.27-3.25 (m, 1H), 3.06-2.98 (m, 1H), 2.82 (t, J=7.5, 2H), 2.23-
2.11 (m, 3H), 1.86-1.24 (m, 14H), 0.96 (t, J=7.6, 3H); 13CNMR (75 MHz, CD3OD), δ 177.1, 
173.94, 173.87, 172.8, 142.9, 142.7, 136.0, 134.9, 133.9, 129.7, 129.5, 129.0, 128.9, 
128.8, 128.61, 128.58, 128.4, 127.1, 126.7, 59.0, 58.4, 56.0, 54.2, 43.4, 40.5, 38.6, 32.2, 
30.5, 30.3, 29.9, 27.9, 26.2, 25.9, 23.7, 10.2. HRMS (ESI-MS) m/z: calculated for 
C42H52N5O4+ 690.4014, found 690.4017 [M+H]+. 
(S)-6-Amino-N-benzhydryl-2-((S)-2-cyclohexyl-2-((S)-3-(naphthalen-2-yl)-2-
propionamidopropanamido)acetamido)hexanamide (23): 1HNMR (300 MHz, 
CD3OD), δ 8.69 (d, J=8.3, 1H), 8.28 (d, J=7.9, 1H), 8.10 (d, J=7.6, 1H), 7.93 (d, J=7.9, 
1H), 7.82-7.77 (m, 3H), 7.69 (s, 1H), 7.46-7.24 (m, 13H), 6.15 (d, J=8.2, 1H), 4.75-4.70 
(m, 1H), 4.46-4.41 (m, 1H), 4.14 (t, J=7.7, 1H), 3.27-3.26 (m, 1H), 3.07-3.00 (m, 1H), 2.82 
(t, J=7.5, 2H), 2.20-2.12 (m, 2H), 1.82-1.55 (m, 9H), 1.40-1.12 (m, 6H), 1.00-0.95 (m, 
5H);; 13CNMR (75 MHz, CD3OD), δ 177.2, 173.9, 173.4, 172.8, 142.9, 142.7, 136.0, 
134.9, 133.9, 129.7, 129.6, 129.1, 128.9, 128.8, 128.6, 128.5, 128.4, 127.1, 126.7, 59.8, 
58.4, 56.0, 54.2, 41.3, 40.5, 38.6, 32.3, 30.7, 30.1, 29.9, 27.9, 27.2, 27.1, 27.0, 23.7, 10.3. 
HRMS (ESI-MS) m/z: calculated for C43H54N5O4+ 704.4170, found 704.4168 [M+H]+. 
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(S)-6-Amino-N-benzhydryl-2-((S)-3-cyclohexyl-2-((S)-3-(naphthalen-2-yl)-2-propion-
amidopropanamido)propanamido)hexanamide (24): 1HNMR (300 MHz, CD3OD), δ 
8.67 (d, J=8.3, 1H), 8.20-8.08 (m, 2H), 7.83-7.77 (m, 3H), 7.69 (s, 1H), 7.46-7.24 (m, 
13H), 6.17 (d, J=8.3, 1H), 4.70-4.65 (m, 1H), 4.45-4.36 (m, 2H), 3.27-3.25 (m, 1H), 3.08-
3.00 (m, 1H), 2.83 (t, J=7.4, 2H), 2.16 (q, J=7.7, 2H), 1.82-1.55 (m, 11H), 1.39-1.14 (m, 
6H), 0.99-0.88 (m, 5H);; 13CNMR (75 MHz, CD3OD), δ 177.2, 174.8, 174.1, 172.9, 142.9, 
142.7, 135.9, 134.9, 133.9, 129.63, 129.56, 129.1, 128.9, 128.7, 128.6, 128.5, 128.44, 
128.40, 127.1, 126.7, 58.3, 56.0, 54.3, 52.8, 40.5, 40.3, 38.6, 35.2, 34.8, 33.3, 32.2, 29.9, 
27.9, 27.5, 27.3, 27.1, 23.7, 10.2. HRMS (ESI-MS) m/z: calculated for C44H56N5O4+ 
718.4327, found 718.4326 [M+H]+. 
(S)-6-Amino-N-benzhydryl-2-((S)-4,4-dimethyl-2-((S)-3-(naphthalen-2-yl)-2-propion-
amidopropanamido)pentanamido)hexanamide (25): 1HNMR (300 MHz, CD3OD), δ 
8.66 (d, J=8.3, 1H), 8.16-8.10 (m, 2H); 7.79-7.74 (m, 3H), 7.66 (s, 1H), 7.43-7.22 (m, 
13H), 6.16-6.13 (m, 1H), 4.67-4.62 (m, 1H), 4.42-4.39 (m, 1H), 3.27-3.22 (m, 1H), 3.03-
2.96 (m, 1H), 2.80 (t, J=7.4, 2H), 2.15-2.08 (m, 2H), 1.81-1.54 (m, 5H), 1.36-1.27 (m, 3H), 
0.95-0.89 (m, 12H);; 13CNMR (75 MHz, CD3OD), δ 177.2, 174.9, 173.6, 172.9, 142.9, 
142.7, 136.0, 134.9, 133.9, 129.6, 129.5, 129.1, 128.8, 128.7, 128.64, 128.62, 128.5, 
128.41, 128.38, 127.1, 126.7, 58.3, 56.1, 54.3, 52.7, 46.0, 40.5, 38.4, 32.3, 31.4, 30.1, 
29.8, 27.9, 23.7, 10.2. HRMS (ESI-MS) m/z: calculated for C42H54N5O4+ 692.4170, found 
692.4161 [M+H]+. 
(S)-6-Amino-N-benzhydryl-2-((S)-4,4,4-trifluoro-2-((S)-3-(naphthalen-2-yl)-2-
propion-amidopropanamido)butanamido)hexanamide (26): 1HNMR (300 MHz, 
CD3OD), δ 8.72 (d, J=8.2, 1H), 8.18 (d, J=6.9, 1H), 7.82-7.77 (m, 3H), 7.68 (s, 1H), 7.47-
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7.23 (m, 13H), 6.17 (d, J=8.3, 1H), 4.61-4.54 (m, 2H), 4.43-4.39 (m, 1H), 3.29-3.27 (m, 
1H), 3.10-3.01 (m, 1H), 2.86-2.59 (m, 4H), 2.15 (q, d=7.6, 2H), 1.84-1.56 (m, 4H), 1.37-
1.29 (m, 2H), 0.94 (t, J=7.6, 3H); HRMS (ESI-MS) m/z: calculated for C42H54N5O4+ 
704.3418, found 704.3416 [M+H]+. 
(S)-6-Amino-N-benzhydryl-2-((S)-2-((S)-3-(naphthalen-2-yl)-2-
propionamidopropanamido)-3-(thiophen-2-yl)propanamido)hexanamide (27): 
1HNMR (300 MHz, CD3OD), δ 8.70 (d, J=8.4, 1H), 8.14 (d, J=7.6, 1H), 8.07 (d, J=7.0, 
1H), 7.82-7.76 (m, 3H), 7.65 (s, 1H), 7.46-7.43 (m, 2H), 7.33-7.27 (m, 11H), 7.17-7.15 
(m, 1H), 6.84-6.82 (m, 2H), 6.18 (d, J=8.3, 1H), 4.61-4.53 (m, 2H), 4.47-4.40 (m, 1H), 
3.28-3.22 (m, 3H), 3.05-2.98 (m, 1H), 2.83 (t, J=7.4, 2H), 2.14 (q, J=7.6, 2H), 1.80-1.58 
(m, 4H), 1.37-1.32 (m, 2H), 0.94 (t, J=7.6, 3H); 13CNMR (75 MHz, CD3OD), δ 177.4, 
174.0, 172.81, 172.78, 142.9, 142.7, 139.6, 135.9, 134.9, 133.9, 129.62, 129.57, 129.1, 
128.8, 128.6, 128.5, 128.3, 128.0, 127.8, 127.1, 126.7, 125.6, 58.3, 56.4, 56.2, 54.4, 40.5, 
38.7, 32.44, 32.38, 29.8, 27.9, 23.6, 10.2. HRMS (ESI-MS) m/z: calculated for 
C42H54N5O4+ 718.3422, found 718.3420 [M+H]+. 
(S)-6-Amino-N-benzhydryl-2-((S)-2-((S)-3-(benzo[d]thiazol-2-yl)-2-propion-
amidopropanamido)-2-cyclopentylacetamido)hexanamide (28): 1HNMR (300 MHz, 
CD3OD), δ 8.63 (d, J=7.6, 1H), 8.31 (t, J=8.2, 1H), 8.10 (d, J=6.7, 1H), 7.93 (d, J=7.9, 
2H), 7.52-7.38 (m, 2H),  7.32-7.23 (m, 10H), 6.14 (d, J=7.8, 1H), 4.95-4.91 (m, 1H), 4.46-
4.43 (m, 1H), 4.14-4.09 (m, 1H), 3.61-3.34 (m, 2H), 2.84 (t, J=7.0, 2H), 2.27-2.17 (m, 3H), 
2.02-1.24 (m, 14H), 1.05 (t, J=7.4, 3H); 13CNMR (75 MHz, CD3OD), δ177.2, 173.9, 172.8, 
172.7, 169.2, 154.0, 142.8, 142.7, 136.5, 129.6, 129.5, 128.8, 128.6, 128.5, 128.4, 127.4, 
126.5, 123.4, 122.9, 59.1, 58.3, 54.2, 43.2, 40.5, 36.22, 32.19, 30.3, 29.9, 27.9, 26.2, 
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25.8, 23.7, 10.1. HRMS (ESI-MS) m/z: calculated for C39H49N6O4S+ 697.3531, found 
697.3532 [M+H]+. 
 (S)-6-Amino-N-benzhydryl-2-((S)-2-cyclopentyl-2-((S)-3-(4-fluorobenzo[d]thiazol-2-
yl)-2-propionamidopropanamido)acetamido)hexanamide (29): 1HNMR (300 MHz, 
CD3OD), δ 8.63 (d, J=7.3, 1H), 8.39-8.30 (m, 2H), 8.12 (d, J=7.0, 1H), 7.75 (d, J=8.0, 1H), 
7.44-7.21 (m, 12H),  6.14 (d, J=8.1, 1H), 4.92-4.90 (m, 1H), 4.46-4.44 (m, 1H), 4.14-4.08 
(m, 1H), 3.62-3.55 (m, 1H), 3.46-3.34 (m, 1H), 2.88 (t, J=7.5, 2H), 2.28-2.14 (m, 3H), 
2.03-1.25 (m, 14H), 1.06 (t, J=7.6, 3H); HRMS (ESI-MS) m/z: calculated for 
C39H48FN6O4S+ 715.3436, found 715.3436 [M+H]+. 
(S)-6-Amino-N-benzhydryl-2-((S)-2-cyclopentyl-2-((S)-3-(5-fluorobenzo[d]thiazol-2-
yl)-2-propionamidopropanamido)acetamido)hexanamide (30): 1HNMR (300 MHz, 
CD3OD), δ 8.65 (d, J=8.2, 1H), 8.39-8.30 (m, 2H), 8.09 (d, J=7.3, 1H), 7.95-7.91 (m, 1H), 
7.64 (dd, J=2.4, 11.9, 1H), 7.35-7.20 (m, 11H),  6.14 (d, J=8.1, 1H), 4.93-4.90 (m, 1H), 
4.47-4.44 (m, 1H), 4.16-4.11 (m, 1H), 3.61-3.54 (m, 1H), 3.45-3.37 (m, 1H), 2.86 (t, J=7.4, 
2H), 2.27-2.14 (m, 3H), 1.84-1.24 (m, 14H), 1.06 (t, J=7.6, 3H); HRMS (ESI-MS) m/z: 
calculated for C39H48FN6O4S+ 715.3436, found 715.3431 [M+H]+.  
(S)-6-Amino-N-benzhydryl-2-((S)-2-cyclopentyl-2-((S)-3-(6-fluorobenzo[d]thiazol-2-
yl)-2-propionamidopropanamido)acetamido)hexanamide (31): 1HNMR (300 MHz, 
CD3OD), δ 8.64 (d, J=7.9, 1H), 8.30 (d, J=8.0, 1H), 8.08 (d, J=7.5, 1H), 7.94-7.89 (m, 1H), 
7.72 (dd, J=2.6, 8.4, 1H), 7.36-7.22 (m, 11H),  6.16-6.13 (m, 1H), 4.82-4.80 (m, 1H), 4.47-
4.42 (m, 1H), 4.15-4.10 (m, 1H), 3.59-3.53 (m, 1H), 3.44-3.36 (m, 1H), 2.86 (t, J=7.4, 2H), 
2.28-2.17 (m, 3H), 1.82-1.29 (m, 14H), 1.06 (t, J=7.6, 3H); HRMS (ESI-MS) m/z: 
calculated for C39H48FN6O4S+ 715.3436, found 715.3436 [M+H]+.  
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(S)-6-Amino-N-benzhydryl-2-((S)-2-((S)-3-(5-chlorobenzo[d]thiazol-2-yl)-2-propion-
amidopropanamido)-2-cyclopentylacetamido)hexanamide (32): 1HNMR (300 MHz, 
CD3OD), δ 8.65 (d, J=8.1, 1H), 8.30 (t, J=7.8, 1H), 8.09 (d, J=7.3, 1H), 7.92-7.89 (m, 2H), 
7.40 (dd, J=1.7, 8.6, 1H), 7.34-7.20 (m, 10H), 6.13 (d, J=8.0, 1H), 4.92-4.91 (m, 1H), 4.45-
4.41 (m, 1H), 4.14-4.10 (m, 1H), 3.60-3.37 (m, 2H), 2.84 (t, J=7.4, 2H), 2.26-2.13 (m, 3H), 
1.83-1.23 (m, 14H), 1.05 (t, J=7.6, 3H); 13CNMR (75 MHz, CD3OD), δ177.2, 173.9, 172.8, 
172.5, 171.5, 155.0, 142.8, 142.7, 135.1, 133.3, 129.6, 129.5, 128.8, 128.6, 128.5, 128.4, 
126.7, 124.0, 123.1, 59.0, 58.3, 54.2, 54.1, 43.3, 40.5, 36.3, 32.2, 30.3, 29.9, 28.0, 26.2, 
25.8, 23.7, 10.2. HRMS (ESI-MS) m/z: calculated for C39H48ClN6O4S+ 731.3141, found 
731.3128 [M+H]+. 
(S)-6-Amino-N-benzhydryl-2-((S)-2-((S)-3-(6-chlorobenzo[d]thiazol-2-yl)-2-propion-
amidopropanamido)-2-cyclopentylacetamido)hexanamide (33): 1HNMR (300 MHz, 
CD3OD:CCl3D=1:1), δ 8.54 (d, J=8.1, 1H), 8.35 (t, J=7.5, 1H), 8.11-8.06 (m, 3H), 7.68 
(dd, J=1.9, 8.7, 1H), 7.57-7.41 (m, 10H), 6.36 (d, J=8.1, 1H), 5.09-5.04 (m, 1H), 4.66-4.61 
(m, 1H), 4.30-4.25 (m, 1H), 3.77-3.61 (m, 2H), 3.07 (t, J=7.1, 2H), 2.51-2.33 (m, 3H), 
2.09-1.38 (m, 14H), 1.31 (t, J=7.6, 3H); 13CNMR (75 MHz, CD3OD:CCl3D=1:1), δ 176.4, 
173.1, 171.8, 171.7, 168.9, 151.7, 141.7, 141.6, 136.9, 131.9, 129.1, 129.0, 128.0, 
127.97, 127.6, 123.7, 121.9, 58.5, 57.6, 53.34, 53.26, 42.3, 39.9, 35.4, 31.3, 29.7, 29.6, 
29.5, 27.1, 25.6, 25.3, 22.8,  9.9. HRMS (ESI-MS) m/z: calculated for C39H48ClN6O4S+ 
731.3141, found 731.3138 [M+H]+. 
(S)-6-Amino-2-((S)-2-((S)-3-(6-chlorobenzo[d]thiazol-2-yl)-2-
propionamidopropanamido)-2-cyclopentylacetamido)-N-((R)-1,2,3,4-
tetrahydronaphthalen-1-yl)hexanamide (34): 1HNMR (300 MHz, CD3OD), δ 8.00 (d, 
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J=2.0, 1H), 7.89 (d, J=8.7, 1H), 7.49 (dd, J=2.1, 8.7, 1H), 7.17-7.08 (m, 2H), 5.05-5.04 
(m, 1H), 4.80-4.74 (m, 1H), 4.35-4.31 (m, 1H), 4.13 (d, J=8.8, 1H), 3.54-3.36 (m, 2H), 
2.94-2.81 (m, 4H), 2.27-2.20 (m, 3H), 1.98-1.29 (m, 18H), 1.06 (t, J=7.6, 3H); 13CNMR 
(75 MHz, CD3OD), δ 177.2, 173.9, 172.9, 170.1, 152.7, 138.7, 138.0, 137.5, 132.2, 130.1, 
129.5, 128.3, 128.0, 127.1, 124.4, 122.5, 59.2, 54.3, 43.2, 40.6, 36.1, 32.3, 31.2, 30.4, 
30.3, 30.2, 29.9, 28.0, 26.2, 25.9, 23.8, 21.4, 10.2. HRMS (ESI-MS) m/z: calculated for 
C36H48ClN6O4S+ 695.3141, found 695.3134 [M+H]+. 
(S)-6-Amino-2-((S)-2-((S)-3-(6-chlorobenzo[d]thiazol-2-yl)-2-
propionamidopropanamido)-2-cyclopentylacetamido)-N-((R)-chroman-4-
yl)hexanamide (35): 1HNMR (300 MHz, CD3OD), δ 8.35-8.22 (m, 2H), 8.06 (d, J=6.9, 
1H), 8.00 (d, J=2.0, 1H), 7.88 (d, J=8.7, 1H), 7.48 (dd, J=2.1, 8.7, 1H), 7.14-7.08 (m, 2H), 
6.85-6.75 (m, 2H), 5.07-5.00 (m, 1H), 4.80-4.74 (m, 1H), 4.34-4.31 (m, 1H), 4.23-4.20 (m, 
2H), 4.13-4.08 (m, 1H), 3.54-3.36 (m, 2H), 2.91 (t, J=7.5, 2H), 2.27-1.28 (m, 19H), 1.06 
(t, J=7.6, 3H); 13CNMR (75 MHz, DMSO-D6), δ 173.8, 171.3, 170.5, 169.6, 155.1, 151.7, 
137.1, 129.9, 129.7, 129.1, 126.9, 123.8, 123.6, 122.2, 120.6, 116.9, 63.6, 56.3, 52.8, 
52.4, 42.8, 36.1, 31.9, 29.1, 29.0, 28.8, 28.6, 27.2, 25.3, 25.0, 22.7, 10.2. HRMS (ESI-
MS) m/z: calculated for C35H46ClN6O5S+ 697.2933, found 697.2923 [M+H]+. 
(S)-6-Amino-2-((S)-2-((S)-3-(6-chlorobenzo[d]thiazol-2-yl)-2-
propionamidopropanamido)-2-(tetrahydro-2H-pyran-4-yl)acetamido)-N-((R)-
chroman-4-yl)hexanamide (36): 1HNMR (300 MHz, DMSO-D6), δ 8.45 (d, J=8.2, 1H), 
8.36 (d, J=8.3, 1H), 8.24-8.21 (m, 2H), 7.95-7.92 (m, 2H), 7.71 (br., 3H), 7.53 (d, J=8.4, 
1H), 7.17-7.08 (m, 2H), 6.86-6.76 (m, 2H), 5.01-4.99 (m, 1H), 4.85-4.84 (m, 1H), 4.31-
4.20 (m, 4H), 3.86-3.83 (m, 2H), 3.35-3.18 (m, 3H), 2.78-2.73 (m, 2H), 2.15-1.89 (m, 5H), 
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1.65-1.14 (m, 11H), 0.94 (t, J=7.5, 3H); 13CNMR (75 MHz, DMSO-D6), δ 173.9, 171.3, 
170.6, 170.4, 169.5, 155.1, 151.7, 137.1, 129.9, 129.6, 129.1, 126.9, 123.8, 123.7, 122.2, 
120.6, 116.9, 67.4, 67.2, 63.6, 56.9, 53.0, 52.5, 42.8, 38.2, 36.1, 31.8, 29.5, 29.1, 28.9, 
28.6, 27.1, 22.8, 10.2. HRMS (ESI-MS) m/z: calculated for C35H46ClN6O6S+ 713.2883, 
found 713.2870 [M+H]+. 
(S)-6-Amino-2-((S)-2-((S)-3-(6-chlorobenzo[d]thiazol-2-yl)-2-
propionamidopropanamido)-2-(piperidin-4-yl)acetamido)-N-((R)-chroman-4-
yl)hexanamide (37): 1HNMR (300 MHz, CD3OD), δ 8.49-8.40 (m, 2H), 8.25 (d, J=7.9, 
1H), 7.99 (d, J=2.0, 1H), 7.90 (d, J=8.7, 1H), 7.48 (dd, J=2.0, 8.7, 1H), 7.18-7.10 (m, 2H), 
6.85-6.82 (m, 1H), 6.76 (d, J=8.1, 1H), 5.08-5.00 (m, 1H), 4.80-4.73 (m, 1H), 4.37-4.32 
(m, 1H), 4.23-4.14 (m, 3H), 3.62-3.34 (m, 4H), 3.06-2.88 (m, 4H), 2.29-2.21 (m, 2H), 2.09-
1.23 (m, 15H), 1.07 (t, J=7.6, 3H); 13CNMR (75 MHz, CD3OD), δ 177.4, 173.4, 172.8, 
171.9, 169.8, 156.5, 152.8, 138.0, 132.3, 130.4, 130.1, 128.1, 124.5, 123.3, 122.6, 121.6, 
118.0, 64.5, 57.8, 54.8, 54.4, 44.9, 44.8, 40.5, 37.8, 36.2, 32.4, 30.2, 29.9, 28.2, 26.9, 
26.0, 24.0, 10.2. HRMS (ESI-MS) m/z: calculated for C35H47ClN7O5S+ 712.3042, found 
712.3028 [M+H]+. 
(S)-2-((S)-2-((S)-3-(6-Chlorobenzo[d]thiazol-2-yl)-2-propionamidopropanamido)-2-
cyclo- pentylacetamido)-N-((R)-chroman-4-yl)-6-(dimethylamino)hexanamide (38): 
Na(AcO)3BH (4 equiv.) was added  to a solution of 35 (1 equiv.) and formaldehyde (10 
equiv.) in ClCH2CH2Cl and the resulting mixture was stirred at room temperature for 1 h. 
The reaction was quenched with 10% NaHCO3 solution and evaporated to give a residue 
which was purified by HPLC to give 38 (81% yield). 1HNMR (400 MHz, DMSO-D6), δ 9.45 
(br., 1H), 8.43 (d, J=8.3, 1H), 8.34 (d, J=8.4, 1H), 8.23 (d, J=2.2, 1H), 8.14 (d, J=8.1, 1H), 
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7.94-7.92 (m, 2H), 7.52 (dd, J=2.2, 8.7, 1H), 7.16-7.10 (m, 2H), 6.85-6.81 (m, 1H), 6.79-
6.77 (m, 1H), 5.03-4.98 (m, 1H), 4.86-4.80 (m, 1H), 4.30-4.15 (m, 4H), 3.55-3.47 (m, 1H), 
3.33-3.26 (m, 1H), 3.03-2.98 (m, 2H), 2.76 (d, J=3.6, 6H), 2.21-2.00 (m, 4H), 1.88-1.83 
(m, 1H), 1.70-1.24 (m, 14H), 0.94 (t, J=7.6, 3H); 13CNMR (100 MHz, DMSO-D6), δ 173.8, 
171.3, 171.2, 170.5, 169.6, 155.1, 151.7, 137.1, 129.9, 129.7, 129.1, 127.0, 123.8, 123.6, 
122.2, 120.6, 116.9, 63.6, 56.9, 56.2, 52.7, 52.5, 42.8, 42.7, 42.6, 36.1, 31.9, 29.2, 29.0, 
28.9, 28.6, 25.3, 25.0, 23.8, 22.8, 10.2. HRMS (ESI-MS) m/z: calculated for 
C37H50ClN6O5S+ 725.3246, found 725.3257 [M+H]+. 
General procedure for the synthesis of amino acids 41a-c: To a solution of (S)-3-
((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(allyloxy)-4-oxobutanoic acid 42 (395 mg, 
1 mmol, 1 equiv.) in DCM (30 mL), oxalyl chloride (257 µL, 3 equiv.) and a catalytic 
amount of DMF were added at 0 oC. After gas evolution ceased, the reaction mixture was 
concentrated. The residue was suspended in toluene (25 mL) and treated with different 
substituted 2-aminobenzenethiols (1 mmol, 1 equiv.). The resultant mixture was stirred 
overnight at room temperature. The solution was diluted with EtOAc and washed with 
saturated NaHCO3, 1.0M HCl, brine and dried over Na2SO4. The solvent was evaporated 
and the crude product was purified by flash chromatography on silica gel. Phenylsilane 
(130 mg, 1.2 mmol, 3 equiv.) was added to a solution of the product of the previous step 
(0.4 mmol, 1 equiv.) and then tetrakis(triphenylphosphine)-palladium(0) (46 mg, 0.04 
mmol, 0.1 equiv.) in DCM was added. The resultant solution was stirred for 1 h before 
being concentrated. The residue was purified by flash chromatography on silica gel to 
afford the Fmoc protected amino acids (41a-c) in 30% to 51% yield over two steps. 
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(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-fluorobenzo[d]thiazol-2-
yl)propanoic acid (41a): 1HNMR (400 MHz, DMSO), δ 13.0 (br. 1H), 7.97-7.87 (m, 4H), 
7.66-7.64 (m, 2H), 7.87 (d, J=7.5, 2H), 7.48-7.22 (m, 6H), 4.54 (dt, J=4.0, 8.8, 1H),  4.28 
(d, J=6.3, 2H), 4.20 (t, J=6.8, 1H), 3.65 (dd, J=4.6, 15.1, 1H), 3.49 (dd, J=9.9, 15.1, 1H);  
ESI-MS m/z: calculated for C25H20FN2O4S+ 463.11, found 463.2 [M+H]+. 
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(5-fluorobenzo[d]thiazol-2-
yl)propanoic acid (41b): 1HNMR (400 MHz, DMSO), δ 13.0 (br. 1H), 8.12-8.09 (m, 1H), 
7.94 (d, J=8.6, 1H), 7.87 (d, J=7.5, 2H), 7.79 (dd, J=2.5, 9.9, 1H), 7.67-7.64 (m, 2H), 7.41-
7.23 (m, 5H), 4.55 (dt, J=4.0, 9.4, 1H),  4.29 (d, J=6.7, 2H), 4.20 (t, J=6.8, 1H), 3.63 (dd, 
J=4.5, 15.1, 1H), 3.47 (dd, J=9.8, 15.1, 1H); 13CNMR (75 MHz, CD3OD). ESI-MS m/z: 
calculated for C25H20FN2O4S+ 463.1, found 463.2 [M+H]+.              
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(6-fluorobenzo[d]thiazol-2-
yl)propanoic acid (41c): 1HNMR (400 MHz, DMSO), δ 13.0 (br. 1H), 7.99-7.92 (m, 3H), 
7.88 (d, J=7.5, 2H), 7.67-7.64 (m, 2H), 7.42-7.34 (m, 3H), 7.30-7.23 (m, 2H), 4.54 (dt, 
J=4.4, 8.6, 1H),  4.28 (d, J=7.0, 2H), 4.20 (t, J=6.8, 1H), 3.60 (dd, J=4.3, 15.1, 1H), 3.45 
(dd, J=9.8, 15.1, 1H); ESI-MS m/z: calculated for C25H20FN2O4S+ 463.11, found 463.2 
[M+H]+. 
General procedure for the synthesis of compounds 43a-c: The amine (10 mmol, 1 
equiv.) was added to a solution of Fmoc-Lys(Boc)-OH 40 (4.7 g, 10 mmol, 1 equiv.), 
HBTU (7.6 g, 20 mmol, 2 equiv.), HOBt (2.7 g, 20 mmol, 2 equiv.) and DIPEA (5.2 mL, 
30 mmol, 3 equiv.) in DMF (50 mL) and the resultant mixture was stirred at room 
temperature for 2 h. The solution was diluted with EtOAc and washed with saturated 
NaHCO3, 1.0M HCl, brine then dried over Na2SO4. After removal of the solvent under 
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vacuum, the residue was treated with diethylamine (10 mL) in CH3CN (90 mL) for 1 h. 
The solvent was evaporated and the crude product was purified by flash chromatography 
on silica gel to afford 43. 
tert-Butyl (S)-(5-amino-6-(benzhydrylamino)-6-oxohexyl)carbamate (43a): 43a was 
produced in 76% yield over two steps. 1HNMR (300 MHz, CDCl3), δ 8.25 (d, J=8.6, 1H), 
7.30-7.18 (m, 10H), 6.19 (d, J=8.6, 1H), 5.05 (brd. 1H), 3.33-3.29 (m, 1H), 3.02-3.00 (m, 
2H), 1.87-1.76 (m, 3H), 1.57-1.30 (m, 14H); 13CNMR (75 MHz, CDCl3), δ 174.4, 156.2, 
141.8, 128.58, 128.56, 127.4, 127.3, 78.8, 56.3, 54.9, 40.1, 34.6, 29.7, 28.5, 22.8. ESI-
MS m/z: calculated for C24H33N3O3+ 412.26, found 412.67 [M+H]+. 
tert-Butyl ((S)-5-amino-6-oxo-6-(((R)-1,2,3,4-tetrahydronaphthalen-1-
yl)amino)hexyl)car-bamate (43b): 1HNMR (300 MHz, CDCl3), δ 7.63 (d, J=8.8, 1H), 
7.32-7.05 (m, 4H), 5.15-5.10 (m, 1H), 4.96 (brd., 1H), 3.37-3.33 (m, 1H), 3.11-3.09 (m, 
2H), 2.82-2.70 (m, 2H), 2.03-1.99 (m, 1H), 1.84-1.75 (m, 6H), 1.57-1.41 (m, 14H); 
13CNMR (75 MHz, CDCl3), δ 174.3, 156.1, 137.4, 136.9, 129.1, 128.4, 127.1, 126.1, 78.9, 
55.0, 46.9, 40.1, 34.7, 30.2, 29.8, 29.2, 28.4, 22.9, 20.1. ESI-MS m/z: calculated for 
C21H34N3O3+ 376.26, found 376.83 [M+H]+. 
tert-Butyl ((S)-5-amino-6-(((R)-chroman-4-yl)amino)-6-oxohexyl)carbamate (43c): 
1HNMR (300 MHz, CDCl3), δ 7.74 (d, J=8.1, 1H), 7.16-7.12 (m, 2H), 6.89-6.78 (m, 2H), 
5.08-5.06 (m, 1H), 4.25-4.12 (m, 1H), 3.35-3.31 (m, 1H), 3.11-3.09 (m, 2H), 2.19-2.17 (m, 
1H), 2.00-1.84 (m, 2H), 1.62-1.41 (m, 16H); 13CNMR (75 MHz, CDCl3), δ 174.7, 156.1, 
154.9, 129.1, 128.9, 122.3, 120.6, 116.9, 78.8, 63.3, 54.9, 42.9, 40.1, 34.6, 29.8, 29.1, 
28.4, 22.9. ESI-MS m/z: calculated for C20H32N3O4+ 378.24, found 378.67 [M+H]+. 
 107 
General procedure for the synthesis of compounds 44a-j: Compound 43 (0.3 mmol, 
1 equiv.) was added to a solution of the corresponding Fmoc protected amino acid (0.3 
mmol, 1 equiv.), HBTU (228 g, 0.6 mmol, 2 equiv.), HOBt (81 mg, 0.6 mmol, 2 equiv.) 
and DIPEA (157 µL, 0.9 mmol, 3 equiv.) in DMF (10 mL) and the resultant mixture was 
stirred at room temperature for 1 h. The solution was diluted with EtOAc and washed with 
saturated NaHCO3, 1.0M HCl, brine then dried over Na2SO4. After removal of the solvent 
under vacuum, the residue was treated with 1 mL diethylamine in CH3CN (9 mL) for 1 h. 
The reaction mixture was evaporated and the crude product was purified by flash 
chromatography on silica gel to afford compounds 44 in 59-75% yield over two steps.  
tert-Butyl ((S)-5-((S)-2-amino-2-cyclopentylacetamido)-6-(benzhydrylamino)-6-
oxohexyl)-carbamate (44a): 1HNMR (300 MHz, CDCl3), δ 8.16 (d, J=8.4, 1H), 7.76 (d, 
J=8.5, 1H), 7.35-7.16 (m, 10H), 6.23 (d, J=8.4, 1H), 4.81 (brd. 1H), 4.74-4.67 (m, 1H), 
3.04-2.98 (m, 3H), 2.09-2.04 (m, 1H), 1.89-1.78 (m, 1H), 1.73-1.43 (m, 20H), 1.36-1.18 
(m, 4H); 13CNMR (75 MHz, CDCl3), δ 175.4, 171.0, 156.1, 141.7, 141.4, 128.6, 128.5, 
127.6, 127.43, 127.38, 127.2, 79.0, 58.4, 56.7, 52.5, 43.7, 40.2, 32.4, 29.5, 29.3, 28.5, 
27.6, 25.6, 25.4, 22.7. ESI-MS m/z: calculated for C31H45N4O4+ 537.34, found 537.92 
[M+H]+. 
tert-Butyl ((S)-5-((S)-2-amino-2-cyclohexylacetamido)-6-(benzhydrylamino)-6-
oxohexyl)-carbamate (44b): 1HNMR (300 MHz, CDCl3), δ 7.80 (d, J=8.2, 1H), 7.72 (d, 
J=8.3, 1H), 7.35-7.18 (m, 10H), 6.21 (d, J=8.3, 1H), 4.65 (brd. 1H), 4.59-4.51 (m, 1H), 
3.06-2.95 (m, 3H), 1.95-1.58 (m, 8H), 1.45-1.42 (m, 11H), 1.36-1.00 (m, 9H); 13CNMR (75 
MHz, CDCl3), δ 175.0, 170.9, 156.1, 141.6, 141.4, 128.64, 128.56, 127.5, 127.3, 79.1, 
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59.9, 56.9, 52.7, 41.0, 40.2, 31.6, 30.2, 29.5, 28.4, 26.7, 26.3, 26.14, 26.07, 22.8. ESI-
MS m/z: calculated for C32H47N4O4+ 551.36, found 551.75 [M+H]+. 
tert-Butyl ((S)-5-((S)-2-amino-3-cyclohexylpropanamido)-6-(benzhydrylamino)-6-
oxo-hexyl)carbamate (44c): 1HNMR (300 MHz, CDCl3), δ 8.02 (d, J=8.5, 1H), 7.85 (d, 
J=8.5, 1H), 7.35-7.15 (m, 10H), 6.22 (d, J=8.3, 1H), 4.72 (t, J=5.8, 1H), 4.67-4.59 (m, 1H), 
3.17-3.13 (m, 1H), 3.04-2.93 (m, 2H),1.90-1.79 (m, 1H), 1.66-1.58 (m, 9H), 1.49-1.42 (m, 
11H), 1.35-1.08 (m, 7H), 0.98-0.77(m, 2H); 13CNMR (75 MHz, CDCl3), δ 176.3, 171.0, 
156.0, 141.6, 141.5, 128.6, 128.5, 127.6, 127.4, 127.2, 78.9, 56.7, 52.63, 52.56, 42.5, 
40.2, 34.2, 34.1, 32.2, 32.0, 29.6, 28.5, 26.4, 26.3, 26.1, 22.7. ESI-MS m/z: calculated for 
C33H49N4O4+ 565.37, found 565.58 [M+H]+. 
tert-Butyl ((S)-5-((S)-2-amino-4,4-dimethylpentanamido)-6-(benzhydrylamino)-6-
oxo-hexyl)carbamate (44d): 1HNMR (300 MHz, CDCl3), δ 7.91 (d, J=8.4, 1H), 7.83 (d, 
J=8.4, 1H), 7.32-7.16 (m, 10H), 6.22 (d, J=8.3, 1H), 4.68 (brd., 1H), 4.61-4.53 (m, 1H), 
3.15-3.02 (m, 3H), 1.94-1.79 (m, 2H), 1.69-1.42 (m, 13H), 1.32-1.09 (m, 4H), 0.93 (s, 9H); 
13CNMR (75 MHz, CDCl3), δ 1768, 170.9, 156.0, 141.6, 141.5, 128.6, 128.5, 127.5, 127.4, 
127.2, 79.0, 56.7, 52.9, 52.7, 49.2, 40.1, 31.9, 30.7, 30.0, 29.6, 28.5, 22.8. ESI-MS m/z: 
calculated for C33H49N4O4+ 539.36, found 539.58 [M+H]+. 
tert-Butyl ((S)-5-((S)-2-amino-4,4,4-trifluorobutanamido)-6-(benzhydrylamino)-6-
oxo-hexyl)carbamate (44e): 1HNMR (300 MHz, CDCl3), δ 8.12 (d, J=8.5, 1H), 7.80 (d, 
J=8.3, 1H), 7.36-7.14 (m, 10H), 6.20 (d, J=8.3, 1H), 4.74 (d, J=5.9, 1H), 4.63-4.56 (m, 
1H), 3.42-3.25 (m, 2H), 3.04-2.95 (m, 2H), 2,78-2.60 (m, 1H), 1.91-1.61 (m, 4H), 1.47-
1.42 (m, 11H), 1.35-1.23 (m, 2H); ESI-MS m/z: calculated for C28H38F3N4O4+ 551.28, 
found 551.92 [M+H]+. 
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tert-Butyl ((S)-5-((S)-2-amino-3-(thiophen-2-yl)propanamido)-6-(benzhydrylamino)-
6-oxo-hexyl)carbamate (44f): 1HNMR (300 MHz, CDCl3), δ 8.07 (d, J=8.2, 1H), 7.95 (d, 
J=8.4, 1H), 7.34-7.15 (m, 11H), 6.93-6.90 (m, 1H), 6.78-6.77 (m, 1H), 6.22 (d, J=8.4, 1H), 
4.76-4.64 (m, 2H), 3.36-2.94 (m, 5H), 1.84-1.63 (m, 3H), 1.45-1.42 (m, 11H), 1.24-1.08 
(m, 3H); 13CNMR (75 MHz, CDCl3), δ 174.0, 170.8, 156.1, 141.6, 141.4, 139.2, 128.64, 
128.56, 127.54, 127.46, 127.3, 127.0, 126.7, 124.7, 79.0, 56.7, 55.9, 52.6, 40.3, 35.0, 
32.3, 29.5, 28.5, 22.6. ESI-MS m/z: calculated for C28H38F3N4O4+ 565.28, found 565.25 
[M+H]+. 
tert-Butyl ((5S)-5-((S)-2-amino-2-cyclopentylacetamido)-6-oxo-6-((1,2,3,4-
tetrahydro-naphthalen-1-yl)amino)hexyl)carbamate (44g): 1HNMR (300 MHz, 
CDCl3), δ 7.77 (d, J=8.5, 1H), 7.58 (d, J=8.1, 1H), 7.18-7.04 (m, 4H), 5.14-5.09 (m, 1H), 
4.92 (br, 1H), 4.62-4.54 (m, 1H),  3.08-3.06 (m, 2H), 2.76-2.72 (m, 3H), 2.03-2.01 (m, 2H), 
1.82-1.77 (m, 4H), 1.66-1.20 (m, 24H); 13CNMR (75 MHz, CDCl3), δ 175.1, 171.1, 156.1, 
137.4, 136.5, 129.0, 128.5, 127.0, 126.1, 78.9, 58.3, 52.3, 47.4, 43.5, 40.3, 32.9, 30.2, 
29.4, 29.3, 28.4, 27.5, 25.6, 25.4, 22.7, 20.2. ESI-MS m/z: calculated for C28H45N4O4+ 
501.34, found 501.83 [M+H]+. 
tert-Butyl ((5S)-5-((S)-2-amino-2-cyclopentylacetamido)-6-(chroman-4-ylamino)-6-
oxo-hexyl)carbamate (44h): 1HNMR (300 MHz, CDCl3), δ 7.95 (d, J=7.4, 1H), 7.80 (d, 
J=8.5, 1H), 7.14-7.10 (m, 2H), 6.87-6.77 (m, 2H), 5.11-5.05 (m, 1H), 4.94 (br, 1H), 4.67-
4.57 (m, 1H),  4.26-4.15 (m, 2H), 3.07-3.05 (m, 2H), 2.71 (d, J=6.1, 1H), 2.19-2.13 (m, 
1H), 2.03-1.99 (m, 2H), 1.81-1.77 (m, 1H), 1.67-1.17 (m, 24H); 13CNMR (75 MHz, CDCl3), 
δ 175.2, 171.3, 156.1, 155.1, 129.4, 128.9, 121.9, 120.6, 116.9, 78.9,77.5, 77.1, 76.7, 
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63.3, 58.1, 52.2, 43.5, 43.4, 40.3, 32.9, 29.4, 29.3, 29.1, 28.4, 27.5, 25.6, 25.4, 22.7. ESI-
MS m/z: calculated for C27H43N4O5+ 503.32, found 503.83 [M+H]+. 
tert-Butyl ((S)-5-((S)-2-amino-2-(tetrahydro-2H-pyran-4-yl)acetamido)-6-(((R)-
chroman-4-yl)amino)-6-oxohexyl)carbamate (44i): 1HNMR (300 MHz, CDCl3), δ 7.91-
7.81 (m, 2H), 7.13-7.08 (m, 2H), 6.85-6.75 (m, 2H), 5.09-5.07 (m, 1H), 4.90 (br, 1H), 4.58-
4.51 (m, 1H),  4.24-4.14 (m, 2H), 3.96-3.92 (m, 2H), 3.36-3.26 (m, 2H), 3.04-3.02 (m, 1H), 
2.70-2.69 (m, 1H), 2.17-2.14 (m, 1H), 2.01-1.97 (m, 1H), 1.82-1.75 (m, 2H), 1.66-1.29 (m, 
20H); 13CNMR (75 MHz, CDCl3), δ 174.0, 171.1, 156.1, 155.0, 129.3, 129.0, 121.9, 120.6, 
117.0, 79.0, 67.7, 63.3, 58.9, 52.4, 43.4, 40.2, 38.3, 32.9, 29.5, 29.2, 28.4, 26.8, 22.8. 
ESI-MS m/z: calculated for C27H43N4O6+ 519.31, found 519.92 [M+H]+. 
tert-Butyl 4-((S)-1-amino-2-(((S)-6-((tert-butoxycarbonyl)amino)-1-(((R)-chroman-4-
yl)-amino)-1-oxohexan-2-yl)amino)-2-oxoethyl)piperidine-1-carboxylate (44j): 
1HNMR (300 MHz, CDCl3), δ 7.92-7.76 (m, 2H), 7.13-7.08 (m, 2H), 6.84-6.74 (m, 2H), 
5.08-5.06 (m, 1H), 4.94 (br, 1H), 4.53-4.51 (m, 1H),  4.19-4.07 (m, 4H), 3.15-3.02 (m, 4H), 
2.84-2.82 (m, 1H), 2.62-2.58 (m, 1H), 2.15-2.13 (m, 1H), 2.00-1.92 (m, 2H), 1.77-1.17 (m, 
30H); 13CNMR (75 MHz, CDCl3), δ 173.9, 171.2, 156.1, 155.0, 154.6, 129.3, 129.0, 121.8, 
120.7, 117.0, 79.5, 79.0, 63.3, 58.9, 52.6, 43.5, 40.1, 39.3, 32.6, 29.5, 29.1, 28.8, 28.4, 
26.1, 22.7. ESI-MS m/z: calculated for C32H52N5O7+ 618.39, found 618.75 [M+H]+.  
Computational Modeling. The crystal structure of DCN1 in a complex with the UBC12 
peptide and cullin 1 (PDB ID 3TDU15) was used to construct the binding models of 
designed molecules with DCN1. Coordinates of DCN1 protein were extracted from the 
co-crystal structure15 and the structurally unresolved side chains in DCN1 were added 
using the MOE program.80 Hydrogen atoms not determined in the crystal structure were 
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added using the “protonate 3D” module in MOE in the physiological conditions. In the 
docking simulations, the designed compounds were first prepared using the MOE 
program and then subject to the docking calculations using the GOLD program (version 
5.1).95, 96 The binding site was centered at F164 in DCN1 and had a radius of 12 Å. In 
each genetic algorithm (GA) run, a maximum number of 200,000 operations were 
performed on a population of 5 islands each with 100 individuals. Operator weights for 
crossover, mutation and migration were set to 95, 95 and 10 respectively. The selection 
of docking poses were assessed by ChemScore (the fitness function) implemented in 
Gold 5.1. The top-ranked conformations based on ChemScore were analyzed to 
determine the predicted docking modes.  
Fluorescence Polarization (FP) competitive binding assays. The immunoprecipitation 
assay was performed as described previously. The Fluorescence Polarization (FP) 
competitive binding assays were performed similarly as described previously16 to 
determine accurately the binding affinities of DCN1 inhibitors. A novel FAM labeled 
fluorescent probe compound (4) was designed and synthesized based on the optimized 
UBC12 peptide. Equilibrium dissociation constant (KD) values of 4 to DCN1 were 
determined from protein saturation experiments by monitoring the total FP values of 
mixtures composed with the fluorescent probe at a fixed concentration and proteins with 
increasing concentrations up to full saturation. Serial dilutions of proteins were mixed with 
4 to a final volume of 200 l in the assay buffer (100 mM phosphate buffer, pH = 6.5, with 
0.02% Tween-20 and 2% DMSO). The final probe concentration was 5 nM for both 
assays. Plates were incubated at room temperature for 30 min with gentle shaking to 
ensure equilibration. FP values in millipolarization units (mP) were measured using the 
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Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, NC) in Microfluor 1 96-
well, black, round-bottom plates (Thermo Scientific, Waltham, MA) at an excitation 
wavelength of 485 nm and an emission wavelength of 530 nm. The KD values of 4 were 
calculated by fitting the sigmoidal dose-dependent FP increases to a function of protein 
concentrations using Graphpad Prism 6.0 software (Graphpad Software, San Diego, CA).  
The IC50 and Ki values of compounds were determined in competitive binding 
experiments. Mixtures of 4 l of compounds in DMSO and 196 l of pre-incubated 
protein/probe complex solution in the assay buffer were added into assay plates which 
were incubated at room temperature for 30 minutes with gentle shaking. Final 
concentrations of DCN1 protein and fluorescent probe (4) were 200 and 5 nM, 
respectively. Negative controls containing protein/probe complex only (equivalent to 0% 
inhibition), and positive controls containing only free probes (equivalent to 100% 
inhibition), were included in each assay plate. FP values were measured as described 
above. IC50 values were determined by nonlinear regression fitting of the competition 
curves. Ki values of competitive inhibitors were obtained directly by nonlinear regression 
fitting, based upon the KD values of the probe (4), concentrations of the protein and probe 
in the competitive assays. All the FP competitive experiments were performed in duplicate 
in three independent experiments. 
Bio-Layer Interferometry (BLI) Method. Bio-Layer Interferometry (BLI) assay was 
performed similarly as described previously.16 Purified recombinant DCN1 protein was 
biotinylated using the Thermo EZ-Link long-chain biotinylation reagent. Briefly, protein 
and biotinylation reagent were mixed in a 1:1 molar ratio in PBS at 4 C. A low 
concentration of biotinylation reagent was applied to avoid protein over-biotinylation. This 
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reaction mixture was incubated at 4 C for 2 h to allow the reaction to complete. The 
reaction mixture was then dialyzed using Fisherscientific 10K MWCO dialysis cassettes 
to remove unreacted biotinylation reagent.  
 
BLI experiments were performed using an OctetRED96 instrument from PALL/ForteBio. 
All assays were run at 30 C with continuous 1000 RPM shaking. PBS with 0.1% BSA, 
0.01% Tween-20 and 2% DMSO was used as the assay buffer. Biotinylated DCN1 protein 
was tethered to Super Streptavidin (SSA) biosensors (ForteBio) by dipping the sensors 
into 10 µg/mL protein solutions. An average saturation response level of 11-12 nm was 
achieved in 15 min. Biotinylated blocked Streptavidin (SAV B4) sensors were prepared 
by following the protocol provided by the manufacturer and were used as the inactive 
reference controls. Sensors with tethered proteins were washed in assay buffer for 10 
min to eliminate loose nonspecific bound protein molecules and establish a stable base 
line before starting association-dissociation cycles of the test compound. Different 
association and dissociation times were used depending on the potencies of compounds 
being tested. A DMSO-only reference was included in all assays. Raw kinetic data 
collected were processed in the Data Analysis software provided by the manufacturer 
using double reference subtraction in which both DMSO-only reference and inactive 
protein reference were subtracted. The resulting data were analyzed based on 1:1 binding 
model from which kon and koff values were obtained and then KD values were calculated. 
All the BLI experiments were performed in two independent experiments. 
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Aqueous Solubility Assay. Aqueous Solubility Assay was performed similarly as 
described previously.16 The equilibrium aqueous solubility of an individual compound at 
pH 7.4 was determined with a small-scale shake-flask method in Eppendorf tubes. 
Compounds were added as powder in excess to phosphate buffer at pH 7.4 until 
heterogeneous suspensions were obtained. Suspensions containing excessive 
compound powder were sonicated in a water bath for 30 min followed by incubation at 
room temperature with shaking for 24 h to achieve thermodynamic equilibrium. 
Suspensions were centrifuged at 15000 RPM for 15 min. Supernatants obtained were 
filtered using Millipore MultiScreen filter plates equipped with 0.45 µm membranes. 
Compound concentrations in the saturated solutions were measured by UV spectroscopy 
at the maximum absorption wavelength of each compound, pre-determined by a 
spectrum scan.  
 
Cloning and Purification of DCN1 proteins. DCN1 proteins were cloned and purified 
similarly as described previously.16 Human DCN1 (residues 58-259) was expressed and 
purified as described previously. Briefly, the N-terminal His6 tagged protein was 
expressed in Rosetta2 cells and purified by Ni-NTA (Qiagen) followed by a Superdex 75 
(GE Healthcare) column pre-equilibrated with 25 mM Tris pH 7.5, 200 mM NaCl and 1 
mM DTT. The uncleaved DCN1 protein was stored at -80 °C without glycerol. 
 
Crystallization and Structure Determination of 38-DCN1 Complex.  Crystallization 
experiments were performed similarly as described previously.16 Prior to crystallization, 
DCN1 in 25 mM Tris-HCl pH 7.5, 200 mM NaCl and 1 mM DTT was concentrated to 10 
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mg/mL and incubated for 1 h at 4 °C with compound 38 in a protein to compound molar 
ratio of 1:1.3. Crystals were grown at 20 °C from sitting drop vapor diffusion experiments. 
The drops contained 1 µL of DCN1:38 and 1 µL of well solution (37 % PEG 300, 0.1 M 
phosphate-citrate pH 4.2). The crystal growth conditions were cryoprotective, therefore 
crystals were mounted directly from the drops and stored in liquid nitrogen prior to data 
collection. 
Diffraction data were collected on a Mar225 detector mounted on the LS-CAT 21-ID-F 
beamline at the Advanced Photon Source and processed with HKL200097. The structure 
was solved by molecular replacement (Molrep98) using an in-house DCN1 structure 
lacking its bound ligand as the search model. The resulting DCN1:38 structure had two 
protein molecules in the asymmetric unit, each containing one bound compound 38 
molecule. The structure was fit iteratively and refined to 2.16 Å resolution using Coot99 
and Buster100, respectively. The coordinates and restraints for the compound were 
determined using Grade100 with the mogul+qm option. Residues 62 – 251 from the A 
chain and residues 62-75; 80-251 from chain B were visible in the electron density maps. 
Data collection and refinement statistics are listed in Table A1.  
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Table A1 Crystallography Data Collection and Refinement Statistics 
 
Cellular Thermal Shift Assay. Cellular thermal shift assay was performed similarly as 
described previously.16 The Cellular Thermal Shift Assay was performed according to the 
reported method16, 72. H2170 cells (5x105 per sample) were treated with a compound or 
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with DMSO for 1 h, washed with PBS three times, and dissolved in 50 µl PBS 
supplemented with a protease inhibitor, followed by heating at indicated temperatures in 
a Mastercycler gradient (Eppendorf, New York, USA). Treated cells were then subjected 
to snap-freezing in liquid nitrogen and thawed on ice for 3 cycles. The protein levels of 
DCN1 in equal amounts of the supernatant were examined by western blots. GAPDH was 
used as the loading control. 
 
Co-immunoprecipitation Assay. The immunoprecipitation assay was performed as 
described previously.101 Briefly, to immunoprecipitate endogenous DCN1, the pre-cleared 
cell lysates were incubated with DCN1 antibody for 3 h, followed by incubation with protein 
A&G beads (Santa Cruz) at 4 °C overnight with rotation. The beads were washed three 
times with lysis buffer, and the immunoprecipitation complexes were subjected to SDS-
PAGE. 
 
Western blot analysis. For direct analysis, cells were lysed in a Triton X-100 or RIPA 
buffer with phosphatase inhibitors. The antibodies used were as follows: UBE2M (Santa 
Cruz), CUL1 (Santa Cruz), CUL-2 (BD Bioscience), CUL3 (Cell Signal), CUL4A (Cell 
Signal), CUL4B (Proteintech), CUL5 (Santa Cruz), NRF2 (Santa Cruz), CDT-1 (Santa 
Cruz), DCN1 (Genway) and β-actin (Sigma).  
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Appendix B: Experimental Section of Chapter 3 
Peptide Synthesis 
All the peptides in Table 1 and Table 2 were synthesized using Fmoc solid phase peptide 
synthesis (SPPS). The synthesis was conducted on the ABI 433A peptide synthesizer. 
Rink amide resin was used as the solid support. The TFA/TES/H2O (36:1:2) cleavage 
cocktail was applied to cleave the peptide from resin. After removal of solvents by 
evaporation, the peptide was purified by RP-HPLC.  
Chemistry. General Information. All reagents and solvents were used as supplied 
without further purification and the reactions were performed under a nitrogen 
atmosphere in anhydrous solvents. The final products were purified by a reverse phase 
HPLC (RP-HPLC) with solvent A (0.1% of TFA in H2O) and solvent B (0.1% of TFA in 
CH3CN) as eluents. The purity was determined by Waters ACQUITY UPLC and all the 
final compounds were > 95% pure. 1HNMR spectra of the synthetic compounds were 
acquired at a proton frequency of 400 MHz and chemical shifts are reported in parts per 
million (ppm) relative to an internal standard. High resolution mass spectra (HRMS) were 
obtained with an Agilent Q-TOF Electrospray mass spectrometer and low resolution mass 
spectral analyses were performed on a Thermo-Scientific LCQ Fleet mass spectrometer. 
General Procedure for the Synthesis of Compounds 1-7.  
Step 1. A solution of compound 37 (2.43 g, 5 mmol, 1 equiv), an amine (5 mmol, 1 equiv), 
HATU (3.8g, 10 mmol, 2 equiv), and DIPEA (2.6 ml, 15 mmol, 3 equiv) in DMF (25 ml) 
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was stirred at rt for 3 h. After the reaction was complete, the solution was diluted with 
EtOAc and washed with saturated NaHCO3, 1.0 M HCl and brine then dried over Na2SO4. 
The organic solvent was removed under vacuum, the residue was treated with 
diethylamine in DCM (1:9) for 1 h. The reaction mixture was evaporated, and the residue 
was dissolved in DCM (25 mL) and treated with propionic anhydride (1.3 ml, 15 mmol, 3 
equiv) and DIPEA (2.6 ml, 15 mmol, 3 equiv) for 30 min. The solvent was evaporated, 
and the crude product was purified by flash chromatography on silica gel to afford the 
common intermediate (39).   
Step 2. Compound 39 (0.1 mmol, 1 equiv), boronic acid (0.2 mmol, 2 equiv), K2CO3 (0.3 
mmol, 3 equiv) were dissolved in dioxane (1ml). The flask was sealed and charged with 
nitrogen gas, then a catalyst, tetrakis(triphenylphosphine)palladium(0) (0.1 equiv) was 
quickly added. The flask was heated in oil bath at 120 oC and stirred for 2 h. After the 
solution cooled to rt, it was diluted with EtOAc and washed with saturated NaHCO3, 1.0 
M HCl and brine and then dried over Na2SO4. The solvent was evaporated, and the crude 
product was purified by flash chromatography on silica gel to afford compound 1-7.   
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-(3-chlorophenyl)-4-methylthiazol-2-yl)-
2-propionamidopropanamide (1): 1H NMR (400 MHz, MeOD) δ 7.54 - 7.40 (m, 3H), 
7.39 - 7.29 (m, 3H), 7.28 - 7.15 (m, 3H), 4.70 (dd, J = 7.8, 5.2 Hz, 1H), 4.42-4.39 (m, 
1H), 3.45 (dd, J = 15.1, 5.2 Hz, 1H), 3.31 - 3.23 (m, 1H), 3.18 (dd, J = 13.0, 3.4 Hz, 1H), 
3.07 (dd, J = 15.8, 7.6 Hz, 1H), 2.98 - 2.84 (m, 2H), 2.43 (s, 3H), 2.26 (q, J = 7.6 Hz, 
2H), 1.10 (t, J = 7.6 Hz, 3H). ESI-MS m/z [M + H] + calculated = 485.17, found = 485.36. 
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(4-methyl-5-(m-tolyl)thiazol-2-yl)-2-
propionamidopropanamide (2): 1H NMR (400 MHz, MeOH-d4) δ 7.33 (dt, J = 10.5, 7.4 
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Hz, 3H), 7.28 – 7.20 (m, 6H), 4.69 (dd, J = 7.8, 5.1 Hz, 1H), 4.45 – 4.36 (m, 1H), 3.45 
(ddd, J = 15.1, 5.2, 1.8 Hz, 1H), 3.31 – 3.25 (m, 1H), 3.18 (dd, J = 13.0, 3.7 Hz, 1H), 
3.11 (s, 1H), 2.91 (dd, J = 7.5, 3.6 Hz, 2H), 2.40 (d, J = 9.1 Hz, 6H), 2.26 (q, J = 7.6 Hz, 
2H), 1.10 (t, J = 7.6 Hz, 3H). ESI-MS m/z [M + H] + calculated = 465.22, found = 465.17. 
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(4-methyl-5-(3-
(trifluoromethyl)phenyl)thiazol-2-yl)-2-propionamidopropanamide (3): 1H NMR (400 
MHz, MeOH-d4) δ 7.72 (q, J = 5.1, 4.6 Hz, 4H), 7.35 – 7.21 (m, 5H), 4.71 (dd, J = 7.9, 
5.2 Hz, 1H), 4.45 – 4.34 (m, 1H), 3.46 (dd, J = 15.1, 5.2 Hz, 1H), 3.32 – 3.26 (m, 1H), 
3.18 (dd, J = 13.1, 3.7 Hz, 1H), 3.08 (dd, J = 13.0, 10.3 Hz, 1H), 2.97 – 2.85 (m, 2H), 
2.44 (s, 3H), 2.31 – 2.21 (m, 2H), 1.11 (t, J = 7.6 Hz, 3H). ESI-MS m/z [M + H] + 
calculated = 519.20, found = 519.11. 
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(4-methyl-5-phenylthiazol-2-yl)-2-
propionamidopropanamide (4): 1H NMR (400 MHz, MeOH-d4) δ 7.51 – 7.37 (m, 5H), 
7.35 – 7.21 (m, 5H), 4.69 (dd, J = 7.8, 5.2 Hz, 1H), 4.41 (d, J = 7.5 Hz, 1H), 3.45 (dd, J 
= 15.1, 5.1 Hz, 1H), 3.27 (dd, J = 15.8, 7.7 Hz, 1H), 3.21 – 3.15 (m, 1H), 3.13 – 3.02 (m, 
1H), 2.98 – 2.84 (m, 2H), 2.47 – 2.38 (m, 3H), 2.26 (q, J = 7.6 Hz, 2H), 1.10 (t, J = 7.6 
Hz, 3H). ESI-MS m/z [M + H] + calculated = 451.21, found = 451.32. 
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-(2-chlorophenyl)-4-methylthiazol-2-yl)-
2-propionamidopropanamide (5): 1H NMR (400 MHz, MeOD) δ 7.59 – 7.53 (m, 1H), 
7.48 – 7.37 (m, 3H), 7.35 – 7.19 (m, 5H), 4.59 (dd, J = 8.5, 5.8 Hz, 1H), 4.49 – 4.32 (m, 
1H), 3.22 – 3.09 (m, 3H), 3.00 (dd, J = 12.9, 10.6 Hz, 1H), 2.92 (dd, J = 13.9, 6.4 Hz, 
1H), 2.82 (dd, J = 13.9, 8.7 Hz, 1H), 2.34 – 2.16 (m, 5H), 1.10 (t, J = 7.6 Hz, 3H).ESI-
MS m/z [M + H] + calculated = 485.17, found = 485.32. 
 121 
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-(2-chlorophenyl)-4-methylthiazol-2-yl)-
2-propionamidopropanamide (6): 1H NMR (400 MHz, MeOD) δ 7.92 – 7.78 (m, 2H), 
7.68 – 7.59 (m, 2H), 7.37 – 7.28 (m, 2H), 7.28 – 7.18 (m, 3H), 4.71 (dd, J = 8.1, 5.1 Hz, 
1H), 4.41-4.38 (m, 1H), 3.46 (dd, J = 15.2, 5.1 Hz, 1H), 3.31 – 3.25 (m, 1H), 3.18 (dd, J 
= 13.1, 3.7 Hz, 1H), 3.11 – 3.02 (m, 1H), 2.92-2.90 (m, 2H), 2.47 (s, 3H), 2.25 (q, J = 7.5 
Hz, 2H), 1.10 (t, J = 7.6 Hz, 3H). ESI-MS m/z [M + H] + calculated = 485.17, found = 
485.36. 
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-cyclopentyl-4-methylthiazol-2-yl)-2-
propionamidopropanamide (7): 1H NMR (400 MHz, MeOH-d4) δ 7.46 – 7.12 (m, 5H), 
4.64 (dd, J = 8.1, 5.1 Hz, 1H), 4.38 (d, J = 8.4 Hz, 1H), 3.45 (dd, J = 15.1, 5.1 Hz, 1H), 
3.25 (dd, J = 15.1, 8.1 Hz, 1H), 3.16 (dd, J = 13.0, 3.8 Hz, 1H), 3.05 (dd, J = 13.0, 10.3 
Hz, 1H), 2.89 (dt, J = 10.4, 4.5 Hz, 2H), 2.33 (d, J = 0.9 Hz, 2H), 2.23 (qd, J = 7.4, 2.4 
Hz, 2H), 2.05 – 1.81 (m, 4H), 1.78 (d, J = 12.8 Hz, 1H), 1.46 (dt, J = 15.8, 11.1 Hz, 2H), 
1.40 – 1.21 (m, 3H), 1.08 (td, J = 7.6, 1.0 Hz, 3H). ESI-MS m/z [M + H] + calculated = 
443.24, found = 443.36. 
General Procedure for the Synthesis of Compounds 8-10.  
An acyl chloride (0.2 mmol, 2 equiv) and DIPEA (0.3 mmol, 3 equiv) were added to a 
solution of compound 40 (52.7 mg, 0.1 mmol, 1 equiv) in DCM and stirred for 1 h at rt. 
The reaction mixture was concentrated and treated with TFA (3 ml) in DCM (10 ml) at rt 
for 1 h. This reaction mixture was concentrated and purified by RP-HPLC to provide the 
compounds 8-10 in 45-76% yield over two steps.  
(2S)-2-Acetamido-N-(1-amino-3-phenylpropan-2-yl)-3-(5-(3-chlorophenyl)-4-
methylthiazol-2-yl)propanamide (8): 1H NMR (400 MHz, MeOH-d4) δ 7.49 – 7.36 (m, 
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4H), 7.35 – 7.29 (m, 2H), 7.29 – 7.22 (m, 3H), 4.70 (dd, J = 7.8, 5.2 Hz, 1H), 4.40 (td, J 
= 10.9, 10.4, 4.9 Hz, 1H), 3.44 (dd, J = 15.2, 5.2 Hz, 1H), 3.28 (ddd, J = 15.1, 7.8, 1.4 
Hz, 1H), 3.18 (dd, J = 13.0, 3.7 Hz, 1H), 3.08 (dd, J = 13.2, 10.3 Hz, 1H), 2.97 – 2.85 
(m, 2H), 2.43 (s, 3H), 1.99 (s, 3H). ESI-MS m/z [M + H] + calculated = 471.15, found = 
471.26. 
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-(3-chlorophenyl)-4-methylthiazol-2-yl)-
2-isobutyramidopropanamide (9): 1H NMR (400 MHz, MeOH-d4) δ 7.50 – 7.34 (m, 
4H), 7.33 – 7.20 (m, 5H), 4.70 (dd, J = 7.8, 5.2 Hz, 1H), 4.40 (ddd, J = 10.9, 7.3, 3.6 Hz, 
1H), 3.46 (dd, J = 15.1, 5.2 Hz, 1H), 3.29 (dd, J = 7.9, 1.2 Hz, 1H), 3.18 (dd, J = 13.0, 
3.7 Hz, 1H), 3.09 (t, J = 11.8 Hz, 1H), 2.92 (d, J = 7.4 Hz, 2H), 2.50 (p, J = 6.8 Hz, 1H), 
2.42 (s, 3H), 1.09 (t, J = 6.8 Hz, 6H). ESI-MS m/z [M + H] + calculated = 499.19, found = 
499.02. 
N-((2S)-1-((1-Amino-3-phenylpropan-2-yl)amino)-3-(5-(3-chlorophenyl)-4-
methylthiazol-2-yl)-1-oxopropan-2-yl)benzamide (10): 1H NMR (400 MHz, MeOH-d4) 
δ 7.88 – 7.83 (m, 2H), 7.63 – 7.58 (m, 1H), 7.54 – 7.50 (m, 2H), 7.46 – 7.39 (m, 3H), 
7.35 (dt, J = 7.1, 1.7 Hz, 1H), 7.24 – 7.14 (m, 5H), 4.47 – 4.36 (m, 1H), 3.56 (dd, J = 
15.1, 5.2 Hz, 1H), 3.46 (dd, J = 15.1, 8.2 Hz, 1H), 3.19 (dd, J = 13.0, 3.7 Hz, 1H), 3.13 – 
3.06 (m, 1H), 2.97 – 2.82 (m, 3H), 2.43 (s, 3H). ESI-MS m/z [M + H] + calculated = 
533.17, found = 533.21. 
General Procedure for the Synthesis of Compounds 11-19.  
A solution of compound 40 (52.7 mg, 0.1 mmol, 1 equiv.), aryl iodide (0.1 mmol, 1 
equiv.), copper iodide (20 mol%), 2-isobutyrylcyclohexanone (30 mol%), Cs2CO3 (0.1 
mmol, 2 equiv.) in DMF in a round bottom flask was sealed and was stirred in oil bath at 
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80 ℃ for 8 h. After cooling down to rt, the mixture was diluted with EtOAc and washed 
with saturated NaHCO3, 1.0 M HCl and brine and then dried over Na2SO4. The solvent 
was evaporated, and the crude product was purified by purified by RP-HPLC to provide 
compounds 11-19. 
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-(3-chlorophenyl)-4-methylthiazol-2-yl)-
2-(phenylamino)propanamide (11): 1H NMR (400 MHz, MeOH-d4) δ 7.55 – 7.36 (m, 
4H), 7.36 – 7.16 (m, 6H), 7.17 – 7.07 (m, 2H), 6.72 (t, J = 7.3 Hz, 1H), 6.63 – 6.59 (m, 
1H), 4.58 (s, 1H), 4.41 (s, 1H), 3.50 (d, J = 2.3 Hz, 1H), 3.18 – 3.12 (m, 1H), 3.04 (d, J = 
11.5 Hz, 1H), 2.96 – 2.81 (m, 2H), 2.42 (s, 3H). ESI-MS m/z [M + H] + calculated = 
505.18, found = 505.53. 
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-(3-chlorophenyl)-4-methylthiazol-2-yl)-
2-((3-chlorophenyl)amino)propanamide (12): 1H NMR (400 MHz, MeOH-d4) δ 7.47 – 
7.37 (m, 3H), 7.33 (dq, J = 7.3, 1.6 Hz, 1H), 7.31 – 7.19 (m, 5H), 7.05 (t, J = 8.0 Hz, 
1H), 6.69 – 6.64 (m, 2H), 6.51 – 6.46 (m, 1H), 4.46 – 4.37 (m, 1H), 4.34 (ddd, J = 6.5, 
5.0, 1.3 Hz, 1H), 3.49 (dd, J = 14.9, 5.0 Hz, 1H), 3.32 – 3.26 (m, 1H), 3.17 (dd, J = 13.0, 
4.1 Hz, 1H), 3.06 (dd, J = 12.8, 9.5 Hz, 1H), 2.90 (qd, J = 14.0, 7.3 Hz, 2H), 2.41 (s, 
3H). ESI-MS m/z [M + H] + calculated = 539.14, found = 539.20. 
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-(3-chlorophenyl)-4-methylthiazol-2-yl)-
2-((2-chlorophenyl)amino)propanamide (13): 1H NMR (400 MHz, MeOH-d4) δ 7.47 – 
7.38 (m, 3H), 7.33 (dt, J = 7.3, 1.7 Hz, 1H), 7.30 – 7.22 (m, 5H), 7.21 (dd, J = 6.7, 2.0 
Hz, 1H), 7.12 – 7.06 (m, 1H), 6.70 (t, J = 7.6 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 4.45 (q, J 
= 7.7, 5.4 Hz, 2H), 3.54 (dd, J = 14.8, 4.8 Hz, 1H), 3.43 (dd, J = 14.8, 6.2 Hz, 1H), 3.20 
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(dd, J = 13.1, 3.8 Hz, 1H), 3.08 (t, J = 11.3 Hz, 1H), 3.00 – 2.81 (m, 2H), 2.41 (s, 3H). 
ESI-MS m/z [M + H] + calculated = 539.14, found = 539.21.  
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-(3-chlorophenyl)-4-methylthiazol-2-yl)-
2-((2-chlorophenyl)amino)propanamide (14): 1H NMR (400 MHz, MeOH-d4) δ 7.48 – 
7.38 (m, 3H), 7.34 (dt, J = 7.2, 1.6 Hz, 1H), 7.31 – 7.21 (m, 5H), 7.10 – 7.00 (m, 2H), 
6.56 – 6.47 (m, 2H), 4.41 (d, J = 6.2 Hz, 1H), 4.27 (dd, J = 7.3, 5.1 Hz, 1H), 3.52 – 3.44 
(m, 1H), 3.22 – 3.14 (m, 1H), 3.11 – 3.01 (m, 2H), 2.95 (dd, J = 14.0, 5.9 Hz, 1H), 2.85 
(dd, J = 14.1, 9.0 Hz, 1H), 2.42 (s, 3H). ESI-MS m/z [M + H] + calculated = 539.14, 
found = 539.22.  
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-(3-chlorophenyl)-4-methylthiazol-2-yl)-
2-((3-fluorophenyl)amino)propanamide (15): 1H NMR (400 MHz, MeOH-d4) δ 7.46 – 
7.39 (m, 3H), 7.34 (dt, J = 7.2, 1.7 Hz, 1H), 7.31 – 7.22 (m, 5H), 7.08 (td, J = 8.3, 6.7 
Hz, 1H), 6.38 (tdd, J = 11.7, 6.4, 2.3 Hz, 3H), 4.42 (td, J = 7.5, 5.9, 2.8 Hz, 1H), 4.32 
(dd, J = 7.3, 5.1 Hz, 1H), 3.52 – 3.46 (m, 1H), 3.17 (dd, J = 13.0, 4.0 Hz, 1H), 3.06 (d, J 
= 10.7 Hz, 1H), 2.98 – 2.92 (m, 1H), 2.93 – 2.80 (m, 2H), 2.42 (s, 3H). ESI-MS m/z [M + 
H] + calculated = 523.17, found = 523.45.  
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-(3-chlorophenyl)-4-methylthiazol-2-yl)-
2-((2-fluorophenyl)amino)propanamide (16): 1H NMR (400 MHz, MeOH-d4) δ 7.50 – 
7.37 (m, 3H), 7.33 (dq, J = 7.2, 1.5 Hz, 1H), 7.31 – 7.15 (m, 5H), 7.05 – 6.87 (m, 2H), 
6.70 (tdd, J = 7.8, 4.9, 1.5 Hz, 1H), 6.61 (td, J = 8.4, 1.5 Hz, 1H), 4.49 – 4.34 (m, 2H), 
3.52 (dd, J = 14.9, 5.0 Hz, 1H), 3.39 (dd, J = 14.8, 6.9 Hz, 1H), 3.18 (dd, J = 13.1, 4.0 
Hz, 1H), 3.07 (dd, J = 12.9, 9.7 Hz, 1H), 3.00 – 2.79 (m, 2H), 2.41 (d, J = 0.9 Hz, 3H). 
ESI-MS m/z [M + H] + calculated = 523.17, found = 523.41.  
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(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-(3-chlorophenyl)-4-methylthiazol-2-yl)-
2-((4-fluorophenyl)amino)propanamide (17): 1H NMR (400 MHz, MeOH-d4) δ 7.48 – 
7.38 (m, 3H), 7.33 (dt, J = 7.3, 1.7 Hz, 1H), 7.29 – 7.16 (m, 5H), 7.03 – 6.90 (m, 2H), 
6.73 – 6.66 (m, 1H), 6.60 (td, J = 8.4, 1.5 Hz, 1H), 4.50 – 4.33 (m, 2H), 3.52 (dd, J = 
14.9, 5.0 Hz, 1H), 3.39 (dd, J = 14.9, 6.9 Hz, 1H), 3.18 (dd, J = 13.0, 4.0 Hz, 1H), 3.07 
(dd, J = 13.0, 9.7 Hz, 1H), 2.99 – 2.81 (m, 2H), 2.41 (s, 3H). ESI-MS m/z [M + H] + 
calculated = 523.17, found = 523.38.  
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-(3-chlorophenyl)-4-methylthiazol-2-yl)-
2-((2,3-difluorophenyl)amino)propanamide (18): 1H NMR (400 MHz, MeOH-d4) δ 
7.47 – 7.38 (m, 3H), 7.35 (dt, J = 7.3, 1.7 Hz, 1H), 7.30 – 7.18 (m, 5H), 6.95 (dt, J = 
10.6, 9.0 Hz, 1H), 6.50 (ddd, J = 13.0, 6.7, 2.8 Hz, 1H), 6.30 (ddd, J = 9.0, 3.3, 1.5 Hz, 
1H), 4.42 (tdt, J = 8.2, 5.7, 2.4 Hz, 1H), 4.29 – 4.22 (m, 1H), 3.48 (dd, J = 15.0, 5.1 Hz, 
1H), 3.18 (dd, J = 13.0, 4.1 Hz, 1H), 3.12 – 3.01 (m, 1H), 3.00 – 2.80 (m, 2H), 2.42 (s, 
3H). ESI-MS m/z [M + H] + calculated = 541.16, found = 541.37.  
(2S)-N-(1-Amino-3-phenylpropan-2-yl)-3-(5-(3-chlorophenyl)-4-methylthiazol-2-yl)-
2-((3,5-difluorophenyl)amino)propanamide (19): 1H NMR (400 MHz, MeOH-d4) δ 
7.48 – 7.39 (m, 3H), 7.35 (dd, J = 7.2, 1.8 Hz, 1H), 7.30 – 7.18 (m, 5H), 6.24 – 6.14 (m, 
3H), 4.47 – 4.38 (m, 1H), 4.32 (ddd, J = 6.6, 5.1, 1.3 Hz, 1H), 3.49 (dd, J = 15.0, 5.1 Hz, 
1H), 3.35 (s, 1H), 3.18 (dd, J = 13.0, 4.0 Hz, 1H), 3.06 (dd, J = 13.0, 9.4 Hz, 1H), 2.98 – 
2.82 (m, 2H), 2.42 (s, 3H). ESI-MS m/z [M + H] + calculated = 541.16, found = 541.39.  
General Procedure for the Synthesis of Compounds 20-34.  
A solution of compound 42 (40 mg, 0.1 mmol, 1 equiv), an amine (0.12 mmol, 1.2 
equiv), HATU (76 mg, 0.2 mmol, 2 equiv), and DIPEA (26 ml, 0.2 mmol, 2 equiv) in 
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DMF (25 ml) was stirred at rt for 3 h. The reaction mixture was diluted with EtOAc and 
washed with saturated NaHCO3, 1.0 M HCl and brine and then dried over with Na2SO4. 
The solvent was evaporated, and the crude product was purified by purified by RP-
HPLC to provide the compounds 20-34. 
(S)-3-(5-(3-Chlorophenyl)-4-methylthiazol-2-yl)-2-((3,5-difluorophenyl)amino)-N-
((S)-1-(dimethylamino)-3-(p-tolyl)propan-2-yl)propanamide (20): 1H NMR (400 MHz, 
MeOH-d4) δ 7.46 – 7.38 (m, 3H), 7.35 – 7.19 (m, 6H), 6.19 (dd, J = 10.2, 7.3 Hz, 3H), 
4.57 (s, 1H), 4.39 – 4.32 (m, 1H), 3.42 (dd, J = 15.1, 3.9 Hz, 2H), 3.28 – 3.14 (m, 2H), 
2.93 (s, 7H), 2.85 (dd, J = 13.9, 8.2 Hz, 1H), 2.41 (s, 3H).ESI-MS m/z [M + H] + 
calculated = 569.19, found = 583.12.  
(S)-3-(5-(3-Chlorophenyl)-4-methylthiazol-2-yl)-2-((3,5-difluorophenyl)amino)-N-
((S)-1-(dimethylamino)propan-2-yl)propanamide (21): 1H NMR (400 MHz, 
Chloroform-d) δ 9.10 (s, 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.52 – 7.41 (m, 2H), 7.34 (dt, J = 
10.4, 1.9 Hz, 1H), 7.25 (ddt, J = 10.7, 7.1, 1.8 Hz, 1H), 6.20 (t, J = 9.5 Hz, 3H), 4.67 – 
4.36 (m, 2H), 4.20 (d, J = 15.1 Hz, 1H), 3.60 (t, J = 12.6 Hz, 1H), 3.46 (t, J = 12.2 Hz, 
1H), 3.06 (s, 1H), 2.98 (s, 6H), 2.51 (d, J = 17.0 Hz, 3H), 1.23 (dd, J = 14.0, 6.5 Hz, 3H). 
ESI-MS m/z [M + H] + calculated = 493.16, found = 493.28.  
(S)-3-(5-(3-Chlorophenyl)-4-methylthiazol-2-yl)-2-((3,5-difluorophenyl)amino)-N-
((S)-1-(dimethylamino)-4-methylpentan-2-yl)propanamide (22): 1H NMR (400 MHz, 
Chloroform-d) δ 10.56 (s, 1H), 8.30 (d, J = 8.9 Hz, 1H), 7.43 (dd, J = 4.9, 1.8 Hz, 2H), 
7.36 (d, J = 1.9 Hz, 1H), 7.26 (dt, J = 5.7, 2.0 Hz, 1H), 6.21 (dd, J = 9.7, 6.7 Hz, 3H), 
4.56 (d, J = 8.9 Hz, 1H), 4.43 (s, 1H), 4.04 (d, J = 14.8 Hz, 1H), 3.61 – 3.41 (m, 2H), 
2.96 (d, J = 13.9 Hz, 6H), 2.88 (d, J = 12.1 Hz, 1H), 2.52 (s, 3H), 1.53 (dd, J = 27.2, 
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14.9 Hz, 2H), 1.27 – 1.14 (m, 1H), 0.86 (dd, J = 17.8, 6.4 Hz, 6H). ESI-MS m/z [M + H] + 
calculated = 535.20, found = 535.11.  
(S)-3-(5-(3-Chlorophenyl)-4-methylthiazol-2-yl)-N-((S)-1-cyclohexyl-2-
(dimethylamino)-ethyl)-2-((3,5-difluorophenyl)amino)propanamide (23): 1H NMR 
(400 MHz, Chloroform-d) δ 10.67 (s, 1H), 8.56 (d, J = 9.3 Hz, 1H), 7.45 – 7.34 (m, 3H), 
7.27 (ddd, J = 4.9, 3.8, 1.8 Hz, 1H), 6.34 – 6.14 (m, 3H), 4.56 (d, J = 8.4 Hz, 1H), 4.23 
(s, 1H), 3.99 (d, J = 14.8 Hz, 1H), 3.73 (td, J = 6.5, 3.3 Hz, 1H), 3.55 (q, J = 13.5 Hz, 
2H), 3.15 (dt, J = 7.4, 3.8 Hz, 1H), 2.90 (d, J = 14.9 Hz, 6H), 2.51 (s, 3H), 1.71 (d, J = 
12.9 Hz, 2H), 1.62 (d, J = 11.4 Hz, 3H), 1.35 (t, J = 7.3 Hz, 1H), 1.23 – 0.98 (m, 4H). 
ESI-MS m/z [M + H] + calculated = 561.22, found = 561.35.  
(S)-3-(5-(3-Chlorophenyl)-4-methylthiazol-2-yl)-N-((S)-1-cyclohexyl-3-
(dimethylamino)-propan-2-yl)-2-((3,5-difluorophenyl)amino)propanamide (24): 1H 
NMR (400 MHz, Chloroform-d) δ 11.25 (s, 1H), 8.35 (s, 1H), 7.46 – 7.36 (m, 3H), 7.27 
(q, J = 3.0 Hz, 1H), 6.36 – 6.15 (m, 3H), 4.47 (d, J = 19.9 Hz, 2H), 3.88 (d, J = 14.9 Hz, 
1H), 3.64 – 3.39 (m, 2H), 2.90 (s, 7H), 2.51 (s, 3H), 1.76 (d, J = 12.5 Hz, 1H), 1.62 (d, J 
= 13.4 Hz, 5H), 1.28 (s, 1H), 1.08 (dq, J = 27.6, 13.3, 12.4 Hz, 4H), 0.91 (d, J = 8.3 Hz, 
1H), 0.78 (q, J = 11.3 Hz, 1H). ESI-MS m/z [M + H] + calculated = 575.23, found = 
575.12.  
(S)-3-(5-(3-Chlorophenyl)-4-methylthiazol-2-yl)-N-((S)-1-cyclohexyl-3-
(dimethylamino)-propan-2-yl)-2-((3,5-difluorophenyl)amino)propanamide (25): 1H 
NMR (400 MHz, Chloroform-d) δ 11.00 (s, 1H), 8.67 (d, J = 8.6 Hz, 1H), 7.39 – 7.36 (m, 
2H), 7.35 (dt, J = 2.3, 1.1 Hz, 2H), 7.28 – 7.22 (m, 2H), 7.21 – 7.15 (m, 2H), 6.23 – 6.10 
(m, 3H), 4.62 (s, 1H), 4.33 (dd, J = 7.6, 4.3 Hz, 1H), 4.00 (d, J = 11.7 Hz, 1H), 3.74 (ddt, 
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J = 10.3, 6.7, 3.7 Hz, 1H), 3.70 – 3.61 (m, 1H), 3.58 – 3.46 (m, 2H), 3.38 (dd, J = 15.2, 
7.6 Hz, 1H), 3.14 (qd, J = 7.5, 4.3 Hz, 1H), 3.07 (dd, J = 7.1, 3.9 Hz, 1H), 2.90 (dd, J = 
13.0, 3.7 Hz, 2H), 2.84 (s, 2H), 2.45 (s, 3H). ESI-MS m/z [M + H] + calculated = 603.15, 
found = 603.20.  
(S)-N-((S)-1-(3-Chlorophenyl)-3-(dimethylamino)propan-2-yl)-3-(5-(3-chlorophenyl)-
4-methylthiazol-2-yl)-2-((3,5-difluorophenyl)amino)propanamide (26): 1H NMR (400 
MHz, Chloroform-d) δ 11.26 (s, 1H), 8.81 (d, J = 8.5 Hz, 1H), 7.42 – 7.39 (m, 2H), 7.38 
– 7.35 (m, 1H), 7.28 – 7.24 (m, 1H), 7.24 – 7.20 (m, 3H), 7.08 (d, J = 5.4 Hz, 1H), 6.21 
(t, J = 9.0 Hz, 1H), 6.14 (d, J = 8.3 Hz, 2H), 4.55 (s, 1H), 4.44 (d, J = 7.3 Hz, 1H), 3.89 
(d, J = 14.8 Hz, 1H), 3.59 (t, J = 12.1 Hz, 1H), 3.44 (dd, J = 15.2, 8.7 Hz, 1H), 3.00 (dd, 
J = 13.8, 6.6 Hz, 1H), 2.81 (dd, J = 29.9, 14.9 Hz, 8H), 2.51 (s, 3H). ESI-MS m/z [M + H] 
+ calculated = 603.15, found = 603.28.  
(S)-N-((S)-1-(4-Chlorophenyl)-3-(dimethylamino)propan-2-yl)-3-(5-(3-chlorophenyl)-
4-methylthiazol-2-yl)-2-((3,5-difluorophenyl)amino)propanamide (27): 1H NMR (400 
MHz, Chloroform-d) δ 11.58 (s, 1H), 8.84 (d, J = 8.3 Hz, 1H), 7.38 (td, J = 4.1, 1.4 Hz, 
3H), 7.28 – 7.20 (m, 3H), 7.13 (d, J = 8.0 Hz, 2H), 6.23 – 6.07 (m, 3H), 4.52 (s, 1H), 
4.40 (d, J = 7.5 Hz, 1H), 3.75 (d, J = 14.9 Hz, 1H), 3.56 (t, J = 11.9 Hz, 1H), 3.41 (dd, J 
= 15.2, 7.9 Hz, 1H), 2.99 (dd, J = 13.9, 6.7 Hz, 1H), 2.91 – 2.62 (m, 8H), 2.48 (s, 3H). 
ESI-MS m/z [M + H] + calculated = 603.15, found = 603.25.  
(S)-3-(5-(3-Chlorophenyl)-4-methylthiazol-2-yl)-2-((3,5-difluorophenyl)amino)-N-
((S)-1-(dimethylamino)-3-(4-fluorophenyl)propan-2-yl)propanamide (28): 1H NMR 
(400 MHz, Chloroform-d) δ 10.83 (s, 1H), 8.76 (s, 1H), 7.42 (d, J = 5.7 Hz, 2H), 7.36 (s, 
1H), 7.26 (d, J = 5.6 Hz, 1H), 7.14 (s, 2H), 6.95 (t, J = 7.4 Hz, 2H), 6.30 – 6.02 (m, 3H), 
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4.52 (d, J = 37.2 Hz, 2H), 4.10 – 3.92 (m, 1H), 3.72 – 3.51 (m, 1H), 3.49 – 3.34 (m, 1H), 




1H NMR (400 MHz, Chloroform-d) δ 11.06 (s, 1H), 8.91 (s, 1H), 7.53 (s, 2H), 7.42 (s, 
2H), 7.34 (dd, J = 12.9, 7.0 Hz, 3H), 7.26 (s, 1H), 6.28 – 6.07 (m, 3H), 4.70 (s, 2H), 4.01 
(dd, J = 27.9, 10.2 Hz, 1H), 3.67 (s, 1H), 3.52 – 3.35 (m, 1H), 3.17 – 3.03 (m, 1H), 3.01 
– 2.65 (m, 8H), 2.52 (s, 3H). ESI-MS m/z [M + H] + calculated = 637.17, found = 637.28.  
(S)-3-(5-(3-Chlorophenyl)-4-methylthiazol-2-yl)-2-((3,5-difluorophenyl)amino)-N-
((S)-1-(dimethylamino)-3-(p-tolyl)propan-2-yl)propanamide (30): 1H NMR (400 MHz, 
Chloroform-d) δ 11.59 (s, 1H), 8.68 (s, 1H), 7.38 (d, J = 5.3 Hz, 3H), 7.27 (t, J = 3.9 Hz, 
1H), 7.09 (q, J = 7.6 Hz, 4H), 6.26 – 6.05 (m, 3H), 4.46 (d, J = 46.6 Hz, 2H), 3.75 (d, J = 
14.1 Hz, 1H), 3.61 – 3.32 (m, 2H), 2.99 (s, 1H), 2.80 (d, J = 22.4 Hz, 8H), 2.48 (s, 3H), 
2.32 (s, 3H). ESI-MS m/z [M + H] + calculated = 583.20, found = 583.35.  
(S)-3-(5-(3-Chlorophenyl)-4-methylthiazol-2-yl)-2-((3,5-difluorophenyl)amino)-N-
((S)-1-(dimethylamino)-3-(4-ethylphenyl)propan-2-yl)propanamide (31): 1H NMR 
(400 MHz, Chloroform-d) δ 11.04 (s, 1H), 8.65 (s, 1H), 7.45 – 7.39 (m, 2H), 7.36 (s, 1H), 
7.28 – 7.22 (m, 1H), 7.11 (q, J = 7.7 Hz, 4H), 6.19 (d, J = 11.8 Hz, 3H), 4.51 (d, J = 30.7 
Hz, 2H), 3.92 (s, 1H), 3.45 (s, 2H), 2.98 (s, 1H), 2.84 (d, J = 20.1 Hz, 8H), 2.62 (q, J = 
7.6 Hz, 2H), 2.50 (s, 3H), 1.22 (t, J = 7.6 Hz, 3H). ESI-MS m/z [M + H] + calculated = 
597.22, found = 597.10. 
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(S)-3-(5-(3-Chlorophenyl)-4-methylthiazol-2-yl)-2-((3,5-difluorophenyl)amino)-N-
((S)-1-(dimethylamino)-3-(4-hydroxyphenyl)propan-2-yl)propanamide (32): 1H NMR 
(400 MHz, Chloroform-d) δ 10.67 (s, 1H), 8.35 (d, J = 8.6 Hz, 1H), 7.86 (s, 1H), 7.44 – 
7.35 (m, 3H), 7.28 – 7.24 (m, 1H), 6.97 (dd, J = 27.1, 8.4 Hz, 2H), 6.77 – 6.70 (m, 2H), 
6.25 – 6.14 (m, 3H), 4.47 (dd, J = 9.4, 4.1 Hz, 2H), 3.94 (d, J = 15.5 Hz, 1H), 3.54 – 
3.39 (m, 3H), 2.87 (d, J = 12.8 Hz, 5H), 2.81 (s, 3H), 2.50 (d, J = 12.9 Hz, 3H). ESI-MS 
m/z [M + H] + calculated = 585.18, found = 585.27.  
(S)-3-(5-(3-Chlorophenyl)-4-methylthiazol-2-yl)-2-((3,5-difluorophenyl)amino)-N-
((S)-1-(2,3-dihydro-1H-inden-2-yl)-2-(dimethylamino)ethyl)propanamide (33): 1H 
NMR (400 MHz, Chloroform-d) δ 10.84 (s, 1H), 8.66 (d, J = 9.3 Hz, 1H), 7.45 – 7.35 (m, 
3H), 7.27 (d, J = 5.4 Hz, 1H), 7.18 – 7.08 (m, 4H), 6.28 – 6.13 (m, 3H), 4.55 (d, J = 8.1 
Hz, 2H), 3.99 (dd, J = 15.4, 3.2 Hz, 1H), 3.62 (t, J = 12.3 Hz, 1H), 3.50 (dd, J = 15.3, 9.0 
Hz, 1H), 2.97 (d, J = 21.3 Hz, 9H), 2.79 – 2.61 (m, 3H), 2.51 (s, 3H). ESI-MS m/z [M + 
H] + calculated = 595.20, found = 595.33.  
(S)-3-(5-(3-Chlorophenyl)-4-methylthiazol-2-yl)-2-((3,5-difluorophenyl)amino)-N-
((S)-1-(dimethylamino)-3-(1H-indol-3-yl)propan-2-yl)propanamide (34): 1H NMR 
(400 MHz, Chloroform-d) δ 10.63 (s, 1H), 8.54 (d, J = 8.6 Hz, 1H), 8.28 (s, 1H), 7.44 – 
7.36 (m, 3H), 7.36 – 7.32 (m, 1H), 7.26 – 7.21 (m, 2H), 7.18 – 7.08 (m, 3H), 6.23 – 6.13 
(m, 3H), 4.70 (s, 1H), 4.54 (d, J = 9.0 Hz, 1H), 4.02 (d, J = 15.0 Hz, 1H), 3.63 – 3.40 (m, 
2H), 3.15 (dd, J = 14.6, 5.8 Hz, 1H), 3.02 – 2.90 (m, 2H), 2.82 (d, J = 17.1 Hz, 6H), 2.49 
(d, J = 11.9 Hz, 3H). ESI-MS m/z [M + H] + calculated = 608.20, found = 608.39.  
tert-Butyl (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-amino-4-
thioxobutanoate (36): Step 1: Fmoc-Asp-OtBu (10.6 g, 27.3 mmol) was dissolved in 
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DMF then ammonium carbonate (4.3 g, 54.6 mmol) and carbonyldiimidazole (13.2 g, 
81.9 mmol) were added. The mixture was stirred at rt and monitored by TLC. After the 
reaction was complete, the mixture was poured into saturated aqueous NaHCO3 and 
extract with DCM. The organic layer was washed with brine and then the solvent was 
evaporated for the next reaction.  
Step 2:  The residues were dissolved in THF (500 mL), Lawesson reagent (11.56 g, 
28.6 mmol) was added, and the mixture was stirred at rt for 18 h. The reaction mixture 
was then poured into saturated aqueous NaHCO3 (300 ml), then extracted with EtOAc 
(2 x 100 ml). The organic fractions were combined, dried over Na2SO4, filtered, and 
concentrated. The crude product was purified by flash column chromatography.  1H 
NMR (400 MHz, DMSO-d6) δ 9.56 (s, 1H), 9.18 (s, 1H), 7.90 (dd, J = 7.5, 2.7 Hz, 2H), 
7.72 (dd, J = 7.2, 3.6 Hz, 2H), 7.69 – 7.64 (m, 1H), 7.43 (td, J = 7.5, 2.7 Hz, 2H), 7.37 – 
7.29 (m, 2H), 4.61 (dq, J = 8.3, 2.7 Hz, 1H), 4.35 – 4.18 (m, 3H), 2.83 (dddd, J = 60.8, 
14.5, 7.3, 2.7 Hz, 2H), 1.38 (d, J = 2.8 Hz, 9H). ESI-MS m/z [M + H] + calculated = 
427.16, found =427.29.  
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(5-bromo-4-methylthiazol-2-
yl)propanoic acid (37): A solution of compound 36 (408 mg, 1 mmol) and 
chloroacetone (227mg, 3 mmol) in DMF was refluxed for 3 h. The reaction mixture was 
evaporated under vacuum and the residue was dissolved in EtOAc. The solution was 
washed with saturated NaHCO3 solution and brine, dried over Na2SO4, then 
concentrated for the next reaction. The residue was redissolved in THF and NBS 
(356mg, 2 mmol) was added then the mixture was stirred for 5 h at rt. The reaction 
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mixture was then poured into saturated aqueous NaHCO3. The mixture was extracted 
with EtOAc. The organic fractions were combined, dried over Na2SO4, filtered, and 
concentrated. The crude was purified by flash column chromatography. ESI-MS m/z [M 
+ H] + calculated = 487.02, found = 487.20.  
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(5-(3-chlorophenyl)-4-
methylthiazol-2-yl)propanoic acid (38): Compound 37 (1 mmol, 1 equiv), 3-
chlorophenylboronic acid (2 mmol, 2 eq), K2CO3 (3 mmol, 3 eq) were dissolved in dioxane. 
The flask was sealed and charged with nitrogen gas, then 
tetrakis(triphenylphosphine)palladium(0) (0.1 equiv) was quickly added to the flask. The flask 
was heated in oil bath at a temperature of 120 oC and stirred for 2 h. After the solution cooled to 
rt, the solution was diluted with EtOAc and washed with saturated NaHCO3, 1.0 M HCl and 
brine and then dried over with Na2SO4. The solvent was evaporated, and the crude product was 
purified by flash chromatography on silica gel to afford compound 38. ESI-MS m/z [M + H] + 
calculated = 519.11, found = 519.28.  
tert-Butyl ((S)-2-((S)-3-(5-bromo-4-methylthiazol-2-yl)-2-
propionamidopropanamido)-3-phenylpropyl)carbamate (39): 1H NMR (400 MHz, 
DMSO-d6) δ 8.07 (d, J = 8.6 Hz, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.31 – 7.10 (m, 5H), 6.82 
(t, J = 5.9 Hz, 1H), 4.55 (td, J = 8.8, 4.8 Hz, 1H), 3.94 (dq, J = 12.1, 6.7, 5.3 Hz, 1H), 
3.27 (dd, J = 14.9, 5.0 Hz, 1H), 3.05 (dd, J = 14.6, 8.5 Hz, 2H), 2.99 – 2.89 (m, 1H), 
2.75 – 2.69 (m, 1H), 2.63 (dd, J = 13.8, 8.1 Hz, 1H), 2.27 (s, 2H), 2.22 (q, J = 7.5 Hz, 
1H), 2.13 – 2.05 (m, 2H), 1.38 (s, 9H), 0.95 (t, J = 7.6 Hz, 3H). ESI-MS m/z [M + H] + 
calculated = 553.14, found =553.35.  
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tert-Butyl ((S)-2-((S)-2-amino-3-(5-(3-chlorophenyl)-4-methylthiazol-2-
yl)propanamido)-3-phenylpropyl)carbamate (40): 1H NMR (400 MHz, MeOH-d4) δ 
7.45 (ddd, J = 16.6, 9.9, 5.2 Hz, 4H), 7.36 – 7.21 (m, 5H), 4.24 (s, 2H), 3.62 (dd, J = 
16.6, 4.3 Hz, 1H), 3.46 – 3.40 (m, 1H), 3.23 (q, J = 7.1 Hz, 1H), 3.14 (dd, J = 14.1, 7.0 
Hz, 1H), 2.90 (dd, J = 14.0, 5.7 Hz, 1H), 2.81 (dd, J = 14.1, 8.5 Hz, 1H), 2.49 (s, 3H), 
1.44 (s, 9H). ESI-MS m/z [M + H] + calculated = 529.20, found = 529.33.  
Allyl (S)-2-amino-3-(5-(3-chlorophenyl)-4-methylthiazol-2-yl)propanoate (41): ESI-
MS m/z [M + H] + calculated = 337.07, found = 337.21.  
(S)-3-(5-(3-Chlorophenyl)-4-methylthiazol-2-yl)-2-((3,5-
difluorophenyl)amino)propanoic acid (41): ESI-MS m/z [M + H] + calculated = 409.05, 
found = 409.14.  
Biolayer Interferometry (BLI)  
The biolayer interferometry (BLI) assay developed for DCN1 was conducted as described 
previously.75, 76 A BLI assay for DCN3 was developed to test new synthesized peptides 
and screen our DCN1 library as described previously. The BLI kinetic experiments were 
performed using the OctetRED96 instrument from PALL/ForteBio. All assays were run at 
30 °C, sample plates were continuously shaken at 1000 RPM to avoid any mass transport 
effect. PBS (pH 7.4) was used as assay buffer, in which 0.1% BSA and 0.01% Tween-20 
were added to reduce non-specific interactions. 1% DMSO was introduced to increase 
compound solubility. Assays were run in Greiner 96-well blackflat-bottom microplates in 
which protein solutions, pure assay buffer for dissociation, and serial dilutions of a tested 
compound were loaded. The biotinylation of purified recombinant DCN3 protein was 
performed using EZ-Link long-chain biotinylation reagent (Thermo) to allow tethering on 
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Super Streptavidin (SSA) biosensors. A 1:1 molar ration of protein and biotinylation 
reagent was applied to avoid overbiotinylation of the proteins. The reaction mixture of 
DCN3 protein and biotinylation reagent in PBS was incubated at 4 °C for 2 h to allow the 
reaction to complete. The mixture was then dialyzed to remove unreacted biotinylation 
reagent, using Fisher Scientific 10K MWCO dialysis cassettes.  
Biotinylated DCN3 protein was tethered to super streptavidin (SSA) biosensors 
(ForteBio) by dipping the sensors into 10 μg/mL protein solutions. The sensor saturation 
response level of 9-10 nm was achieved in 20 min. Biotinylated blocked streptavidin (SAV 
B4) sensors were prepared following the protocol provided by the manufacturer and were 
used as the inactive reference controls. Sensors with tethered proteins were washed in 
assay buffer for 10 min to eliminate loose nonspecific bound protein molecules and 
establish a stable baseline before starting association–dissociation cycles of the test 
compound. Association and dissociation times of 10 min were used in the assay. A 
DMSO-only reference was included in all assays. Raw kinetic data collected were 
processed in the data analysis software provided by the manufacturer using double 
reference subtraction in which both DMSO-only reference and inactive protein reference 
were subtracted. The resulting data were analyzed based on 1:1 binding model from 
which kon and koff values were obtained, and then KD values were calculated. All the BLI 
experiments were performed in at least two independent experiments. 
Fluorescence Polarization (FP) Competitive Binding Assays 
The fluorescence polarization (FP) competitive binding assays for accurately testing 
newly designed DCN1 inhibitors were performed as described previously.75, 76 In this 
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case, we developed a new FP competitive binding assay to determine the binding affinity 
of all synthesized DCN3 inhibitors. A novel FAM tethered fluorescent probe compound 
(DCN3-Flu1) was designed and synthesized based on the optimized UBE2F peptide. 
Equilibrium dissociation constant (KD) values of DCN3-Flu1to DCN3 were determined 
from protein saturation experiments by monitoring the total FP values of mixtures 
composed with the fluorescent probe at a fixed concentration and proteins with increasing 
concentrations up to full saturation. Serial dilutions of proteins were mixed with DCN3-
Flu1 to a final volume of 200 μL in the assay buffer (100 mM phosphate buffer, pH = 6.5, 
with 0.02% Tween-20 and 1% DMSO). The final probe concentration was 5 nM. Plates 
were incubated at rt for 30 min with gentle shaking to ensure equilibration. FP values in 
millipolarization units (mP) were measured using the Infinite M-1000 plate reader (Tecan 
U.S., Research Triangle Park, NC) in Microfluor 1 96-well, black round-bottom plates 
(Thermo Scientific, Waltham, MA) at an excitation wavelength of 485 nm and an emission 
wavelength of 530 nm. The KD values of DCN3-Flu1 were calculated by fitting the 
sigmoidal dose-dependent FP increases to a function of protein concentration using 
Graphpad Prism 7.0 software (Graphpad Software, San Diego, CA). 
The IC50 and Ki values of compounds were determined in competitive binding 
experiments. Mixtures of 4 μL of compounds in DMSO and 196 μL of preincubated 
protein/probe complex solution in the assay buffer were added into assay plates which 
were incubated at rt for 30 min with gentle shaking. Final concentrations of DCN3 protein 
and fluorescent probe DCN3-Flu1 were 400 and 5 nM, respectively. Negative controls 
containing protein/probe complex only (equivalent to 0% inhibition) and positive controls 
containing only free probes (equivalent to 100% inhibition) were included in each assay 
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plate. FP values were measured as described above. IC50 values were determined by 
nonlinear regression fitting of the competition curves. Ki values of competitive inhibitors 
were obtained directly by nonlinear regression fitting, based upon the KD values of the 
probe DCN3-Flu1 and concentrations of the protein and probe in the competitive assays. 
Ki values were calculated using the methods described previously.102 All the FP 
competitive experiments were performed in duplicate in three independent experiments.  
Computational Modeling. Coordinates of DCN3 protein in the co-crystal structure of DCN3 
and the NEDD8 E2 peptide (PDB ID 4GBA82) were extracted to build the binding models 
of designed inhibitors with DCN3. To accommodate our designed compounds, the 
rotamer state of F142 in DCN3 was modeled based on F117 in the structure of the 
DCN1/DI-591 complex (PDB ID 5UFI16) and the side chain atoms of the modeled DCN3 
structure were minimized while the backbone atoms were constrained using default 
parameters in the MOE program.80 Hydrogen atoms in DCN3 were added using the 
“protonate 3D” module in MOE in the physiological conditions. In the docking calculations, 
the structures of the designed compounds were prepared using MOE and then subject to 
the docking simulations using default parameters in the GOLD program (version 5.6.2).95, 
96 The center of the binding site was set at M139 in DCN3 and the radius of the binding 
site was 13 Å. The docking poses were assessed by the GoldScore fitness function and 
the top-ranked poses were analyzed to determine the predicted docking modes.  
 The Cellular Thermal Shift Assay  
Cellular Thermal Shift Assay was performed according to the reported method.103 Briefly, 
cells (5 × 105 per sample) were treated with a compound as indicated or with DMSO for 
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1 h, washed with PBS three times, and dissolved in 50 µl PBS supplemented with a 
protease inhibitor, followed by heating at the indicated temperatures in a Mastercycler 
gradient (Eppendorf, New York, USA). Treated cells were then subjected to snap-freezing 
in liquid nitrogen and thawed on ice for 3 cycles. The protein levels of DCN1 and DCN3 
in equal amounts of the supernatant were examined by western blots. GAPDH was used 
as the control. 
Western Blotting Analysis 
Treated cells were lysed by RIPA buffer supplemented with protease inhibitors. The 
expression levels of indicated proteins were examined by western blotting analysis. 
GAPDH was used as the loading control. Anti-Cullin 1 (sc-11384) and anti-Cullin 2 (sc-
10781) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); anti-Cullin 4A 
(PA5-14542), anti-Cullin 4B (PA5-35239) and anti-DCN3 antibodies (DCUN1D3, PA5-
44000) were from ThermoFisher Scientific (Wayne, MI); anti-Cullin 3 (2759) antibodies 
from Cell Signaling Technology (Boston, MA); anti-DCN1 (GWB-E3D700) antibody from 
GenWay Biotech (San Diego, CA). Anti-Cullin 5 antibody (A302-173A) from Bethyl 




Appendix C: Experimental Section of Chapter 4 
In vitro histone methyltransferase (HMT) assay. The HMT assay was performed as 
described previously (Dou et al., 2005). Small molecule inhibitors were tested in reaction 
buffer consisting of 50 mM Tris–HCl, pH 8.0, 150 mM NaCl, and 10% glycerol. Equal 
stoichiometry of human MLL1 SET domain, WDR5, RbBP5 and ASH2L were mixed to 
form the active MLL1 complex at a final concentration of 125 nM. MLL1 complex were 
mixed with small molecules inhibitors at a final concentration of 10uM and incubated on 
ice. After 10 minutes the methyltransferase reaction was initiated by adding 1 μM of 3H-
SAM and 4 μM of histone H3 (1–21) peptide. The reactions proceeded for 1 h at 22 °C 
and was terminated by adding 10 μL of reaction mixture onto Whatman P81 ion exchange 
filter paper. The filter paper was air dried and washed in three 10-min washes in 50 mM 
sodium bicarbonate pH 9.0 to remove excess SAM. Filter paper was heat-dried for 20 
min and placed in 10 mL Ultima Gold scintillation fluid for 3H signal acquisition in the unit 
of counts per minute (c.p.m.).  
Alpha LISA assay 
The method for Alpah LISA assay developed by our group has been described.86  
Preparation of tert-butyl (S)-4-((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)amino)-2-((tert-
butoxycarbonyl)amino)butanoate (20) 
Sodium triacetoxyborohydride  (1.5 eq) was added to a solution of 5'-amino-5'-deoxy-2',
3'-o-(1-methylethylidene)-adenosine (0.9 eq) and t-butyl (S)-2-[(tert-butoxycarbonyl)
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amino]-4-oxo-butanoate  (1 eq) in DCE and stirred at rt for 4 h. Then saturated sodium 
bicarbonate solution was added and stirring was continued for 20 min. The reaction 
mixture was extracted with DCM and the combined organic layers were dried over MgSO4 
and concentrated under reduced pressure. The compound was purified by preparative 
HPLC. 
1H NMR (400 MHz, Methanol-d4) δ 8.41 (s, 1H), 8.40 (s, 1H), 6.37 (d, J = 2.2 Hz, 1H), 
5.42 (dd, J = 6.3, 2.2 Hz, 1H), 5.19 (dd, J = 6.3, 3.9 Hz, 1H), 4.55 (dt, J = 9.8, 3.5 Hz, 1H), 
4.04 (dd, J = 9.3, 5.0 Hz, 1H), 3.61 (dd, J = 13.1, 9.8 Hz, 1H), 3.51 (dd, J = 13.1, 3.3 Hz, 
1H), 3.08 (t, J = 7.7 Hz, 2H), 2.14 (dt, J = 13.3, 4.7 Hz, 1H), 1.96 – 1.83 (m, 1H), 1.64 (s, 
3H), 1.46 (s, 10H), 1.43 (s, 8H), 1.42 – 1.40 (m, 3H). ESI-MS m/z [M + H] + calculated = 
564.31, found = 564.22.  
Preparation of tert-butyl (S)-4-((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)(azetidin-3-ylmethyl)amino)-
2-((tert-butoxycarbonyl)amino)butanoate (21) 
Benzyl 3-formylazetidine-1-carboxylate (1.2 eq) and sodium triacetoxyborohydride (1.5 
eq) in DCE were added to a solution of 5'-deoxy-5'-[[(3S)-4-(1,1-dimethylethoxy)-3-[[(1,1-
dimethylethoxy)carbonyl]amino]-4-oxobutyl]amino]-2',3'-O-(1-
methylethylidene)adenosine (1 eq) and stirred for 3 h at rt. Then saturated sodium 
bicarbonate solution was added and stirring was continued for 20 min. The reaction 
mixture was extracted with DCM and the combined organic layers were dried over MgSO4 
and concentrated under reduced pressure. Then the crude product was dissolved in 
MeOH, Pd/C (0.05%) was added and the mixture was stirred under a hydrogen 
atmosphere. The black particles were filtered off and washed with MeOH several times. 
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The filtrate was then concentrated under reduced pressure and purified by preparative 
HPLC. 
1H NMR (400 MHz, Methanol-d4) δ 8.52 – 8.39 (m, 2H), 6.38 (d, J = 2.1 Hz, 1H), 5.36 (d, 
J = 6.3 Hz, 1H), 5.13 (d, J = 5.5 Hz, 1H), 4.64 (s, 1H), 4.25 – 4.08 (m, 2H), 3.97 (s, 3H), 
3.60 (s, 2H), 3.54 – 3.36 (m, 3H), 3.25 (s, 1H), 3.18 – 2.92 (m, 2H), 2.13 (d, J = 63.5 Hz, 
2H), 1.81 (s, 1H), 1.64 (d, J = 6.2 Hz, 2H), 1.52 – 1.50 (m, 1H), 1.45 (d, J = 1.9 Hz, 15H), 
1.40 (s, 3H), 1.32 (d, J = 9.8 Hz, 1H). ESI-MS m/z [M + H] + calculated =  633.36, found 
= 633.28. 
Synthesis of compound 11-19. Sodium triacetoxyborohydride  (1.5 eq) was added to a 
solution of t-butyl (S)-4-((((3aR,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl)(azetidin-3-ylmethyl)amino)-2-((tert-
butoxycarbonyl)amino)butanoate (1 eq) and the aldehyde (1.2 eq) in DCE and stirred for 
2 h at rt. Then saturated sodium bicarbonate solution was added and stirring was 
continued for 20 min. The reaction mixture was extracted with DCM. The combined 
organic layers dried over MgSO4 and concentrated under reduced pressure. Then the 
crude product was dissolved in water/trifluoroacetic acid solution (1:4) and stirred for 16 




yl)amino)butanoic acid (1) 
1H NMR (400 MHz, Methanol-d4) δ 8.36 (s, 1H), 8.34 (s, 1H), 6.02 (dd, J = 3.9, 1.4 Hz, 
1H), 4.70 (t, J = 4.6 Hz, 1H), 4.29 (t, J = 5.9 Hz, 1H), 4.21 (s, 2H), 4.07 (t, J = 6.1 Hz, 1H), 
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3.93 (s, 3H), 3.16 – 3.08 (m, 3H), 2.83 (t, J = 6.6 Hz, 2H), 2.10 (dq, J = 31.9, 7.2 Hz, 2H), 
1.77 (dt, J = 14.4, 8.8 Hz, 4H), 1.70 – 1.44 (m, 8H), 1.19 – 1.03 (m, 3H). ESI-MS m/z [M 
+ H] + calculated = 533.31, found = 533.22. 
 (S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)(2-aminoethyl)amino)butanoic acid (2) 
1H NMR (400 MHz, Methanol-d4) δ 8.45 (s, 1H), 8.43 (s, 1H), 6.07 (d, J = 3.6 Hz, 1H), 
4.65 (dd, J = 5.5, 3.7 Hz, 1H), 4.32 (t, J = 5.9 Hz, 1H), 4.26 (d, J = 7.4 Hz, 1H), 4.05 (t, J 
= 6.3 Hz, 1H), 3.07 (q, J = 4.6 Hz, 4H), 2.99 – 2.85 (m, 4H), 2.17 (td, J = 17.3, 14.8, 7.4 
Hz, 1H), 2.05 (s, 1H). ESI-MS m/z [M + H] + calculated = 411.20, found = 411.12. 
(S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)(3-((3-
cyclopentylpropyl)amino)cyclobutyl)amino)butanoic acid (3) 
1H NMR (400 MHz, Methanol-d4) δ 8.38 (s, 1H), 8.37 (s, 1H), 6.08 (d, J = 3.6 Hz, 1H), 
4.71 (dd, J = 5.4, 3.6 Hz, 1H), 4.44 (t, J = 5.8 Hz, 1H), 4.40 – 4.33 (m, 1H), 4.20 – 4.09 
(m, 1H), 4.01 (dd, J = 7.8, 5.1 Hz, 1H), 3.80 (tdd, J = 7.4, 4.2, 1.7 Hz, 1H), 3.54 (dd, J = 
14.5, 9.6 Hz, 1H), 3.43 (d, J = 14.1 Hz, 1H), 3.28 (t, J = 6.9 Hz, 2H), 2.95 – 2.88 (m, 2H), 
2.84 – 2.73 (m, 2H), 2.66 – 2.48 (m, 2H), 2.35 – 2.27 (m, 1H), 2.19 – 2.09 (m, 1H), 1.87 
– 1.78 (m, 3H), 1.76 – 1.57 (m, 6H), 1.41 (dt, J = 11.1, 6.3 Hz, 2H), 1.19 – 1.08 (m, 2H). 
ESI-MS m/z [M + H] + calculated = 547.33, found = 547.45. 
 (S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)((1-butylazetidin-3-
yl)methyl)amino)butanoic acid (4) 
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1H NMR (400 MHz, Methanol-d4) δ 8.45 (s, 1H), 8.42 (d, J = 5.4 Hz, 1H), 6.11 (d, J = 3.8 
Hz, 1H), 4.79 (dt, J = 27.8, 4.9 Hz, 1H), 4.68 (t, J = 4.1 Hz, 1H), 4.42 (d, J = 5.2 Hz, 2H), 
4.29 (ddd, J = 17.4, 9.5, 4.7 Hz, 1H), 4.20 – 4.08 (m, 1H), 4.03 (dt, J = 7.7, 4.0 Hz, 1H), 
3.98 – 3.83 (m, 1H), 3.59 – 3.38 (m, 5H), 3.37 (d, J = 8.0 Hz, 1H), 3.29 (t, J = 8.7 Hz, 1H), 
3.17 (d, J = 21.3 Hz, 2H), 2.37 (dq, J = 15.0, 7.5 Hz, 1H), 2.17 (dd, J = 14.5, 6.2 Hz, 1H), 
1.58 – 1.45 (m, 2H), 1.38 (q, J = 7.9, 7.3 Hz, 2H), 0.97 (t, J = 7.2 Hz, 3H). ESI-MS m/z [M 
+ H] + calculated = 493.28, found = 493.11. 
 (S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)((1-(furan-3-ylmethyl)azetidin-3-
yl)methyl)amino)butanoic acid (5) 
1H NMR (400 MHz, Methanol-d4) δ 8.36 (dd, J = 8.8, 3.8 Hz, 2H), 7.73 (s, 1H), 7.64 – 
7.57 (m, 1H), 6.54 (d, J = 1.8 Hz, 1H), 6.07 (t, J = 3.7 Hz, 1H), 4.69 (dd, J = 5.2, 3.7 Hz, 
1H), 4.39 (qd, J = 9.5, 8.5, 4.3 Hz, 3H), 4.23 (s, 3H), 4.16 (d, J = 25.5 Hz, 2H), 3.97 (dd, 
J = 7.8, 4.9 Hz, 3H), 3.27 – 3.14 (m, 3H), 2.28 (dd, J = 15.8, 8.2 Hz, 1H), 2.11 – 2.01 (m, 
1H), 1.42 (d, J = 4.9 Hz, 2H). ESI-MS m/z [M + H] + calculated = 517.24, found = 517.15. 
(S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)((1-(3-cyclopentylpropyl)azetidin-3-
yl)methyl)amino)butanoic acid (6) 
1H NMR (400 MHz, Methanol-d4) δ 8.37 (s, 1H), 8.35 (s, 1H), 6.08 (d, J = 3.9 Hz, 1H), 
4.71 (t, J = 4.5 Hz, 1H), 4.38 (qd, J = 7.3, 4.8, 3.9 Hz, 2H), 4.26 (s, 1H), 4.17 – 4.03 (m, 
1H), 3.96 (dd, J = 7.9, 4.8 Hz, 1H), 3.86 (d, J = 22.2 Hz, 1H), 3.36 (d, J = 9.1 Hz, 3H), 
3.32 – 3.04 (m, 6H), 2.30 (h, J = 7.3 Hz, 1H), 2.06 (dq, J = 15.1, 5.2 Hz, 1H), 1.85 – 1.73 
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(m, 3H), 1.69 – 1.60 (m, 2H), 1.59 – 1.48 (m, 4H), 1.34 (q, J = 7.2 Hz, 2H), 1.18 – 1.05 
(m, 2H). ESI-MS m/z [M + H] + calculated = 547.33, found = 547.45. 
(S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)((1-(3-phenylpropyl)azetidin-3-
yl)methyl)amino)butanoic acid (7) 
1H NMR (400 MHz, Methanol-d4) δ 8.32 (d, J = 2.8 Hz, 2H), 7.34 – 7.28 (m, 2H), 7.24 – 
7.19 (m, 3H), 6.08 – 6.03 (m, 1H), 4.71 (dd, J = 5.3, 3.7 Hz, 1H), 4.39 (t, J = 5.8 Hz, 1H), 
4.33 (s, 2H), 4.13 – 4.02 (m, 1H), 3.95 (t, J = 6.3 Hz, 2H), 3.27 (s, 4H), 3.14 (s, 5H), 2.68 
(t, J = 7.5 Hz, 2H), 2.25 (d, J = 14.3 Hz, 1H), 2.03 (s, 1H), 1.84 (q, J = 7.9 Hz, 2H), 1.44 
– 1.29 (m, 1H).  ESI-MS m/z [M + H] + calculated = 555.30, found = 555.22. 
(S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)(3-((3-
phenylpropyl)amino)propyl)amino)butanoic acid (8) 
1H NMR (400 MHz, Methanol-d4) δ 8.27 (d, J = 4.1 Hz, 2H), 7.32 – 7.26 (m, 2H), 7.19 (dd, 
J = 12.6, 7.1 Hz, 3H), 6.04 (d, J = 3.8 Hz, 1H), 4.78 – 4.73 (m, 1H), 4.46 – 4.42 (m, 1H), 
3.85 (dd, J = 8.9, 3.8 Hz, 1H), 3.50 (dt, J = 3.3, 1.6 Hz, 1H), 3.42 – 3.39 (m, 1H), 3.30 – 
3.25 (m, 1H), 3.15 (dt, J = 3.3, 1.6 Hz, 1H), 2.98 – 2.92 (m, 2H), 2.67 (t, J = 7.0 Hz, 2H), 
2.23 – 2.19 (m, 1H), 2.09 – 1.95 (m, 5H), 1.67 (s, 5H). ESI-MS m/z [M + H] + calculated = 
543.30, found = 543.21. 
 (S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)(3-(((3-
phenylpropyl)amino)methyl)cyclobutyl)amino)butanoic acid (9) 
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1H NMR (400 MHz, Methanol-d4) δ 8.29 (d, J = 2.7 Hz, 2H), 7.29 (t, J = 7.5 Hz, 2H), 7.25 
– 7.14 (m, 3H), 6.06 (d, J = 3.2 Hz, 1H), 4.70 (t, J = 4.3 Hz, 1H), 4.51 (t, J = 5.9 Hz, 1H), 
4.39 (t, J = 8.2 Hz, 1H), 3.85 (d, J = 6.4 Hz, 2H), 3.64 (t, J = 12.2 Hz, 2H), 3.09 (s, 1H), 
3.07 (s, 1H), 3.02 – 2.93 (m, 2H), 2.70 (t, J = 7.2 Hz, 2H), 2.61 – 2.54 (m, 2H), 2.24 – 
2.16 (m, 1H), 2.04 (ddt, J = 23.9, 19.0, 10.1 Hz, 4H), 1.71 (q, J = 5.4, 3.3 Hz, 4H). ESI-
MS m/z [M + H] + calculated = 569.31, found = 569.49. 
(S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)(3-(((3-
phenylpropyl)amino)methyl)cyclobutyl)amino)butanoic acid (10) 
1H NMR (400 MHz, Methanol-d4) δ 8.30 (s, 2H), 7.79 (s, 1H), 7.29 – 7.19 (m, 3H), 7.16 – 
7.08 (m, 2H), 6.06 (d, J = 4.1 Hz, 1H), 4.76 – 4.71 (m, 1H), 4.71 – 4.62 (m, 2H), 4.47 – 
4.41 (m, 1H), 4.34 (t, J = 5.4 Hz, 1H), 4.22 (s, 2H), 3.87 (t, J = 6.4 Hz, 1H), 3.27 (d, J = 
11.6 Hz, 1H), 3.21 (t, J = 6.9 Hz, 3H), 3.17 – 3.13 (m, 1H), 2.35 – 2.25 (m, 1H), 2.10 – 




yl)methyl)amino)butanoic acid (11) 
This title compound was prepared following General Procedure A using benzaldehyde 
(6.0 mg, 0.056 mmol)and 5 (30 mg, 0.047 mmol) 1H NMR (400 MHz, Methanol-d4) δ 8.34 
– 8.19 (m, 2H), 7.57 – 7.37 (m, 5H), 6.01 (d, J = 3.8 Hz, 1H), 4.80 – 4.70 (m, 1H), 4.44 – 
4.29 (m, 3H), 4.30 – 4.01 (m, 4H), 3.94 (dt, J = 24.7, 9.0 Hz, 2H), 3.80 (s, 1H), 3.22 – 
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3.13 (m, 1H), 3.11 – 2.83 (m, 5H), 2.23 – 2.11 (m, 1H), 1.97 (dt, J = 14.8, 6.0 Hz, 1H). 
ESI-MS m/z [M + H] + calculated = 527.27, found = 527.15. 
(S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)((1-(3-chlorobenzyl)azetidin-3-
yl)methyl)amino)butanoic acid (12) 
This title compound was prepared following General Procedure A using benzaldehyde 
(7.8 mg, 0.056 mmol) and 5 (30 mg, 0.047 mmol) 1H NMR (400 MHz, Methanol-d4) δ 
8.43 (s, 1H), 8.40 (s, 1H), 7.54 – 7.36 (m, 4H), 6.10 (d, J = 3.7 Hz, 1H), 4.67 (dd, J = 4.8, 
3.7 Hz, 1H), 4.44 – 4.34 (m, 4H), 4.29 – 4.14 (m, 2H), 4.12 – 3.96 (m, 3H), 3.44 (tdd, J = 
20.2, 9.2, 6.4 Hz, 5H), 3.26 (dq, J = 13.2, 6.8, 6.2 Hz, 2H), 2.34 (dq, J = 14.9, 7.4 Hz, 1H), 




yl)methyl)amino)butanoic acid (13) 
1H NMR (400 MHz, Methanol-d4) δ 8.41 (s, 1H), 8.38 (s, 1H), 7.52 (ddd, J = 7.4, 3.0, 1.6 
Hz, 2H), 7.42 (dtd, J = 23.7, 7.4, 1.5 Hz, 2H), 6.07 (d, J = 3.6 Hz, 1H), 4.62 (dd, J = 4.9, 
3.5 Hz, 1H), 4.54 (s, 2H), 4.36 (dd, J = 5.7, 3.1 Hz, 2H), 4.32 – 4.27 (m, 1H), 4.22 (td, J = 
8.8, 7.8, 4.9 Hz, 1H), 4.11 (ddd, J = 19.8, 10.6, 7.3 Hz, 2H), 3.99 (dd, J = 7.7, 5.2 Hz, 1H), 
3.47 – 3.34 (m, 5H), 3.25 (dd, J = 13.8, 6.9 Hz, 2H), 2.30 (dt, J = 14.9, 7.4 Hz, 1H), 2.13 





yl)methyl)amino)butanoic acid (14) 
This title compound was prepared following General Procedure A using 2-
chlorobenzaldehyde  (11.6 mg, 0.064 mmol) and 5 (30 mg, 0.069 mmol) 1H NMR (400 
MHz, Methanol-d4) δ 8.43 (s, 1H), 8.40 (s, 1H), 7.49 – 7.43 (m, 4H), 6.10 (d, J = 3.7 Hz, 
1H), 4.67 (dd, J = 4.9, 3.6 Hz, 1H), 4.43 – 4.34 (m, 4H), 4.26 – 4.20 (m, 1H), 4.16 (td, J = 
8.5, 7.6, 4.5 Hz, 1H), 4.10 – 3.98 (m, 3H), 3.42 (ddd, J = 20.3, 9.0, 4.5 Hz, 5H), 3.24 (dq, 
J = 13.3, 6.4 Hz, 2H), 2.33 (dd, J = 14.9, 7.4 Hz, 1H), 2.16 – 2.08 (m, 1H). ESI-MS m/z 
[M + H] + calculated = 561.23, found = 561.10. 
(S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)((1-(3,3-diphenylpropyl)azetidin-3-
yl)methyl)amino)butanoic acid (18) 
1H NMR (400 MHz, Methanol-d4) δ 8.39 (s, 1H), 8.37 (s, 1H), 7.32 – 7.26 (m, 8H), 7.20 
(ddd, J = 8.6, 5.6, 2.3 Hz, 2H), 6.07 (d, J = 3.7 Hz, 1H), 4.65 (dd, J = 4.9, 3.7 Hz, 1H), 
4.42 – 3.71 (m, 9H), 3.41 – 3.33 (m, 3H), 3.27 – 3.06 (m, 5H), 2.28 (dq, J = 13.8, 7.5 Hz, 




yl)methyl)amino)butanoic acid (17) 
1H NMR (400 MHz, Methanol-d4) δ 8.34 (s, 1H), 8.32 (s, 1H), 7.66 (dt, J = 7.8, 1.0 Hz, 
1H), 7.53 (dd, J = 8.3, 1.0 Hz, 1H), 7.39 (ddd, J = 8.5, 7.2, 1.4 Hz, 1H), 7.30 (td, J = 7.5, 
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1.0 Hz, 1H), 7.06 (s, 1H), 6.05 (d, J = 3.9 Hz, 1H), 4.70 (dd, J = 5.2, 3.8 Hz, 1H), 4.60 (s, 
2H), 4.40 – 4.22 (m, 5H), 4.14 (dd, J = 10.8, 7.1 Hz, 1H), 4.08 (dd, J = 10.7, 7.0 Hz, 1H), 
3.94 (dd, J = 7.6, 5.1 Hz, 1H), 3.31 – 3.20 (m, 4H), 3.17 – 3.11 (m, 2H), 2.25 (dt, J = 14.8, 




yl)methyl)amino)butanoic acid (16) 
1H NMR (400 MHz, Methanol-d4) δ 8.33 (d, J = 5.3 Hz, 2H), 7.60 (dd, J = 5.1, 1.2 Hz, 
1H), 7.30 – 7.23 (m, 1H), 7.13 (dd, J = 5.1, 3.5 Hz, 1H), 6.05 (d, J = 3.7 Hz, 1H), 4.69 (dd, 
J = 5.4, 3.7 Hz, 1H), 4.57 (s, 2H), 4.38 (t, J = 5.9 Hz, 1H), 4.35 – 4.29 (m, 1H), 4.23 (t, J 
= 8.9 Hz, 1H), 4.14 (t, J = 9.3 Hz, 1H), 3.99 (dt, J = 22.6, 7.7 Hz, 3H), 3.30 – 3.08 (m, 7H), 
2.25 (dd, J = 14.9, 7.3 Hz, 1H), 2.08 – 1.96 (m, 1H). ESI-MS m/z [M + H] + calculated = 
533.22, found = 533.13. 
(S)-2-amino-4-((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)methyl)((1-(thiophen-2-ylmethyl)azetidin-3-
yl)methyl)amino)butanoic acid (15) 
1H NMR (400 MHz, Methanol-d4) δ 8.34 (s, 1H), 8.32 (s, 1H), 7.62 (s, 1H), 7.57 (dd, J = 
5.0, 3.1 Hz, 1H), 7.16 (d, J = 5.2 Hz, 1H), 6.05 (d, J = 3.9 Hz, 1H), 4.70 (dd, J = 5.2, 3.5 
Hz, 1H), 4.48 – 3.89 (m, 9H), 3.31 – 3.07 (m, 6H), 2.35 – 2.19 (m, 1H), 2.09 – 1.97 (m, 
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